[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Advanced Bionics, LLC\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":177},{"warningLetters":4,"total":176},[5,31,52,65,87,110,132,153],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},1840,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2023-09-15T19:00:00Z\">09\u002F15\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-14T04:00:00Z\">09\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-vapor-663742-09142023\">Advanced Vapor\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>William Rubiski\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Advanced Vapor\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>817 US-9\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Manahawkin\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08050\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:advancedvaporinc@yahoo.com\"> advancedvaporinc@yahoo.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 14, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Rubiski:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our inspection records, and determined that Advanced Vapor manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States e-liquid products without a marketing authorization order, including: Unicorn Vomit.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are a new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C.§ 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco product on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2300891, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nWilliam Rubiski\n\nRecipient Title\n\nOwner\n\nAdvanced Vapor\n\n817 US-9\n\nManahawkin, NJ 08050\n\nUnited States\n\nadvancedvaporinc@yahoo.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nSeptember 14, 2023\n\nWARNING LETTER\n\nDear Mr. Rubiski:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our inspection records, and determined that Advanced Vapor manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States e-liquid products without a marketing authorization order, including: Unicorn Vomit.\n\nThe e-liquid products listed above are a new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C.§ 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nFDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco product on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2300891, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Advanced Vapor","advanced-vapor-663742-09142023","2026-08-18T06:42:28.994808+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-vapor-663742-09142023","2026-10-26T08:07:50.62041+00:00","Warning Letter","Issued","2023-09-15","663742","Tobacco","William Rubiski","2026-08-20T00:39:50.569+00:00","VIA UPS and Electronic Mail","2023-09-14",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":51,"medical_device_id":19,"response_letter_date":19},326,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2026-02-24T05:00:00Z\">02\u002F24\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-01-28T05:00:00Z\">01\u002F28\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbeta-bionics-inc-717927-01282026\">Beta Bionics, Inc.\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Sean Saint\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Beta Bionics, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>11 Hughes\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Irvine\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92618\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)@betabionics.com\"> (b)(6)@betabionics.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS #717927\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>January 28, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Saint:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Irvine, CA from June 9, 2025, through June 26, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the iLet Dosing Decision Software and the iLet ACE Pump, which are part of the iLet Bionic Pancreas System. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received responses from Neal Grant, Director, Quality Systems dated July 18, 2025, August 29, 2025, and October 29, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a). For example:\u003C\u002Fp>\u003Cp>A. Your firm failed to adequately analyze quality data, such as complaints, to identify existing and potential causes of nonconforming product or other quality problems and utilize appropriate statistical methodology to detect recurring quality problems. For example:\u003C\u002Fp>\u003Cp>i. Your firm failed to implement corrective and preventive actions (CAPA) for complaints related to device malfunctions that led to serious adverse health outcomes, as required by Section 6.1.3 (Section 1.4 of Revs G and H) of your firm's corrective and preventive action procedure, Corrective and Preventive Actions, SOP05, Rev I, Section 6.1 (Section 6.6 of Rev I) of the firm's complaint handling procedure, Product Complaints, SOP13, Rev H, and Section 9 (Section 6.9 Rev I) of the firm's complaint handling procedure, Product Complaints, SOP13, Rev H.\u003C\u002Fp>\u003Cp>a. Investigators observed \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints reporting Faulty Motors, including one reporting the patient suffered Diabetic Ketoacidosis, confirmed by your firm to be device malfunctions, where you took no corrective actions and provided no justification for inaction, despite identified safety risks.\u003Cbr>b. Investigators observed \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints reporting hypoglycemic episodes that were attributed to Use Error – Unintended Insulin Delivery associated with the patients’ incorrectly changing the insulin cartridges. 107 complaints were submitted to the FDA as serious injury Medical Device Reports for severe hypoglycemia or intervention required to prevent severe hypoglycemia. Your firm's User-Related Risk Analysis, RA000021, identified that use errors with the iLet Bionic Pancreas System could trigger unintended insulin doses potentially large enough to cause death (classified as the highest risk level, Severity \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Despite this identified safety risk, your firm closed 56 related complaints without implementing corrective actions to address the identified use errors or documenting justification for why corrective actions were deemed unnecessary.\u003C\u002Fp>\u003Cp>ii. Your firm conducts complaint trending through your risk management procedure, Risk Management Review, SOP 14.1, Rev B, Release Date 2023-03-13, to determine if escalation to corrective and preventive action (CAPA) is warranted. Your firm’s complaint trending process is inadequate, in that:\u003Cbr>a. Inconsistencies were observed between what your firm claims to analyze versus what is documented in your trending analysis. For example:\u003C\u002Fp>\u003Cp>1. Your firm’s complaint trending provided uses “As Reported Complaint Code: Term” and the part of the system (e.g., iLet device, luer connector, cartridge, etc.), but it does not trend complaints by “Complaint Conclusion” unless there was an associated MDR. Your firm’s Vice President of Quality Assurance stated that they also look at complaint conclusions on everything (with the exception of “not our product”) but that it was just not in the presentation.\u003C\u002Fp>\u003Cp>2. Multiple codes with identical or nearly identical meanings were found (e.g., \"Use Error – User Did Not Announce Meals\" vs. \"User Error – Did Not Announce Meals\"). Similar codes could dilute trending data for specific complaint types like meal announcements.\u003C\u002Fp>\u003Cp>b. Your firm uses multiple trending rates for complaint analysis that could lead to underestimation of meal announcement complaint rates, potentially affecting safety signals and risk assessment accuracy. For example: Your firm’s complaint trending uses trending rates, such as quantity of complaints per month and as a percentage of the total iLet shipments within a given time period. Your firm’s Vice President of Quality Assurance explained that they also use rates per opportunity. For example, users have approximately ten (10) opportunities to change their cartridge per month, so your firm will trend the percentage by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. A second example is that users have approximately 90 opportunities to meal announce (three times a day over 30 days), so your firm will trend the same as previous except \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your trending rate for meal announcements (90 per month) is not representative of all users’ eating habits and as such might be affecting the rate at which your firm is trending meal announcement related complaints. In addition, your firm’s instructions state that “If you eat a very low carb diet or no carbs at all, you should not announce meals.”\u003C\u002Fp>\u003Cp>B. Your firm's verification of effectiveness (VOE) for CAPA 0050 is inadequate, in that, it tested \u003Cstrong>(b)(4)\u003C\u002Fstrong> employees on updated training materials, rather than actual iLet users, which was not representative of user population base (e.g. people 6 years of age or older with diabetes mellitus). Additionally, your CAPA 0050 does not address the allegations of hypoglycemia during the adaptation phase of initial use of the iLet.\u003C\u002Fp>\u003Cp>Your firm opened CAPA 0050 to investigate hypoglycemia allegations during the iLet Bionic Pancreas System's initial adaptation phase. Your firm determined that the root cause was users' inadequate understanding of diabetes management while using the device, leading to maladaptive behaviors and misuses. Your firm documented the related misuses in RA000021, Rev. E, User-Related Risk Analysis. Your firm initiated preventive actions for CAPA 0050, to include: 1) Holding office hours for health care providers; 2) Improving user training materials; 3) Creating information materials for users transitions from hybrid closed-loop systems and for users new to pump therapy; and 4) Improving guidance materials for health care providers.\u003C\u002Fp>\u003Cp>Additionally, Section 2.8.3 of your firm's corrective and preventive action procedure, Corrective and Preventive Actions, SOP05, Rev H, Release Date 2024-01-09, and section 1.1 of your firm’s work instruction, CAPA Process, WI000053, Rev C, Release Date 2024-01-09, state that an independent investigator and not the CAPA owner is responsible for executing the verification of effectiveness plan and documenting such activity. However, your firm’s CAPA owner also completed the verification of effectiveness activities for CAPA 0050.\u003C\u002Fp>\u003Cp>C. Your firm’s procedure, Corrective and Preventive Actions, SOP05, Revs G – I, states that CAPA requests are warranted for systemic issues that affect the quality of products or services, especially if: an incident caused injury or death; there are multiple occurrences of the same event, typically three within a rolling \u003Cstrong>(b)(4)\u003C\u002Fstrong> period; or a risk assessment identifies the issue as critical. Your firm failed to maintain records to demonstrate that the cause of nonconformities was investigated; the appropriate action(s) needed to correct and prevent recurrence of nonconforming product were identified; actions taken were verified or validated to ensure the actions were effective and did not adversely affect the products; changes in methods and procedures were implemented; and that information related to the nonconforming products was disseminated to those directly responsible for assuring the quality of the products or prevention of such products.\u003C\u002Fp>\u003Cp>Specifically, investigators observed 15 complaints (dated from July 2023 – December 2023) reporting damaged pump displays, where your firm's product evaluation confirmed the screens were bowed or delaminated. Per your firm’s System Risk Analysis, iLet Bionic Pancreas System, DeLorean (Insulin), RA000005, the risk to patients from being unable to read the display can result in hyper or hypoglycemia and is assigned a Severity of \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Life-threatening serious injury that requires emergency professional medical intervention). Your firm implemented design changes to address these nonconformities (adding Vent to housing to vent internal volume of iLet to ambient pressure, per QP000171); however, no records were maintained to document any corrective actions or reference to CAPA records.\u003C\u002Fp>\u003Cp>D. Your firm failed to adequately document its investigation into device failures due to 5-minute delayed glucose readings instead of real-time data. Your associated Health Hazard Analysis, HHA-2024-002, dated 04\u002F12\u002F2024, states that this issue could potentially lead to the basal and\u002For correction controller not increasing insulin dosing for high or upward trending Continued Glucose Monitoring (CGM) values or the basal controller not reducing or suspending insulin based on downward trending CGM values. Reportedly, this issue was investigated in collaboration with your CGM supplier, resulting in your firm implementing a temporary software change on 04\u002F05\u002F2024 to mitigate patient risks, while your supplier implemented a permanent solution, however, your firm failed to document this investigation.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses dated July 18, 2025, August 29, 2025, and October 29, 2025, and conclude that they are not adequate. Your firm's assessment conducted in CAPA 0061 - CAPA VoE Review states, in relation to CAPA-0050, that the Verification of Effectiveness (VoE) was appropriate because it directly measured users' understanding after updated training, addressing the identified root cause, user knowledge gaps. The 100% pass rate on the assessment demonstrates that the revised training effectively improved comprehension related to safe iLet use. However, your firm also indicated in your response that you updated your VoE plan for CAPA-0050 and established a new plan to evaluate CGM-measured percent median time below 54 mg\u002FdL in the user population before and after corrective measures implementation. Your success criteria was established as a \u003Cstrong>(b)(4)\u003C\u002Fstrong>% or greater reduction in percent median time below 54 mg\u002FdL, which you state would indicate effectiveness of the corrective measures. Supporting evidence of new CAPA-0050 Verification of Effectiveness (VoE) plan was not provided. The root cause determination and verification of effectiveness criteria for CAPA-0050 is deficient in that it fails to distinguish between system design issues versus user training deficiencies and subsequently the preventive actions were solely focused on training improvements without addressing potential device design issues. It is not clear if an evaluation was made of whether the iLet's design of device (e.g. user interface, alert systems, or other potential design issues) could have contributed to maladaptive behaviors.\u003C\u002Fp>\u003Cp>2. Failure to adequately establish and maintain procedures for validating the device design to include an adequate risk analysis, as required by 21 CFR 820.30(g). For example:\u003C\u002Fp>\u003Cp>Your firm’s risk management procedure, Risk Management Review, SOP 14.1, Rev B, Release Date: 2023-03-13 states in Sections 1.2 – 1.3 that the Head of QA has overall responsibility for collecting and reporting post market feedback information to management to determine if the product is performing within the risk profile as determined by the products risk management documentation. The following sources provide information that is assessed against the associated risk management documentation: Management Review, Design Testing (non-clinical), Regulatory affairs information pertinent to the bionic pancreas, Nonconforming Material Reports (NCMRs), Manufacturing Data (e.g., yields), Complaints, Health Hazard Assessments, Competitor Information, Published Literature, Customer Feedback including surveys, Clinical Investigations and Follow up. The review of design, production and post market surveillance data and its assessment against the risk profiles per the related risk management documentation shall occur \u003Cstrong>(b)(4)\u003C\u002Fstrong>, at a minimum.\u003C\u002Fp>\u003Cp>Your firm's System Risk Analysis, RA000005, for your iLet Bionic Pancreas, failed to include post-market risks identified through your firm’s complaint data, as required by your procedure. Specifically,\u003C\u002Fp>\u003Cp>A. Your firm has failed to incorporate known post-market safety data into your risk management processes.\u003C\u002Fp>\u003Cp>i. Investigators observed \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints, dated October 2024 – June 2025, reporting various malfunctions of the iLet Bionic Pancreas Model TA000036 caused by failure of the devices’ printed circuit board assembly manufactured by a supplier. Your firm’s risk analysis does not assess, or control identified hardware hazards.\u003Cbr>ii. Investigators observed two complaints, received on 02\u002F07\u002F2024, and 01\u002F01\u002F2025, reporting over infusion of insulin resulting in severe hypoglycemia or hypoglycemia requiring medical intervention where the users reported involuntary meal announcements. Your firm’s risk analysis fails to assess hypoglycemia risk from involuntary meal announcements.\u003C\u002Fp>\u003Cp>B. Your firm’s risk management procedure, Risk Management Review, SOP 14.1, Rev B, Release Date: 2023-03-13 states in Section 4 – Unanticipated Risks that as a result of the risk management assessment per this SOP, any unanticipated events are assessed based upon the severity and occurrence of the associated harm and hazard. This assessment includes a review of prior Design Verification Testing (DVT) and\u002For Process Validation activities to verify potential, applicable risk mitigations previously established. Rationale for non-escalation shall be documented in the RMRR and approved by the Head of Quality.\u003C\u002Fp>\u003Cp>Your firm has identified a hazard; however, the risk control implementation and validation are absent in your firm’s risk analysis. Specifically,\u003C\u002Fp>\u003Cp>Complaint # COM-0000000790 was reviewed reporting a patient with dementia gave themselves multiple successive meal boluses, although they were not eating. The following morning the patient’s blood glucose was 40 mg\u002Fdl. The caregiver attempted to wake the patient, but the patient was unresponsive. While your firm’s System Risk Analysis identifies that vulnerable populations (patients with diminished capacity), might be making inappropriate therapy decisions, resulting in hyper or hypo glycemia, your risk analysis fails to: 1) Document any risk control measures to address this specific hazard; 2) Demonstrate calculation of post-mitigation risks; 3) Show how the identified risk is being adequately controlled.\u003C\u002Fp>\u003Cp>C. Despite approximately 529 complaints reporting insulin cartridges or cartridge connectors leaking while in use, your firm's System Risk Analysis, RA000005, for the iLet Bionic Pancreas does not evaluate the risk to patients from cartridges and cartridge connectors leaking during use.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses dated July 18, 2025, August 29, 2025, and October 29, 2025, and conclude that they are not adequate. Your firm’s response states that you plan to update your risk management procedures; however, it does not address whether and how data sources from your firm’s quality system, such as complaints, CAPAs, nonconforming product, etc., will interface with your firm’s risk analysis process to determine if further corrective actions or regulatory decisions are required.\u003C\u002Fp>\u003Cp>3. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\u003C\u002Fp>\u003Cp>A. Your firm failed to adequately investigate complaints involving the possible failure of a device, labeling, or packaging to meet any of its specifications. For example:\u003C\u002Fp>\u003Cp>i. Investigators review of complaint data from June 2023 – June 2025 found over 500 complaints reporting iLet Bionic Pancreas system insulin cartridges or cartridge connectors leaking. The System Risk Analysis, iLet Bionic Pancreas System, DeLorean (Insulin), RA000005, does not identify the risk to patient from cartridge\u002Fconnector leaks leading to under delivery of insulin to patients; however, the Risk Analysis identifies the risk of system under-delivery of drug resulting in hyper or hypo glycemia due to administration sets leaking as Critical - Results in permanent impairment of life-threatening injury.\u003C\u002Fp>\u003Cp>Your firm did not adequately address 31 complaints relating to cartridge or connector leaking. Specifically, your firm closed these complaints without investigation, concluding that no product deficiencies or defects were indicated, and that the complaints did not warrant an investigation. Additionally, by not investigating these product failures, your firm failed to recognize safety risks that could cause adverse events. For example, 18 of the 31 complaints (e.g., COM-0000007869, COM-0000007398, and COM-0000007157) reported that patients experienced hyperglycemic health effects.\u003C\u002Fp>\u003Cp>ii. Investigators observed that your firm failed to adequately investigate 21 complaints involving bent cannulas or infusion set failures associated with reports of diabetic ketoacidosis (DKA). Your iLet Bionic Pancreas System is distributed to customers with Convatec Inset and Contact Detach infusion sets manufactured for you by your infusion set supplier. Your firm is responsible for intake of complaints for the infusion sets and forwarding them to Convatec. Review of your complaint data shows that approximately 33% of the complaints in your complaint database are related to failure of the infusion sets, with the top failures reported as bent cannula, adhesive issues, and infusion set failures, and with 99.7% of the affected sets not returned by the customers. However, your firm did not request the sets to be returned for further investigation by your infusion set supplier.\u003C\u002Fp>\u003Cp>B. Your firm failed to implement and maintain adequate complaint files, per your procedures.\u003C\u002Fp>\u003Cp>Specifically, investigators observed that your firm had not adequately implemented your complaint handling procedure, Product Complaints, SOP13, Rev H, Release Date 2023-01-28, which requires review of all reported product experiences within \u003Cstrong>(b)(4)\u003C\u002Fstrong> to determine if they constitute a complaint. \u003Cstrong>(b)(4)\u003C\u002Fstrong> is the electronic quality management system, used by your firm. Your firm’s work instruction, WI000085, provides instructions for completing the product complaint process. Section 6 of work instruction WI000085, Revs A-C, state that if a complaint was created via \u003Cstrong>(b)(4)\u003C\u002Fstrong> (e.g., Case), various fields such as Event as Reported, Event Date, Aware Date, etc. will be auto filled into \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It also describes how new complaints can be directly entered into \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>For example, your firm did not adequately address a user reported hyperglycemic event, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Case 00015304, involving your iLet device. Specifically, on June 3, 2024, a user reported hyperglycemic event requiring emergency room treatment and insulin administration. On June 5, 2024, the user provided additional details including blood glucose reached 476 mg\u002Fdl, stayed high for over 4 hours, and patient developed diabetic ketoacidosis (DKA). On June 5, 2024, your firm closed the case without proper evaluation to determine if it required escalating to a product complaint or if it required reporting. Your firm’s Vice President of Quality Assurance confirmed this was a complaint on June 11, 2025.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time, as corrective actions are ongoing. Your firm has committed to implementing a new complaint handling system by October 29, 2025. Corrective actions, such as a retrospective review of complaints, are ongoing, and your firm did not provide complete evidence of implementation of your new complaint handling system. Without this documentation in hand, FDA cannot make an assessment with respect to adequacy. Please continue to send updates regarding the implementation of your corrective actions.\u003C\u002Fp>\u003Cp>4. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements, as required by 21CFR 820.90(a). For example:\u003C\u002Fp>\u003Cp>Your firm failed to adequately control product that does not conform to specified requirements. Firm's procedure for controlling nonconforming product is SOP09, Nonconformance Reporting.\u003C\u002Fp>\u003Cp>Nonconformance Report NCR #191 was opened after 61 out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> iLet Bionic Pancreas printed circuit board assembly (PCBA) Mainboards failed testing due to faulty \u003Cstrong>(b)(4)\u003C\u002Fstrong> connections. Your firm claimed to have investigated with their supplier, your Vice President of Quality Assurance acknowledged that this investigation was not documented, and no corrective action was taken from the supplier, because this was considered a first-time issue. Your firm later received 19 customer complaints related to iLet Bionic Pancreas Model TA000036 failures caused by defective PCBA Mainboards with improperly installed compone\u003Ca>nts.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses dated July 18, 2025, August 29, 2025, and October 29, 2025, and conclude that they are not adequate. Your firm’s CAPA 0064 NCR\u002FSCAR Review table shows instances where your firm has decided no SCAR is to be opened. The justifications for the following instances are inadequate:\u003C\u002Fp>\u003Cul>\u003Cli>Components no longer active (\u003Cem>i.e. Component is no longer active in current iLet (TA000048) configuration\u003C\u002Fem>). It is not clear if these non-conformances still being tracked and adequately investigated. Your response does not address if there are devices in the field that still contain this component or if the supplier still provides components that are active. There are repeated instances in table where the same supplier has sent mixed lots of components, manufactured to incorrect part number or sent mislabeled components, but no SCARs were issued.\u003C\u002Fli>\u003Cli>Component manufactured to incorrect Part Number or Revision (\u003Cem>i.e. the components were found manufactured to the incorrect part number. […] No SCAR will be issued as the parts were manufactured using equivalent materials. […] No additional NCRs were issued for a similar incident.\u003C\u002Fem>)\u003C\u002Fli>\u003Cli>Damage during transportation (\u003Cem>i.e. Damage to external shippers\u003C\u002Fem>). It is not clear if these non-conformances still being tracked and adequately investigated.\u003C\u002Fli>\u003Cli>Typographical errors (\u003Cem>i.e. Expiration Date on CoC was incorrect. […] The incorrect expiration on the CoC was a typographical error. The CoC was updated to the correct expiration date that was stated on the product.\u003C\u002Fem>)\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection also revealed that your firm’s iLet Dosing Decision Software and the iLet ACE Pump are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i. 21 CFR Part 803 - Medical Device Reporting was promulgated under section 519 of the Act, among other provisions. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to report to the FDA the information required by 21 CFR 803.52 in accordance with the requirements of § 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1). Manufacturers should submit a separate report for each device that it markets that may have caused or contributed to a death or serious injury. For example,\u003C\u002Fp>\u003Cp>A. The information included for Complaint COM-0000008592 describes an event in which a patient experienced hyperglycemia and chest pains while using your firm’s iLet Dosing Decision Software and was subsequently treated with IV fluids and Insulin. The IV fluids rehydrated the patient and corrected electrolyte imbalances, while IV insulin provided a way to lower the high blood sugar (hyperglycemia). If left untreated, chronic hyperglycemia can lead to diabetes complications, such as cardiovascular disease, nerve damage, eye disease and kidney damage. Based on the information included for the complaint and the medical intervention given to the patient, we determined that your firm’s device may have caused or contributed to a serious injury as defined by 21 CFR 803.3(w)(3). The medical intervention was necessary to preclude permanent impairment of a body function or permanent damage to a body structure. Therefore, this event meets the definition of a MDR reportable event under 21 CFR 803.3(o)(2)(i) because the serious injury was or may have been attributed to the iLet Dosing Decision Software, or the iLet Dosing Decision Software was or may have been a factor in a serious injury. Your firm became aware of the event on August 19, 2024, when you acquired the information in this complaint that reasonably suggested a reportable event had occurred. However, no MDR was\u003C\u002Fp>\u003Cp>B. The information included for Complaints COM-0000025536, COM-0000026475, COM-0000026763, COM-0000003142 and COM-0000005866 describe adverse events in which patients experienced hypoglycemia with blood sugar levels below 70 mg\u002FdL, while using your firm’s iLet Dosing Decision Software, and were treated with glucose drink or candies to raise their blood glucose level. We determined that treatment for hypoglycemia that includes glucose drinks or candies is a medical intervention necessary to preclude permanent impairment of a body function or permanent damage to a body structure because, if left untreated, hypoglycemia can lead to confusion, shakiness, dizziness, and weakness, but if severe and untreated, it can progress to serious complications like seizures, loss of consciousness (fainting), brain damage, coma, and even death. Repeated episodes can also cause reduced cognitive function, cardiovascular issues, and increased risk for future severe lows. Therefore, based on the information included for the complaints involving your firm’s device and the medical intervention given to the patients, we determined that your firm’s device may have caused or contributed to a serious injury as defined by 21 CFR 803.3(w)(3). Each of these events therefore meet the definition of an MDR reportable event under 21 CFR 803.3(o)(2)(i) because the serious injury was or may have been attributed to the iLet Dosing Decision Software, or the iLet Dosing Decision Software was or may have been a factor in a serious injury. Your firm became aware of the information included for Complaint COM-0000025536, which reasonably suggests a reportable event has occurred, on April 23, 2025, and FDA received the corresponding MDR 3019004087-2025-00443 on July 14, 2025, which exceeds the required 30-calendar day timeframe in 21 CFR 803.50(a). Your firm became aware of the information included for Complaint COM-0000026475, which reasonably suggests a reportable event has occurred, on April 30, 2025, and FDA received the corresponding MDR 3019004087-2025-00461 on July 9, 2025, which exceeds the required 30-calendar day timeframe. Your firm became aware of the information corresponding to Complaint COM-0000026763, which reasonably suggests a reportable event has occurred, on May 3, 2025, and FDA received the corresponding MDR 3019004087-2025-00581 on June 10, 2025, which exceeds the required 30-calendar day timeframe. Your firm became aware of the information corresponding to Complaint COM-0000003142, which reasonably suggests a reportable event has occurred, on April 1, 2024, and FDA has not yet received an MDR. Your firm became aware of the information included for Complaint COM-0000005866 on June 20, 2024, however, FDA has not yet received an MDR.\u003C\u002Fp>\u003Cp>2. Failure to report to FDA the information required by 21 CFR 803.52 in accordance with the requirements of § 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003C\u002Fp>\u003Cp>For example, the information included for complaints COM-0000004919, COM-0000008065 and COM-0000008452 reasonably suggests that the firm’s iLet ACE Pump malfunctioned (e.g. component failures: memory chips,) while in use, meaning the device failed to meet its performance specifications or otherwise perform as intended under 21 CFR 803.3(k). Specifically, complaint COM-0000004919 describes an “Alert 60 - Bluetooth Communication” error, complaint COM-0000008065 describes a “Touchscreen unresponsive” error, and complaint COM-0000008452 describes a sleep\u002Fwake button unresponsive” error. Although the malfunction alerts reference different alert codes, each malfunction is associated with a defective hoverboard. A device malfunction that is associated with a defective hoverboard has previously resulted in a patient sustaining a serious injury. (Refer to complaint COM-0000003142). This prior incident demonstrates that such a malfunction (i.e., one that is associated with a defective hoverboard) is linked to a serious injury. It is reasonable to conclude that a recurrence of these malfunctions that are associated with a defective hoverboard would therefore be likely to cause or contribute to a serious injury. As such, the malfunctions listed in these complaints represent MDR reportable events for which MDRs must be submitted. Your firm became aware of Complaint COM-0000004919 on 5\u002F25\u002F2024, Complaint COM-0000008065 on 8\u002F8\u002F2024 and Complaint COM-0000008065 on 8\u002F8\u002F2024 however, based on our records, FDA has not yet received an MDR for each of the referenced malfunction events.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response dated July 18, 2025, cannot be determined at this time. In the response, your firm noted it initiated corrective actions to address the reporting issue, including a retrospective review of complaints received since June 2023. However, documentation of these corrective actions was not provided, as they are still ongoing.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response dated August 28, 2025, cannot be determined at this time. Your firm’s response dated August 28, 2025, is a periodic update and did not include any additional new information.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response dated October 29, 2025, cannot be determined at this time. Your firm’s response dated October 29, 2025, noted that your firm has a three-phase plan to address the reporting issue. However, documentation of the completion of these corrective actions was not provided, as they are still ongoing.\u003C\u002Fp>\u003Cp>In addition, the inspection revealed that your firm failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17(a)(1). For example, during the inspection, your firm presented a document titled “Guidelines for FDA Reporting”, SOP 13.1, Rev. A, dated 2023-10-23, as its MDR procedure. After reviewing the procedure, we conclude that the procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, there are inadequate definitions of what constitutes a reportable event under 21 CFR Part 803. The fact that the procedure does not include a definition from 21 CFR 803.3 for the term “cause or contributed” may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\u003Cp>Your firm’s response dated August 28, 2025, appears to be adequate. In the response, your firm included a copy of its revised MDR procedure titled “Guidelines for FDA Reporting”, Documents Number: SOP 13.1, Rev. B, dated 2025-07-16, along with staff training records. Upon review, the revised procedures have adequately addressed the deficiency described above.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Corrections and Removals Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection also revealed that your firm’s iLet Dosing Decision Software and the iLet ACE Pump are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i. 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals was promulgated under section 519 of the Act, among other provisions. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit to the FDA within 10 working days of initiating a correction or removal a report required by 21 CFR 806.10. For example:\u003C\u002Fp>\u003Cp>A. Your firm discovered that the iLet Dosing Decision Software had failures regarding glucose values that were 5 minutes old (delayed readings), instead of using new readings as expected. The iLet Dosing Decision Software autonomously determines and commands an increase, decrease, maintenance, or suspension of all basal doses of insulin and autonomously determines and commands correction doses of insulin based on glucose readings, and it autonomously determines, and commands meal doses of insulin based on meal announcements. Use of the delayed glucose readings resulted in your iLet Dosing Decision Software not performing as intended, not dosing insulin to the patient and patient experiencing elevated blood glucose levels that presents a risk to health. Your firm implemented a software change\u002Frelease version 1.4.4 to mitigate the risk to health posed by your iLet Dosing Decision Software. The new software version was uploaded to the cloud and made available to the customers for download on 4\u002F5\u002F2024. This action constitutes a medical device correction or removal initiated to reduce a risk to health posed by your device or remedy a violation of the Act caused by your device which may present a risk to health, under 21 CFR 806.10(a). You have not already provided this information as set forth in 21 CFR 806.10(f) (see 21 CFR 806.10(a)(2)), nor was the correction or removal action exempt from the reporting requirements under 21 CFR 806.1(b) (see 21 CFR 806.10(a)(2)). You were therefore required to submit a Report of Correction or Removal to FDA within 10 working days of initiation, under 21 CFR 806.10(b).\u003C\u002Fp>\u003Cp>B. Your firm discovered that the iLet ACE Pump had cybersecurity vulnerability for the Limited Access feature of the iLet Bionic Pancreas System, which is used as a security measure to prevent unwanted access to the pump controls. When either the lockscreen or Limited Access Passcode screen is viewed on the iLet display, other icons are present and active, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This results in unsecured access to change settings, including stopping insulin delivery or giving boluses inappropriately, both of which present a risk to health. Your firm implemented a software fix via DCO #3203 and released Software Version 1.4.3 on 3\u002F26\u002F2024. Beta Bionics sent an email to all customers on 4\u002F1\u002F2024, titled “iLet Software Update”, notifying them that Beta Bionics, Inc. released an iLet Bionic Pancreas Software update. This action constitutes a medical device correction or removal initiated to reduce a risk to health posed by the device or remedy a violation of the Act caused by the device which may present a risk to health, under 21 CFR 806.10(a). You have not already provided this information as set forth in 21 CFR 806.10(f) (see 21 CFR 806.10(a)(2)), nor was the correction or removal action exempt from the reporting requirements under 21 CFR 806.1(b) (see 21 CFR 806.10(a)(2)). You were therefore required to submit a Report of Correction or Removal to FDA within 10 working days of initiation, under 806.10(b).\u003C\u002Fp>\u003Cp>Your firm’s responses to the FDA-483, dated July 18, 2025, August 29, 2025, and October 29, 2025, are not adequate. For the issue related to delayed glucose readings described in paragraph A above, you categorized your action as a device enhancement, stating that the change was to improve a non-violative device’s safety or performance. Even if you categorized the software update as a “device enhancement,” the evidence still indicates that a report of correction or removal was required to have been submitted to FDA because you initiated the correction (i.e., updated the software) in order to reduce a risk to health posed by the device (i.e., inaccurate insulin dosing). The fact that the issue might have also involved a third-party CGM does not change the fact that you initiated the correction to reduce a risk to health posed by your device. Furthermore, there is no evidence that you designed and tested the iLet device to function with the particular CGM at issue.\u003C\u002Fp>\u003Cp>For the issue related to the cybersecurity vulnerability for the Limited Access feature described in paragraph B above, your firm alleges that the issue is non-reportable. We do not agree with this assessment. The evidence indicates that a report of correction or removal was required to have been submitted to FDA because you initiated the correction (i.e., updated the software) in order to reduce a risk to health posed by the device (i.e., prevent unsecured access to the pump controls).\u003C\u002Fp>\u003Cp>In addition, regarding your statement that your firm was conducting a Class III recall, we note that a recall’s classification is assigned by FDA, not the recalling firm (e.g., 21 CFR 7.3(m) and 7.41(b)), and that conducting a voluntary recall does not exempt a firm from the requirement to submit a report of correction or removal under Part 806 (e.g., 21 CFR 806.10(a)(2)). As explained above, you were required to submit a report of correction or removal to FDA.\u003C\u002Fp>\u003Cp>You have not submitted Reports of Correction or Removal to FDA as of 01\u002F15\u002F2026 for either of the failures listed above.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “\u003Cstrong>CMS Case 717927\u003C\u002Fstrong>” when replying. If you have any questions about the contents of this letter, please contact: Shaquenta Perkins at shaquenta.perkins@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or concerning your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden\u003Cbr>Acting Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nSean Saint\n\nRecipient Title\n\nChief Executive Officer\n\nBeta Bionics, Inc.\n\n11 Hughes\n\nIrvine, CA 92618\n\nUnited States\n\n(b)(6)@betabionics.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS #717927\nJanuary 28, 2026\nDear Mr. Saint:\nDuring an inspection of your firm located in Irvine, CA from June 9, 2025, through June 26, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the iLet Dosing Decision Software and the iLet ACE Pump, which are part of the iLet Bionic Pancreas System. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received responses from Neal Grant, Director, Quality Systems dated July 18, 2025, August 29, 2025, and October 29, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to adequately establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a). For example:\nA. Your firm failed to adequately analyze quality data, such as complaints, to identify existing and potential causes of nonconforming product or other quality problems and utilize appropriate statistical methodology to detect recurring quality problems. For example:\ni. Your firm failed to implement corrective and preventive actions (CAPA) for complaints related to device malfunctions that led to serious adverse health outcomes, as required by Section 6.1.3 (Section 1.4 of Revs G and H) of your firm's corrective and preventive action procedure, Corrective and Preventive Actions, SOP05, Rev I, Section 6.1 (Section 6.6 of Rev I) of the firm's complaint handling procedure, Product Complaints, SOP13, Rev H, and Section 9 (Section 6.9 Rev I) of the firm's complaint handling procedure, Product Complaints, SOP13, Rev H.\na. Investigators observed (b)(4) complaints reporting Faulty Motors, including one reporting the patient suffered Diabetic Ketoacidosis, confirmed by your firm to be device malfunctions, where you took no corrective actions and provided no justification for inaction, despite identified safety risks.\nb. Investigators observed (b)(4) complaints reporting hypoglycemic episodes that were attributed to Use Error – Unintended Insulin Delivery associated with the patients’ incorrectly changing the insulin cartridges. 107 complaints were submitted to the FDA as serious injury Medical Device Reports for severe hypoglycemia or intervention required to prevent severe hypoglycemia. Your firm's User-Related Risk Analysis, RA000021, identified that use errors with the iLet Bionic Pancreas System could trigger unintended insulin doses potentially large enough to cause death (classified as the highest risk level, Severity (b)(4)). Despite this identified safety risk, your firm closed 56 related complaints without implementing corrective actions to address the identified use errors or documenting justification for why corrective actions were deemed unnecessary.\nii. Your firm conducts complaint trending through your risk management procedure, Risk Management Review, SOP 14.1, Rev B, Release Date 2023-03-13, to determine if escalation to corrective and preventive action (CAPA) is warranted. Your firm’s complaint trending process is inadequate, in that:\na. Inconsistencies were observed between what your firm claims to analyze versus what is documented in your trending analysis. For example:\n1. Your firm’s complaint trending provided uses “As Reported Complaint Code: Term” and the part of the system (e.g., iLet device, luer connector, cartridge, etc.), but it does not trend complaints by “Complaint Conclusion” unless there was an associated MDR. Your firm’s Vice President of Quality Assurance stated that they also look at complaint conclusions on everything (with the exception of “not our product”) but that it was just not in the presentation.\n2. Multiple codes with identical or nearly identical meanings were found (e.g., \"Use Error – User Did Not Announce Meals\" vs. \"User Error – Did Not Announce Meals\"). Similar codes could dilute trending data for specific complaint types like meal announcements.\nb. Your firm uses multiple trending rates for complaint analysis that could lead to underestimation of meal announcement complaint rates, potentially affecting safety signals and risk assessment accuracy. For example: Your firm’s complaint trending uses trending rates, such as quantity of complaints per month and as a percentage of the total iLet shipments within a given time period. Your firm’s Vice President of Quality Assurance explained that they also use rates per opportunity. For example, users have approximately ten (10) opportunities to change their cartridge per month, so your firm will trend the percentage by (b)(4). A second example is that users have approximately 90 opportunities to meal announce (three times a day over 30 days), so your firm will trend the same as previous except (b)(4). Your trending rate for meal announcements (90 per month) is not representative of all users’ eating habits and as such might be affecting the rate at which your firm is trending meal announcement related complaints. In addition, your firm’s instructions state that “If you eat a very low carb diet or no carbs at all, you should not announce meals.”\nB. Your firm's verification of effectiveness (VOE) for CAPA 0050 is inadequate, in that, it tested (b)(4) employees on updated training materials, rather than actual iLet users, which was not representative of user population base (e.g. people 6 years of age or older with diabetes mellitus). Additionally, your CAPA 0050 does not address the allegations of hypoglycemia during the adaptation phase of initial use of the iLet.\nYour firm opened CAPA 0050 to investigate hypoglycemia allegations during the iLet Bionic Pancreas System's initial adaptation phase. Your firm determined that the root cause was users' inadequate understanding of diabetes management while using the device, leading to maladaptive behaviors and misuses. Your firm documented the related misuses in RA000021, Rev. E, User-Related Risk Analysis. Your firm initiated preventive actions for CAPA 0050, to include: 1) Holding office hours for health care providers; 2) Improving user training materials; 3) Creating information materials for users transitions from hybrid closed-loop systems and for users new to pump therapy; and 4) Improving guidance materials for health care providers.\nAdditionally, Section 2.8.3 of your firm's corrective and preventive action procedure, Corrective and Preventive Actions, SOP05, Rev H, Release Date 2024-01-09, and section 1.1 of your firm’s work instruction, CAPA Process, WI000053, Rev C, Release Date 2024-01-09, state that an independent investigator and not the CAPA owner is responsible for executing the verification of effectiveness plan and documenting such activity. However, your firm’s CAPA owner also completed the verification of effectiveness activities for CAPA 0050.\nC. Your firm’s procedure, Corrective and Preventive Actions, SOP05, Revs G – I, states that CAPA requests are warranted for systemic issues that affect the quality of products or services, especially if: an incident caused injury or death; there are multiple occurrences of the same event, typically three within a rolling (b)(4) period; or a risk assessment identifies the issue as critical. Your firm failed to maintain records to demonstrate that the cause of nonconformities was investigated; the appropriate action(s) needed to correct and prevent recurrence of nonconforming product were identified; actions taken were verified or validated to ensure the actions were effective and did not adversely affect the products; changes in methods and procedures were implemented; and that information related to the nonconforming products was disseminated to those directly responsible for assuring the quality of the products or prevention of such products.\nSpecifically, investigators observed 15 complaints (dated from July 2023 – December 2023) reporting damaged pump displays, where your firm's product evaluation confirmed the screens were bowed or delaminated. Per your firm’s System Risk Analysis, iLet Bionic Pancreas System, DeLorean (Insulin), RA000005, the risk to patients from being unable to read the display can result in hyper or hypoglycemia and is assigned a Severity of (b)(4) (Life-threatening serious injury that requires emergency professional medical intervention). Your firm implemented design changes to address these nonconformities (adding Vent to housing to vent internal volume of iLet to ambient pressure, per QP000171); however, no records were maintained to document any corrective actions or reference to CAPA records.\nD. Your firm failed to adequately document its investigation into device failures due to 5-minute delayed glucose readings instead of real-time data. Your associated Health Hazard Analysis, HHA-2024-002, dated 04\u002F12\u002F2024, states that this issue could potentially lead to the basal and\u002For correction controller not increasing insulin dosing for high or upward trending Continued Glucose Monitoring (CGM) values or the basal controller not reducing or suspending insulin based on downward trending CGM values. Reportedly, this issue was investigated in collaboration with your CGM supplier, resulting in your firm implementing a temporary software change on 04\u002F05\u002F2024 to mitigate patient risks, while your supplier implemented a permanent solution, however, your firm failed to document this investigation.\nWe reviewed your firm’s responses dated July 18, 2025, August 29, 2025, and October 29, 2025, and conclude that they are not adequate. Your firm's assessment conducted in CAPA 0061 - CAPA VoE Review states, in relation to CAPA-0050, that the Verification of Effectiveness (VoE) was appropriate because it directly measured users' understanding after updated training, addressing the identified root cause, user knowledge gaps. The 100% pass rate on the assessment demonstrates that the revised training effectively improved comprehension related to safe iLet use. However, your firm also indicated in your response that you updated your VoE plan for CAPA-0050 and established a new plan to evaluate CGM-measured percent median time below 54 mg\u002FdL in the user population before and after corrective measures implementation. Your success criteria was established as a (b)(4)% or greater reduction in percent median time below 54 mg\u002FdL, which you state would indicate effectiveness of the corrective measures. Supporting evidence of new CAPA-0050 Verification of Effectiveness (VoE) plan was not provided. The root cause determination and verification of effectiveness criteria for CAPA-0050 is deficient in that it fails to distinguish between system design issues versus user training deficiencies and subsequently the preventive actions were solely focused on training improvements without addressing potential device design issues. It is not clear if an evaluation was made of whether the iLet's design of device (e.g. user interface, alert systems, or other potential design issues) could have contributed to maladaptive behaviors.\n2. Failure to adequately establish and maintain procedures for validating the device design to include an adequate risk analysis, as required by 21 CFR 820.30(g). For example:\nYour firm’s risk management procedure, Risk Management Review, SOP 14.1, Rev B, Release Date: 2023-03-13 states in Sections 1.2 – 1.3 that the Head of QA has overall responsibility for collecting and reporting post market feedback information to management to determine if the product is performing within the risk profile as determined by the products risk management documentation. The following sources provide information that is assessed against the associated risk management documentation: Management Review, Design Testing (non-clinical), Regulatory affairs information pertinent to the bionic pancreas, Nonconforming Material Reports (NCMRs), Manufacturing Data (e.g., yields), Complaints, Health Hazard Assessments, Competitor Information, Published Literature, Customer Feedback including surveys, Clinical Investigations and Follow up. The review of design, production and post market surveillance data and its assessment against the risk profiles per the related risk management documentation shall occur (b)(4), at a minimum.\nYour firm's System Risk Analysis, RA000005, for your iLet Bionic Pancreas, failed to include post-market risks identified through your firm’s complaint data, as required by your procedure. Specifically,\nA. Your firm has failed to incorporate known post-market safety data into your risk management processes.\ni. Investigators observed (b)(4) complaints, dated October 2024 – June 2025, reporting various malfunctions of the iLet Bionic Pancreas Model TA000036 caused by failure of the devices’ printed circuit board assembly manufactured by a supplier. Your firm’s risk analysis does not assess, or control identified hardware hazards.\nii. Investigators observed two complaints, received on 02\u002F07\u002F2024, and 01\u002F01\u002F2025, reporting over infusion of insulin resulting in severe hypoglycemia or hypoglycemia requiring medical intervention where the users reported involuntary meal announcements. Your firm’s risk analysis fails to assess hypoglycemia risk from involuntary meal announcements.\nB. Your firm’s risk management procedure, Risk Management Review, SOP 14.1, Rev B, Release Date: 2023-03-13 states in Section 4 – Unanticipated Risks that as a result of the risk management assessment per this SOP, any unanticipated events are assessed based upon the severity and occurrence of the associated harm and hazard. This assessment includes a review of prior Design Verification Testing (DVT) and\u002For Process Validation activities to verify potential, applicable risk mitigations previously established. Rationale for non-escalation shall be documented in the RMRR and approved by the Head of Quality.\nYour firm has identified a hazard; however, the risk control implementation and validation are absent in your firm’s risk analysis. Specifically,\nComplaint # COM-0000000790 was reviewed reporting a patient with dementia gave themselves multiple successive meal boluses, although they were not eating. The following morning the patient’s blood glucose was 40 mg\u002Fdl. The caregiver attempted to wake the patient, but the patient was unresponsive. While your firm’s System Risk Analysis identifies that vulnerable populations (patients with diminished capacity), might be making inappropriate therapy decisions, resulting in hyper or hypo glycemia, your risk analysis fails to: 1) Document any risk control measures to address this specific hazard; 2) Demonstrate calculation of post-mitigation risks; 3) Show how the identified risk is being adequately controlled.\nC. Despite approximately 529 complaints reporting insulin cartridges or cartridge connectors leaking while in use, your firm's System Risk Analysis, RA000005, for the iLet Bionic Pancreas does not evaluate the risk to patients from cartridges and cartridge connectors leaking during use.\nWe reviewed your firm’s responses dated July 18, 2025, August 29, 2025, and October 29, 2025, and conclude that they are not adequate. Your firm’s response states that you plan to update your risk management procedures; however, it does not address whether and how data sources from your firm’s quality system, such as complaints, CAPAs, nonconforming product, etc., will interface with your firm’s risk analysis process to determine if further corrective actions or regulatory decisions are required.\n3. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\nA. Your firm failed to adequately investigate complaints involving the possible failure of a device, labeling, or packaging to meet any of its specifications. For example:\ni. Investigators review of complaint data from June 2023 – June 2025 found over 500 complaints reporting iLet Bionic Pancreas system insulin cartridges or cartridge connectors leaking. The System Risk Analysis, iLet Bionic Pancreas System, DeLorean (Insulin), RA000005, does not identify the risk to patient from cartridge\u002Fconnector leaks leading to under delivery of insulin to patients; however, the Risk Analysis identifies the risk of system under-delivery of drug resulting in hyper or hypo glycemia due to administration sets leaking as Critical - Results in permanent impairment of life-threatening injury.\nYour firm did not adequately address 31 complaints relating to cartridge or connector leaking. Specifically, your firm closed these complaints without investigation, concluding that no product deficiencies or defects were indicated, and that the complaints did not warrant an investigation. Additionally, by not investigating these product failures, your firm failed to recognize safety risks that could cause adverse events. For example, 18 of the 31 complaints (e.g., COM-0000007869, COM-0000007398, and COM-0000007157) reported that patients experienced hyperglycemic health effects.\nii. Investigators observed that your firm failed to adequately investigate 21 complaints involving bent cannulas or infusion set failures associated with reports of diabetic ketoacidosis (DKA). Your iLet Bionic Pancreas System is distributed to customers with Convatec Inset and Contact Detach infusion sets manufactured for you by your infusion set supplier. Your firm is responsible for intake of complaints for the infusion sets and forwarding them to Convatec. Review of your complaint data shows that approximately 33% of the complaints in your complaint database are related to failure of the infusion sets, with the top failures reported as bent cannula, adhesive issues, and infusion set failures, and with 99.7% of the affected sets not returned by the customers. However, your firm did not request the sets to be returned for further investigation by your infusion set supplier.\nB. Your firm failed to implement and maintain adequate complaint files, per your procedures.\nSpecifically, investigators observed that your firm had not adequately implemented your complaint handling procedure, Product Complaints, SOP13, Rev H, Release Date 2023-01-28, which requires review of all reported product experiences within (b)(4) to determine if they constitute a complaint. (b)(4) is the electronic quality management system, used by your firm. Your firm’s work instruction, WI000085, provides instructions for completing the product complaint process. Section 6 of work instruction WI000085, Revs A-C, state that if a complaint was created via (b)(4) (e.g., Case), various fields such as Event as Reported, Event Date, Aware Date, etc. will be auto filled into (b)(4). It also describes how new complaints can be directly entered into (b)(4).\nFor example, your firm did not adequately address a user reported hyperglycemic event, (b)(4) Case 00015304, involving your iLet device. Specifically, on June 3, 2024, a user reported hyperglycemic event requiring emergency room treatment and insulin administration. On June 5, 2024, the user provided additional details including blood glucose reached 476 mg\u002Fdl, stayed high for over 4 hours, and patient developed diabetic ketoacidosis (DKA). On June 5, 2024, your firm closed the case without proper evaluation to determine if it required escalating to a product complaint or if it required reporting. Your firm’s Vice President of Quality Assurance confirmed this was a complaint on June 11, 2025.\nThe adequacy of your firm’s responses cannot be determined at this time, as corrective actions are ongoing. Your firm has committed to implementing a new complaint handling system by October 29, 2025. Corrective actions, such as a retrospective review of complaints, are ongoing, and your firm did not provide complete evidence of implementation of your new complaint handling system. Without this documentation in hand, FDA cannot make an assessment with respect to adequacy. Please continue to send updates regarding the implementation of your corrective actions.\n4. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements, as required by 21CFR 820.90(a). For example:\nYour firm failed to adequately control product that does not conform to specified requirements. Firm's procedure for controlling nonconforming product is SOP09, Nonconformance Reporting.\nNonconformance Report NCR #191 was opened after 61 out of (b)(4) iLet Bionic Pancreas printed circuit board assembly (PCBA) Mainboards failed testing due to faulty (b)(4) connections. Your firm claimed to have investigated with their supplier, your Vice President of Quality Assurance acknowledged that this investigation was not documented, and no corrective action was taken from the supplier, because this was considered a first-time issue. Your firm later received 19 customer complaints related to iLet Bionic Pancreas Model TA000036 failures caused by defective PCBA Mainboards with improperly installed components.\nWe reviewed your firm’s responses dated July 18, 2025, August 29, 2025, and October 29, 2025, and conclude that they are not adequate. Your firm’s CAPA 0064 NCR\u002FSCAR Review table shows instances where your firm has decided no SCAR is to be opened. The justifications for the following instances are inadequate:\nComponents no longer active (i.e. Component is no longer active in current iLet (TA000048) configuration). It is not clear if these non-conformances still being tracked and adequately investigated. Your response does not address if there are devices in the field that still contain this component or if the supplier still provides components that are active. There are repeated instances in table where the same supplier has sent mixed lots of components, manufactured to incorrect part number or sent mislabeled components, but no SCARs were issued.\nComponent manufactured to incorrect Part Number or Revision (i.e. the components were found manufactured to the incorrect part number. […] No SCAR will be issued as the parts were manufactured using equivalent materials. […] No additional NCRs were issued for a similar incident.)\nDamage during transportation (i.e. Damage to external shippers). It is not clear if these non-conformances still being tracked and adequately investigated.\nTypographical errors (i.e. Expiration Date on CoC was incorrect. […] The incorrect expiration on the CoC was a typographical error. The CoC was updated to the correct expiration date that was stated on the product.)\nMedical Device Reporting (MDR) Violations\nOur inspection also revealed that your firm’s iLet Dosing Decision Software and the iLet ACE Pump are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i. 21 CFR Part 803 - Medical Device Reporting was promulgated under section 519 of the Act, among other provisions. Significant violations include, but are not limited to, the following:\n1. Failure to report to the FDA the information required by 21 CFR 803.52 in accordance with the requirements of § 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1). Manufacturers should submit a separate report for each device that it markets that may have caused or contributed to a death or serious injury. For example,\nA. The information included for Complaint COM-0000008592 describes an event in which a patient experienced hyperglycemia and chest pains while using your firm’s iLet Dosing Decision Software and was subsequently treated with IV fluids and Insulin. The IV fluids rehydrated the patient and corrected electrolyte imbalances, while IV insulin provided a way to lower the high blood sugar (hyperglycemia). If left untreated, chronic hyperglycemia can lead to diabetes complications, such as cardiovascular disease, nerve damage, eye disease and kidney damage. Based on the information included for the complaint and the medical intervention given to the patient, we determined that your firm’s device may have caused or contributed to a serious injury as defined by 21 CFR 803.3(w)(3). The medical intervention was necessary to preclude permanent impairment of a body function or permanent damage to a body structure. Therefore, this event meets the definition of a MDR reportable event under 21 CFR 803.3(o)(2)(i) because the serious injury was or may have been attributed to the iLet Dosing Decision Software, or the iLet Dosing Decision Software was or may have been a factor in a serious injury. Your firm became aware of the event on August 19, 2024, when you acquired the information in this complaint that reasonably suggested a reportable event had occurred. However, no MDR was\nB. The information included for Complaints COM-0000025536, COM-0000026475, COM-0000026763, COM-0000003142 and COM-0000005866 describe adverse events in which patients experienced hypoglycemia with blood sugar levels below 70 mg\u002FdL, while using your firm’s iLet Dosing Decision Software, and were treated with glucose drink or candies to raise their blood glucose level. We determined that treatment for hypoglycemia that includes glucose drinks or candies is a medical intervention necessary to preclude permanent impairment of a body function or permanent damage to a body structure because, if left untreated, hypoglycemia can lead to confusion, shakiness, dizziness, and weakness, but if severe and untreated, it can progress to serious complications like seizures, loss of consciousness (fainting), brain damage, coma, and even death. Repeated episodes can also cause reduced cognitive function, cardiovascular issues, and increased risk for future severe lows. Therefore, based on the information included for the complaints involving your firm’s device and the medical intervention given to the patients, we determined that your firm’s device may have caused or contributed to a serious injury as defined by 21 CFR 803.3(w)(3). Each of these events therefore meet the definition of an MDR reportable event under 21 CFR 803.3(o)(2)(i) because the serious injury was or may have been attributed to the iLet Dosing Decision Software, or the iLet Dosing Decision Software was or may have been a factor in a serious injury. Your firm became aware of the information included for Complaint COM-0000025536, which reasonably suggests a reportable event has occurred, on April 23, 2025, and FDA received the corresponding MDR 3019004087-2025-00443 on July 14, 2025, which exceeds the required 30-calendar day timeframe in 21 CFR 803.50(a). Your firm became aware of the information included for Complaint COM-0000026475, which reasonably suggests a reportable event has occurred, on April 30, 2025, and FDA received the corresponding MDR 3019004087-2025-00461 on July 9, 2025, which exceeds the required 30-calendar day timeframe. Your firm became aware of the information corresponding to Complaint COM-0000026763, which reasonably suggests a reportable event has occurred, on May 3, 2025, and FDA received the corresponding MDR 3019004087-2025-00581 on June 10, 2025, which exceeds the required 30-calendar day timeframe. Your firm became aware of the information corresponding to Complaint COM-0000003142, which reasonably suggests a reportable event has occurred, on April 1, 2024, and FDA has not yet received an MDR. Your firm became aware of the information included for Complaint COM-0000005866 on June 20, 2024, however, FDA has not yet received an MDR.\n2. Failure to report to FDA the information required by 21 CFR 803.52 in accordance with the requirements of § 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\nFor example, the information included for complaints COM-0000004919, COM-0000008065 and COM-0000008452 reasonably suggests that the firm’s iLet ACE Pump malfunctioned (e.g. component failures: memory chips,) while in use, meaning the device failed to meet its performance specifications or otherwise perform as intended under 21 CFR 803.3(k). Specifically, complaint COM-0000004919 describes an “Alert 60 - Bluetooth Communication” error, complaint COM-0000008065 describes a “Touchscreen unresponsive” error, and complaint COM-0000008452 describes a sleep\u002Fwake button unresponsive” error. Although the malfunction alerts reference different alert codes, each malfunction is associated with a defective hoverboard. A device malfunction that is associated with a defective hoverboard has previously resulted in a patient sustaining a serious injury. (Refer to complaint COM-0000003142). This prior incident demonstrates that such a malfunction (i.e., one that is associated with a defective hoverboard) is linked to a serious injury. It is reasonable to conclude that a recurrence of these malfunctions that are associated with a defective hoverboard would therefore be likely to cause or contribute to a serious injury. As such, the malfunctions listed in these complaints represent MDR reportable events for which MDRs must be submitted. Your firm became aware of Complaint COM-0000004919 on 5\u002F25\u002F2024, Complaint COM-0000008065 on 8\u002F8\u002F2024 and Complaint COM-0000008065 on 8\u002F8\u002F2024 however, based on our records, FDA has not yet received an MDR for each of the referenced malfunction events.\nThe adequacy of your firm’s response dated July 18, 2025, cannot be determined at this time. In the response, your firm noted it initiated corrective actions to address the reporting issue, including a retrospective review of complaints received since June 2023. However, documentation of these corrective actions was not provided, as they are still ongoing.\nThe adequacy of your firm’s response dated August 28, 2025, cannot be determined at this time. Your firm’s response dated August 28, 2025, is a periodic update and did not include any additional new information.\nThe adequacy of your firm’s response dated October 29, 2025, cannot be determined at this time. Your firm’s response dated October 29, 2025, noted that your firm has a three-phase plan to address the reporting issue. However, documentation of the completion of these corrective actions was not provided, as they are still ongoing.\nIn addition, the inspection revealed that your firm failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17(a)(1). For example, during the inspection, your firm presented a document titled “Guidelines for FDA Reporting”, SOP 13.1, Rev. A, dated 2023-10-23, as its MDR procedure. After reviewing the procedure, we conclude that the procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, there are inadequate definitions of what constitutes a reportable event under 21 CFR Part 803. The fact that the procedure does not include a definition from 21 CFR 803.3 for the term “cause or contributed” may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\nYour firm’s response dated August 28, 2025, appears to be adequate. In the response, your firm included a copy of its revised MDR procedure titled “Guidelines for FDA Reporting”, Documents Number: SOP 13.1, Rev. B, dated 2025-07-16, along with staff training records. Upon review, the revised procedures have adequately addressed the deficiency described above.\nCorrections and Removals Violation(s)\nOur inspection also revealed that your firm’s iLet Dosing Decision Software and the iLet ACE Pump are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i. 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals was promulgated under section 519 of the Act, among other provisions. Significant violations include, but are not limited to, the following:\nFailure to submit to the FDA within 10 working days of initiating a correction or removal a report required by 21 CFR 806.10. For example:\nA. Your firm discovered that the iLet Dosing Decision Software had failures regarding glucose values that were 5 minutes old (delayed readings), instead of using new readings as expected. The iLet Dosing Decision Software autonomously determines and commands an increase, decrease, maintenance, or suspension of all basal doses of insulin and autonomously determines and commands correction doses of insulin based on glucose readings, and it autonomously determines, and commands meal doses of insulin based on meal announcements. Use of the delayed glucose readings resulted in your iLet Dosing Decision Software not performing as intended, not dosing insulin to the patient and patient experiencing elevated blood glucose levels that presents a risk to health. Your firm implemented a software change\u002Frelease version 1.4.4 to mitigate the risk to health posed by your iLet Dosing Decision Software. The new software version was uploaded to the cloud and made available to the customers for download on 4\u002F5\u002F2024. This action constitutes a medical device correction or removal initiated to reduce a risk to health posed by your device or remedy a violation of the Act caused by your device which may present a risk to health, under 21 CFR 806.10(a). You have not already provided this information as set forth in 21 CFR 806.10(f) (see 21 CFR 806.10(a)(2)), nor was the correction or removal action exempt from the reporting requirements under 21 CFR 806.1(b) (see 21 CFR 806.10(a)(2)). You were therefore required to submit a Report of Correction or Removal to FDA within 10 working days of initiation, under 21 CFR 806.10(b).\nB. Your firm discovered that the iLet ACE Pump had cybersecurity vulnerability for the Limited Access feature of the iLet Bionic Pancreas System, which is used as a security measure to prevent unwanted access to the pump controls. When either the lockscreen or Limited Access Passcode screen is viewed on the iLet display, other icons are present and active, and (b)(4). This results in unsecured access to change settings, including stopping insulin delivery or giving boluses inappropriately, both of which present a risk to health. Your firm implemented a software fix via DCO #3203 and released Software Version 1.4.3 on 3\u002F26\u002F2024. Beta Bionics sent an email to all customers on 4\u002F1\u002F2024, titled “iLet Software Update”, notifying them that Beta Bionics, Inc. released an iLet Bionic Pancreas Software update. This action constitutes a medical device correction or removal initiated to reduce a risk to health posed by the device or remedy a violation of the Act caused by the device which may present a risk to health, under 21 CFR 806.10(a). You have not already provided this information as set forth in 21 CFR 806.10(f) (see 21 CFR 806.10(a)(2)), nor was the correction or removal action exempt from the reporting requirements under 21 CFR 806.1(b) (see 21 CFR 806.10(a)(2)). You were therefore required to submit a Report of Correction or Removal to FDA within 10 working days of initiation, under 806.10(b).\nYour firm’s responses to the FDA-483, dated July 18, 2025, August 29, 2025, and October 29, 2025, are not adequate. For the issue related to delayed glucose readings described in paragraph A above, you categorized your action as a device enhancement, stating that the change was to improve a non-violative device’s safety or performance. Even if you categorized the software update as a “device enhancement,” the evidence still indicates that a report of correction or removal was required to have been submitted to FDA because you initiated the correction (i.e., updated the software) in order to reduce a risk to health posed by the device (i.e., inaccurate insulin dosing). The fact that the issue might have also involved a third-party CGM does not change the fact that you initiated the correction to reduce a risk to health posed by your device. Furthermore, there is no evidence that you designed and tested the iLet device to function with the particular CGM at issue.\nFor the issue related to the cybersecurity vulnerability for the Limited Access feature described in paragraph B above, your firm alleges that the issue is non-reportable. We do not agree with this assessment. The evidence indicates that a report of correction or removal was required to have been submitted to FDA because you initiated the correction (i.e., updated the software) in order to reduce a risk to health posed by the device (i.e., prevent unsecured access to the pump controls).\nIn addition, regarding your statement that your firm was conducting a Class III recall, we note that a recall’s classification is assigned by FDA, not the recalling firm (e.g., 21 CFR 7.3(m) and 7.41(b)), and that conducting a voluntary recall does not exempt a firm from the requirement to submit a report of correction or removal under Part 806 (e.g., 21 CFR 806.10(a)(2)). As explained above, you were required to submit a report of correction or removal to FDA.\nYou have not submitted Reports of Correction or Removal to FDA as of 01\u002F15\u002F2026 for either of the failures listed above.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 717927” when replying. If you have any questions about the contents of this letter, please contact: Shaquenta Perkins at shaquenta.perkins@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or concerning your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nActing Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Beta Bionics, Inc.","beta-bionics-inc-717927-01282026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbeta-bionics-inc-717927-01282026","2026-10-26T08:08:03.74786+00:00","2026-02-24","717927","Medical Devices","Sean Saint","2026-08-19T04:56:48.261+00:00","2026-01-28",{"id":53,"raw":54,"subject":38,"body_html":57,"body_text":58,"firm_name":41,"letter_id":59,"created_at":43,"fei_number":19,"letter_url":60,"updated_at":61,"action_type":22,"case_status":23,"posted_date":62,"marcs_cms_no":19,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":63,"delivery_method":64,"recipient_title":19,"reference_number":19,"action_taken_date":51,"medical_device_id":19,"response_letter_date":19},291,[55,35,56,37,38,13,13,13],"\u003Ctime datetime=\"2026-03-03T05:00:00Z\">03\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbeta-bionics-inc-717927-01282026-0\">Beta Bionics, Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Sean Saint\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Beta Bionics, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>11 Hughes\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Irvine\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92618\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)@betabionics.com\"> (b)(6)@betabionics.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS #717927\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>January 28, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Saint:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Irvine, CA from June 9, 2025, through June 26, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the iLet Dosing Decision Software and the iLet ACE Pump, which are part of the iLet Bionic Pancreas System. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received responses from Neal Grant, Director, Quality Systems dated July 18, 2025, August 29, 2025, and October 29, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a). For example:\u003C\u002Fp>\u003Cp>A. Your firm failed to adequately analyze quality data, such as complaints, to identify existing and potential causes of nonconforming product or other quality problems and utilize appropriate statistical methodology to detect recurring quality problems. For example:\u003C\u002Fp>\u003Cp>i. Your firm failed to implement corrective and preventive actions (CAPA) for complaints related to device malfunctions that led to serious adverse health outcomes, as required by Section 6.1.3 (Section 1.4 of Revs G and H) of your firm's corrective and preventive action procedure, Corrective and Preventive Actions, SOP05, Rev I, Section 6.1 (Section 6.6 of Rev I) of the firm's complaint handling procedure, Product Complaints, SOP13, Rev H, and Section 9 (Section 6.9 Rev I) of the firm's complaint handling procedure, Product Complaints, SOP13, Rev H.\u003C\u002Fp>\u003Cp>a. Investigators observed \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints reporting Faulty Motors, including one reporting the patient suffered Diabetic Ketoacidosis, confirmed by your firm to be device malfunctions, where you took no corrective actions and provided no justification for inaction, despite identified safety risks.\u003C\u002Fp>\u003Cp>b. Investigators observed \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints reporting hypoglycemic episodes that were attributed to Use Error – Unintended Insulin Delivery associated with the patients’ incorrectly changing the insulin cartridges. 107 complaints were submitted to the FDA as serious injury Medical Device Reports for severe hypoglycemia or intervention required to prevent severe hypoglycemia. Your firm's User-Related Risk Analysis, RA000021, identified that use errors with the iLet Bionic Pancreas System could trigger unintended insulin doses potentially large enough to cause death (classified as the highest risk level, Severity \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Despite this identified safety risk, your firm closed 56 related complaints without implementing corrective actions to address the identified use errors or documenting justification for why corrective actions were deemed unnecessary.\u003C\u002Fp>\u003Cp>ii. Your firm conducts complaint trending through your risk management procedure, Risk Management Review, SOP 14.1, Rev B, Release Date 2023-03-13, to determine if escalation to corrective and preventive action (CAPA) is warranted. Your firm’s complaint trending process is inadequate, in that:\u003C\u002Fp>\u003Cp>a. Inconsistencies were observed between what your firm claims to analyze versus what is documented in your trending analysis. For example:\u003C\u002Fp>\u003Cp>1. Your firm’s complaint trending provided uses “As Reported Complaint Code: Term” and the part of the system (e.g., iLet device, luer connector, cartridge, etc.), but it does not trend complaints by “Complaint Conclusion” unless there was an associated MDR. Your firm’s Vice President of Quality Assurance stated that they also look at complaint conclusions on everything (with the exception of “not our product”) but that it was just not in the presentation.\u003C\u002Fp>\u003Cp>2. Multiple codes with identical or nearly identical meanings were found (e.g., \"Use Error – User Did Not Announce Meals\" vs. \"User Error – Did Not Announce Meals\"). Similar codes could dilute trending data for specific complaint types like meal announcements.\u003C\u002Fp>\u003Cp>b. Your firm uses multiple trending rates for complaint analysis that could lead to underestimation of meal announcement complaint rates, potentially affecting safety signals and risk assessment accuracy. For example: Your firm’s complaint trending uses trending rates, such as quantity of complaints per month and as a percentage of the total iLet shipments within a given time period. Your firm’s Vice President of Quality Assurance explained that they also use rates per opportunity. For example, users have approximately ten (10) opportunities to change their cartridge per month, so your firm will trend the percentage by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. A second example is that users have approximately 90 opportunities to meal announce (three times a day over 30 days), so your firm will trend the same as previous except \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your trending rate for meal announcements (90 per month) is not representative of all users’ eating habits and as such might be affecting the rate at which your firm is trending meal announcement related complaints. In addition, your firm’s instructions state that “If you eat a very low carb diet or no carbs at all, you should not announce meals.”\u003C\u002Fp>\u003Cp>B. Your firm's verification of effectiveness (VOE) for CAPA 0050 is inadequate, in that, it tested \u003Cstrong>(b)(4)\u003C\u002Fstrong> employees on updated training materials, rather than actual iLet users, which was not representative of user population base (e.g. people 6 years of age or older with diabetes mellitus). Additionally, your CAPA 0050 does not address the allegations of hypoglycemia during the adaptation phase of initial use of the iLet.\u003C\u002Fp>\u003Cp>Your firm opened CAPA 0050 to investigate hypoglycemia allegations during the iLet Bionic Pancreas System's initial adaptation phase. Your firm determined that the root cause was users' inadequate understanding of diabetes management while using the device, leading to maladaptive behaviors and misuses. Your firm documented the related misuses in RA000021, Rev. E, User-Related Risk Analysis. Your firm initiated preventive actions for CAPA 0050, to include: 1) Holding office hours for health care providers; 2) Improving user training materials; 3) Creating information materials for users transitions from hybrid closed-loop systems and for users new to pump therapy; and 4) Improving guidance materials for health care providers.\u003C\u002Fp>\u003Cp>Additionally, Section 2.8.3 of your firm's corrective and preventive action procedure, Corrective and Preventive Actions, SOP05, Rev H, Release Date 2024-01-09, and section 1.1 of your firm’s work instruction, CAPA Process, WI000053, Rev C, Release Date 2024-01-09, state that an independent investigator and not the CAPA owner is responsible for executing the verification of effectiveness plan and documenting such activity. However, your firm’s CAPA owner also completed the verification of effectiveness activities for CAPA 0050.\u003C\u002Fp>\u003Cp>C. Your firm’s procedure, Corrective and Preventive Actions, SOP05, Revs G – I, states that CAPA requests are warranted for systemic issues that affect the quality of products or services, especially if: an incident caused injury or death; there are multiple occurrences of the same event, typically three within a rolling \u003Cstrong>(b)(4)\u003C\u002Fstrong> period; or a risk assessment identifies the issue as critical. Your firm failed to maintain records to demonstrate that the cause of nonconformities was investigated; the appropriate action(s) needed to correct and prevent recurrence of nonconforming product were identified; actions taken were verified or validated to ensure the actions were effective and did not adversely affect the products; changes in methods and procedures were implemented; and that information related to the nonconforming products was disseminated to those directly responsible for assuring the quality of the products or prevention of such products.\u003C\u002Fp>\u003Cp>Specifically, investigators observed 15 complaints (dated from July 2023 – December 2023) reporting damaged pump displays, where your firm's product evaluation confirmed the screens were bowed or delaminated. Per your firm’s System Risk Analysis, iLet Bionic Pancreas System, DeLorean (Insulin), RA000005, the risk to patients from being unable to read the display can result in hyper or hypoglycemia and is assigned a Severity of \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Life-threatening serious injury that requires emergency professional medical intervention). Your firm implemented design changes to address these nonconformities (adding Vent to housing to vent internal volume of iLet to ambient pressure, per QP000171); however, no records were maintained to document any corrective actions or reference to CAPA records.\u003C\u002Fp>\u003Cp>D. Your firm failed to adequately document its investigation into device failures due to 5-minute delayed glucose readings instead of real-time data. Your associated Health Hazard Analysis, HHA-2024-002, dated 04\u002F12\u002F2024, states that this issue could potentially lead to the basal and\u002For correction controller not increasing insulin dosing for high or upward trending Continued Glucose Monitoring (CGM) values or the basal controller not reducing or suspending insulin based on downward trending CGM values. Reportedly, this issue was investigated in collaboration with your CGM supplier, resulting in your firm implementing a temporary software change on 04\u002F05\u002F2024 to mitigate patient risks, while your supplier implemented a permanent solution, however, your firm failed to document this investigation.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses dated July 18, 2025, August 29, 2025, and October 29, 2025, and conclude that they are not adequate. Your firm's assessment conducted in CAPA 0061 - CAPA VoE Review states, in relation to CAPA-0050, that the Verification of Effectiveness (VoE) was appropriate because it directly measured users' understanding after updated training, addressing the identified root cause, user knowledge gaps. The 100% pass rate on the assessment demonstrates that the revised training effectively improved comprehension related to safe iLet use. However, your firm also indicated in your response that you updated your VoE plan for CAPA-0050 and established a new plan to evaluate CGM-measured percent median time below 54 mg\u002FdL in the user population before and after corrective measures implementation. Your success criteria was established as a \u003Cstrong>(b)(4)\u003C\u002Fstrong>% or greater reduction in percent median time below 54 mg\u002FdL, which you state would indicate effectiveness of the corrective measures. Supporting evidence of new CAPA-0050 Verification of Effectiveness (VoE) plan was not provided. The root cause determination and verification of effectiveness criteria for CAPA-0050 is deficient in that it fails to distinguish between system design issues versus user training deficiencies and subsequently the preventive actions were solely focused on training improvements without addressing potential device design issues. It is not clear if an evaluation was made of whether the iLet's design of device (e.g. user interface, alert systems, or other potential design issues) could have contributed to maladaptive behaviors.\u003C\u002Fp>\u003Cp>2. Failure to adequately establish and maintain procedures for validating the device design to include an adequate risk analysis, as required by 21 CFR 820.30(g). For example:\u003C\u002Fp>\u003Cp>Your firm’s risk management procedure, Risk Management Review, SOP 14.1, Rev B, Release Date: 2023-03-13 states in Sections 1.2 – 1.3 that the Head of QA has overall responsibility for collecting and reporting post market feedback information to management to determine if the product is performing within the risk profile as determined by the products risk management documentation. The following sources provide information that is assessed against the associated risk management documentation: Management Review, Design Testing (non-clinical), Regulatory affairs information pertinent to the bionic pancreas, Nonconforming Material Reports (NCMRs), Manufacturing Data (e.g., yields), Complaints, Health Hazard Assessments, Competitor Information, Published Literature, Customer Feedback including surveys, Clinical Investigations and Follow up. The review of design, production and post market surveillance data and its assessment against the risk profiles per the related risk management documentation shall occur \u003Cstrong>(b)(4)\u003C\u002Fstrong>, at a minimum.\u003C\u002Fp>\u003Cp>Your firm's System Risk Analysis, RA000005, for your iLet Bionic Pancreas, failed to include post-market risks identified through your firm’s complaint data, as required by your procedure. Specifically,\u003C\u002Fp>\u003Cp>A. Your firm has failed to incorporate known post-market safety data into your risk management processes.\u003C\u002Fp>\u003Cp>i. Investigators observed \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints, dated October 2024 – June 2025, reporting various malfunctions of the iLet Bionic Pancreas Model TA000036 caused by failure of the devices’ printed circuit board assembly manufactured by a supplier. Your firm’s risk analysis does not assess, or control identified hardware hazards.\u003C\u002Fp>\u003Cp>ii. Investigators observed two complaints, received on 02\u002F07\u002F2024, and 01\u002F01\u002F2025, reporting over infusion of insulin resulting in severe hypoglycemia or hypoglycemia requiring medical intervention where the users reported involuntary meal announcements. Your firm’s risk analysis fails to assess hypoglycemia risk from involuntary meal announcements.\u003C\u002Fp>\u003Cp>B. Your firm’s risk management procedure, Risk Management Review, SOP 14.1, Rev B, Release Date: 2023-03-13 states in Section 4 – Unanticipated Risks that as a result of the risk management assessment per this SOP, any unanticipated events are assessed based upon the severity and occurrence of the associated harm and hazard. This assessment includes a review of prior Design Verification Testing (DVT) and\u002For Process Validation activities to verify potential, applicable risk mitigations previously established. Rationale for non-escalation shall be documented in the RMRR and approved by the Head of Quality.\u003C\u002Fp>\u003Cp>Your firm has identified a hazard; however, the risk control implementation and validation are absent in your firm’s risk analysis. Specifically,\u003C\u002Fp>\u003Cp>Complaint # COM-0000000790 was reviewed reporting a patient with dementia gave themselves multiple successive meal boluses, although they were not eating. The following morning the patient’s blood glucose was 40 mg\u002Fdl. The caregiver attempted to wake the patient, but the patient was unresponsive. While your firm’s System Risk Analysis identifies that vulnerable populations (patients with diminished capacity), might be making inappropriate therapy decisions, resulting in hyper or hypo glycemia, your risk analysis fails to: 1) Document any risk control measures to address this specific hazard; 2) Demonstrate calculation of post-mitigation risks; 3) Show how the identified risk is being adequately controlled.\u003C\u002Fp>\u003Cp>C. Despite approximately 529 complaints reporting insulin cartridges or cartridge connectors leaking while in use, your firm's System Risk Analysis, RA000005, for the iLet Bionic Pancreas does not evaluate the risk to patients from cartridges and cartridge connectors leaking during use.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses dated July 18, 2025, August 29, 2025, and October 29, 2025, and conclude that they are not adequate. Your firm’s response states that you plan to update your risk management procedures; however, it does not address whether and how data sources from your firm’s quality system, such as complaints, CAPAs, nonconforming product, etc., will interface with your firm’s risk analysis process to determine if further corrective actions or regulatory decisions are required.\u003C\u002Fp>\u003Cp>3. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\u003C\u002Fp>\u003Cp>A. Your firm failed to adequately investigate complaints involving the possible failure of a device, labeling, or packaging to meet any of its specifications. For example:\u003C\u002Fp>\u003Cp>i. Investigators review of complaint data from June 2023 – June 2025 found over 500 complaints reporting iLet Bionic Pancreas system insulin cartridges or cartridge connectors leaking. The System Risk Analysis, iLet Bionic Pancreas System, DeLorean (Insulin), RA000005, does not identify the risk to patient from cartridge\u002Fconnector leaks leading to under delivery of insulin to patients; however, the Risk Analysis identifies the risk of system under-delivery of drug resulting in hyper or hypo glycemia due to administration sets leaking as Critical - Results in permanent impairment of life-threatening injury.\u003C\u002Fp>\u003Cp>Your firm did not adequately address 31 complaints relating to cartridge or connector leaking. Specifically, your firm closed these complaints without investigation, concluding that no product deficiencies or defects were indicated, and that the complaints did not warrant an investigation. Additionally, by not investigating these product failures, your firm failed to recognize safety risks that could cause adverse events. For example, 18 of the 31 complaints (e.g., COM-0000007869, COM-0000007398, and COM-0000007157) reported that patients experienced hyperglycemic health effects.\u003C\u002Fp>\u003Cp>ii. Investigators observed that your firm failed to adequately investigate 21 complaints involving bent cannulas or infusion set failures associated with reports of diabetic ketoacidosis (DKA). Your iLet Bionic Pancreas System is distributed to customers with Convatec Inset and Contact Detach infusion sets manufactured for you by your infusion set supplier. Your firm is responsible for intake of complaints for the infusion sets and forwarding them to Convatec. Review of your complaint data shows that approximately 33% of the complaints in your complaint database are related to failure of the infusion sets, with the top failures reported as bent cannula, adhesive issues, and infusion set failures, and with 99.7% of the affected sets not returned by the customers. However, your firm did not request the sets to be returned for further investigation by your infusion set supplier.\u003C\u002Fp>\u003Cp>B. Your firm failed to implement and maintain adequate complaint files, per your procedures.\u003C\u002Fp>\u003Cp>Specifically, investigators observed that your firm had not adequately implemented your complaint handling procedure, Product Complaints, SOP13, Rev H, Release Date 2023-01-28, which requires review of all reported product experiences within \u003Cstrong>(b)(4)\u003C\u002Fstrong> to determine if they constitute a complaint. \u003Cstrong>(b)(4)\u003C\u002Fstrong> is the electronic quality management system, used by your firm. Your firm’s work instruction, WI000085, provides instructions for completing the product complaint process. Section 6 of work instruction WI000085, Revs A-C, state that if a complaint was created via \u003Cstrong>(b)(4)\u003C\u002Fstrong> (e.g., Case), various fields such as Event as Reported, Event Date, Aware Date, etc. will be auto filled into \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It also describes how new complaints can be directly entered into \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>For example, your firm did not adequately address a user reported hyperglycemic event, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Case 00015304, involving your iLet device. Specifically, on June 3, 2024, a user reported hyperglycemic event requiring emergency room treatment and insulin administration. On June 5, 2024, the user provided additional details including blood glucose reached 476 mg\u002Fdl, stayed high for over 4 hours, and patient developed diabetic ketoacidosis (DKA). On June 5, 2024, your firm closed the case without proper evaluation to determine if it required escalating to a product complaint or if it required reporting. Your firm’s Vice President of Quality Assurance confirmed this was a complaint on June 11, 2025.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time, as corrective actions are ongoing. Your firm has committed to implementing a new complaint handling system by October 29, 2025. Corrective actions, such as a retrospective review of complaints, are ongoing, and your firm did not provide complete evidence of implementation of your new complaint handling system. Without this documentation in hand, FDA cannot make an assessment with respect to adequacy. Please continue to send updates regarding the implementation of your corrective actions.\u003C\u002Fp>\u003Cp>4. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements, as required by 21CFR 820.90(a). For example:\u003C\u002Fp>\u003Cp>Your firm failed to adequately control product that does not conform to specified requirements. Firm's procedure for controlling nonconforming product is SOP09, Nonconformance Reporting.\u003C\u002Fp>\u003Cp>Nonconformance Report NCR #191 was opened after 61 out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> iLet Bionic Pancreas printed circuit board assembly (PCBA) Mainboards failed testing due to faulty \u003Cstrong>(b)(4)\u003C\u002Fstrong> connections. Your firm claimed to have investigated with their supplier, your Vice President of Quality Assurance acknowledged that this investigation was not documented, and no corrective action was taken from the supplier, because this was considered a first-time issue. Your firm later received 19 customer complaints related to iLet Bionic Pancreas Model TA000036 failures caused by defective PCBA Mainboards with improperly installed compone\u003Ca>nts.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses dated July 18, 2025, August 29, 2025, and October 29, 2025, and conclude that they are not adequate. Your firm’s CAPA 0064 NCR\u002FSCAR Review table shows instances where your firm has decided no SCAR is to be opened. The justifications for the following instances are inadequate:\u003C\u002Fp>\u003Cul>\u003Cli>Components no longer active (\u003Cem>i.e. Component is no longer active in current iLet (TA000048) configuration\u003C\u002Fem>). It is not clear if these non-conformances still being tracked and adequately investigated. Your response does not address if there are devices in the field that still contain this component or if the supplier still provides components that are active. There are repeated instances in table where the same supplier has sent mixed lots of components, manufactured to incorrect part number or sent mislabeled components, but no SCARs were issued.\u003C\u002Fli>\u003Cli>Component manufactured to incorrect Part Number or Revision (\u003Cem>i.e. the components were found manufactured to the incorrect part number. […] No SCAR will be issued as the parts were manufactured using equivalent materials. […] No additional NCRs were issued for a similar incident.\u003C\u002Fem>)\u003C\u002Fli>\u003Cli>Damage during transportation (\u003Cem>i.e. Damage to external shippers\u003C\u002Fem>). It is not clear if these non-conformances still being tracked and adequately investigated.\u003C\u002Fli>\u003Cli>Typographical errors (\u003Cem>i.e. Expiration Date on CoC was incorrect. […] The incorrect expiration on the CoC was a typographical error. The CoC was updated to the correct expiration date that was stated on the product.\u003C\u002Fem>)\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection also revealed that your firm’s iLet Dosing Decision Software and the iLet ACE Pump are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i. 21 CFR Part 803 - Medical Device Reporting was promulgated under section 519 of the Act, among other provisions. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to report to the FDA the information required by 21 CFR 803.52 in accordance with the requirements of § 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1). Manufacturers should submit a separate report for each device that it markets that may have caused or contributed to a death or serious injury. For example,\u003C\u002Fp>\u003Cp>A. The information included for Complaint COM-0000008592 describes an event in which a patient experienced hyperglycemia and chest pains while using your firm’s iLet Dosing Decision Software and was subsequently treated with IV fluids and Insulin. The IV fluids rehydrated the patient and corrected electrolyte imbalances, while IV insulin provided a way to lower the high blood sugar (hyperglycemia). If left untreated, chronic hyperglycemia can lead to diabetes complications, such as cardiovascular disease, nerve damage, eye disease and kidney damage. Based on the information included for the complaint and the medical intervention given to the patient, we determined that your firm’s device may have caused or contributed to a serious injury as defined by 21 CFR 803.3(w)(3). The medical intervention was necessary to preclude permanent impairment of a body function or permanent damage to a body structure. Therefore, this event meets the definition of a MDR reportable event under 21 CFR 803.3(o)(2)(i) because the serious injury was or may have been attributed to the iLet Dosing Decision Software, or the iLet Dosing Decision Software was or may have been a factor in a serious injury. Your firm became aware of the event on August 19, 2024, when you acquired the information in this complaint that reasonably suggested a reportable event had occurred. However, no MDR was received by the FDA.\u003C\u002Fp>\u003Cp>B. The information included for Complaints COM-0000025536, COM-0000026475, COM-0000026763, COM-0000003142 and COM-0000005866 describe adverse events in which patients experienced hypoglycemia with blood sugar levels below 70 mg\u002FdL, while using your firm’s iLet Dosing Decision Software, and were treated with glucose drink or candies to raise their blood glucose level. We determined that treatment for hypoglycemia that includes glucose drinks or candies is a medical intervention necessary to preclude permanent impairment of a body function or permanent damage to a body structure because, if left untreated, hypoglycemia can lead to confusion, shakiness, dizziness, and weakness, but if severe and untreated, it can progress to serious complications like seizures, loss of consciousness (fainting), brain damage, coma, and even death. Repeated episodes can also cause reduced cognitive function, cardiovascular issues, and increased risk for future severe lows. Therefore, based on the information included for the complaints involving your firm’s device and the medical intervention given to the patients, we determined that your firm’s device may have caused or contributed to a serious injury as defined by 21 CFR 803.3(w)(3). Each of these events therefore meet the definition of an MDR reportable event under 21 CFR 803.3(o)(2)(i) because the serious injury was or may have been attributed to the iLet Dosing Decision Software, or the iLet Dosing Decision Software was or may have been a factor in a serious injury. Your firm became aware of the information included for Complaint COM-0000025536, which reasonably suggests a reportable event has occurred, on April 23, 2025, and FDA received the corresponding MDR 3019004087-2025-00443 on July 14, 2025, which exceeds the required 30-calendar day timeframe in 21 CFR 803.50(a). Your firm became aware of the information included for Complaint COM-0000026475, which reasonably suggests a reportable event has occurred, on April 30, 2025, and FDA received the corresponding MDR 3019004087-2025-00461 on July 9, 2025, which exceeds the required 30-calendar day timeframe. Your firm became aware of the information corresponding to Complaint COM-0000026763, which reasonably suggests a reportable event has occurred, on May 3, 2025, and FDA received the corresponding MDR 3019004087-2025-00581 on June 10, 2025, which exceeds the required 30-calendar day timeframe. Your firm became aware of the information corresponding to Complaint COM-0000003142, which reasonably suggests a reportable event has occurred, on April 1, 2024, and FDA has not yet received an MDR. Your firm became aware of the information included for Complaint COM-0000005866 on June 20, 2024, however, FDA has not yet received an MDR.\u003C\u002Fp>\u003Cp>2. Failure to report to FDA the information required by 21 CFR 803.52 in accordance with the requirements of § 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003C\u002Fp>\u003Cp>For example, the information included for complaints COM-0000004919, COM-0000008065 and COM-0000008452 reasonably suggests that the firm’s iLet ACE Pump malfunctioned (e.g. component failures: memory chips,) while in use, meaning the device failed to meet its performance specifications or otherwise perform as intended under 21 CFR 803.3(k). Specifically, complaint COM-0000004919 describes an “Alert 60 - Bluetooth Communication” error, complaint COM-0000008065 describes a “Touchscreen unresponsive” error, and complaint COM-0000008452 describes a sleep\u002Fwake button unresponsive” error. Although the malfunction alerts reference different alert codes, each malfunction is associated with a defective hoverboard. A device malfunction that is associated with a defective hoverboard has previously resulted in a patient sustaining a serious injury. (Refer to complaint COM-0000003142). This prior incident demonstrates that such a malfunction (i.e., one that is associated with a defective hoverboard) is linked to a serious injury. It is reasonable to conclude that a recurrence of these malfunctions that are associated with a defective hoverboard would therefore be likely to cause or contribute to a serious injury. As such, the malfunctions listed in these complaints represent MDR reportable events for which MDRs must be submitted. Your firm became aware of Complaint COM-0000004919 on 5\u002F25\u002F2024, Complaint COM-0000008065 on 8\u002F8\u002F2024 and Complaint COM-0000008065 on 8\u002F8\u002F2024 however, based on our records, FDA has not yet received an MDR for each of the referenced malfunction events.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response dated July 18, 2025, cannot be determined at this time. In the response, your firm noted it initiated corrective actions to address the reporting issue, including a retrospective review of complaints received since June 2023. However, documentation of these corrective actions was not provided, as they are still ongoing.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response dated August 28, 2025, cannot be determined at this time. Your firm’s response dated August 28, 2025, is a periodic update and did not include any additional new information.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response dated October 29, 2025, cannot be determined at this time. Your firm’s response dated October 29, 2025, noted that your firm has a three-phase plan to address the reporting issue. However, documentation of the completion of these corrective actions was not provided, as they are still ongoing.\u003C\u002Fp>\u003Cp>In addition, the inspection revealed that your firm failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17(a)(1). For example, during the inspection, your firm presented a document titled “Guidelines for FDA Reporting”, SOP 13.1, Rev. A, dated 2023-10-23, as its MDR procedure. After reviewing the procedure, we conclude that the procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, there are inadequate definitions of what constitutes a reportable event under 21 CFR Part 803. The fact that the procedure does not include a definition from 21 CFR 803.3 for the term “cause or contributed” may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\u003Cp>Your firm’s response dated August 28, 2025, appears to be adequate. In the response, your firm included a copy of its revised MDR procedure titled “Guidelines for FDA Reporting”, Documents Number: SOP 13.1, Rev. B, dated 2025-07-16, along with staff training records. Upon review, the revised procedures have adequately addressed the deficiency described above.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Corrections and Removals Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection also revealed that your firm’s iLet Dosing Decision Software and the iLet ACE Pump are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i. 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals was promulgated under section 519 of the Act, among other provisions. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit to the FDA within 10 working days of initiating a correction or removal a report required by 21 CFR 806.10. For example:\u003C\u002Fp>\u003Cp>A. Your firm discovered that the iLet Dosing Decision Software had failures regarding glucose values that were 5 minutes old (delayed readings), instead of using new readings as expected. The iLet Dosing Decision Software autonomously determines and commands an increase, decrease, maintenance, or suspension of all basal doses of insulin and autonomously determines and commands correction doses of insulin based on glucose readings, and it autonomously determines, and commands meal doses of insulin based on meal announcements. Use of the delayed glucose readings resulted in your iLet Dosing Decision Software not performing as intended, not dosing insulin to the patient and patient experiencing elevated blood glucose levels that presents a risk to health. Your firm implemented a software change\u002Frelease version 1.4.4 to mitigate the risk to health posed by your iLet Dosing Decision Software. The new software version was uploaded to the cloud and made available to the customers for download on 4\u002F5\u002F2024. This action constitutes a medical device correction or removal initiated to reduce a risk to health posed by your device or remedy a violation of the Act caused by your device which may present a risk to health, under 21 CFR 806.10(a). You have not already provided this information as set forth in 21 CFR 806.10(f) (see 21 CFR 806.10(a)(2)), nor was the correction or removal action exempt from the reporting requirements under 21 CFR 806.1(b) (see 21 CFR 806.10(a)(2)). You were therefore required to submit a Report of Correction or Removal to FDA within 10 working days of initiation, under 21 CFR 806.10(b).\u003C\u002Fp>\u003Cp>B. Your firm discovered that the iLet ACE Pump had cybersecurity vulnerability for the Limited Access feature of the iLet Bionic Pancreas System, which is used as a security measure to prevent unwanted access to the pump controls. When either the lockscreen or Limited Access Passcode screen is viewed on the iLet display, other icons are present and active, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This results in unsecured access to change settings, including stopping insulin delivery or giving boluses inappropriately, both of which present a risk to health. Your firm implemented a software fix via DCO #3203 and released Software Version 1.4.3 on 3\u002F26\u002F2024. Beta Bionics sent an email to all customers on 4\u002F1\u002F2024, titled “iLet Software Update”, notifying them that Beta Bionics, Inc. released an iLet Bionic Pancreas Software update. This action constitutes a medical device correction or removal initiated to reduce a risk to health posed by the device or remedy a violation of the Act caused by the device which may present a risk to health, under 21 CFR 806.10(a). You have not already provided this information as set forth in 21 CFR 806.10(f) (see 21 CFR 806.10(a)(2)), nor was the correction or removal action exempt from the reporting requirements under 21 CFR 806.1(b) (see 21 CFR 806.10(a)(2)). You were therefore required to submit a Report of Correction or Removal to FDA within 10 working days of initiation, under 806.10(b).\u003C\u002Fp>\u003Cp>Your firm’s responses to the FDA-483, dated July 18, 2025, August 29, 2025, and October 29, 2025, are not adequate. For the issue related to delayed glucose readings described in paragraph A above, you categorized your action as a device enhancement, stating that the change was to improve a non-violative device’s safety or performance. Even if you categorized the software update as a “device enhancement,” the evidence still indicates that a report of correction or removal was required to have been submitted to FDA because you initiated the correction (i.e., updated the software) in order to reduce a risk to health posed by the device (i.e., inaccurate insulin dosing). The fact that the issue might have also involved a third-party CGM does not change the fact that you initiated the correction to reduce a risk to health posed by your device. Furthermore, there is no evidence that you designed and tested the iLet device to function with the particular CGM at issue.\u003C\u002Fp>\u003Cp>For the issue related to the cybersecurity vulnerability for the Limited Access feature described in paragraph B above, your firm alleges that the issue is non-reportable. We do not agree with this assessment. The evidence indicates that a report of correction or removal was required to have been submitted to FDA because you initiated the correction (i.e., updated the software) in order to reduce a risk to health posed by the device (i.e., prevent unsecured access to the pump controls).\u003C\u002Fp>\u003Cp>In addition, regarding your statement that your firm was conducting a Class III recall, we note that a recall’s classification is assigned by FDA, not the recalling firm (e.g., 21 CFR 7.3(m) and 7.41(b)), and that conducting a voluntary recall does not exempt a firm from the requirement to submit a report of correction or removal under Part 806 (e.g., 21 CFR 806.10(a)(2)). As explained above, you were required to submit a report of correction or removal to FDA.\u003C\u002Fp>\u003Cp>You have not submitted Reports of Correction or Removal to FDA as of 01\u002F15\u002F2026 for either of the failures listed above.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “\u003Cstrong>CMS Case 717927\u003C\u002Fstrong>” when replying. If you have any questions about the contents of this letter, please contact: Shaquenta Perkins at shaquenta.perkins@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or concerning your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden\u003Cbr>Acting Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nSean Saint\n\nRecipient Title\n\nChief Executive Officer\n\nBeta Bionics, Inc.\n\n11 Hughes\n\nIrvine, CA 92618\n\nUnited States\n\n(b)(6)@betabionics.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS #717927\nJanuary 28, 2026\nDear Mr. Saint:\nDuring an inspection of your firm located in Irvine, CA from June 9, 2025, through June 26, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the iLet Dosing Decision Software and the iLet ACE Pump, which are part of the iLet Bionic Pancreas System. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received responses from Neal Grant, Director, Quality Systems dated July 18, 2025, August 29, 2025, and October 29, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to adequately establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a). For example:\nA. Your firm failed to adequately analyze quality data, such as complaints, to identify existing and potential causes of nonconforming product or other quality problems and utilize appropriate statistical methodology to detect recurring quality problems. For example:\ni. Your firm failed to implement corrective and preventive actions (CAPA) for complaints related to device malfunctions that led to serious adverse health outcomes, as required by Section 6.1.3 (Section 1.4 of Revs G and H) of your firm's corrective and preventive action procedure, Corrective and Preventive Actions, SOP05, Rev I, Section 6.1 (Section 6.6 of Rev I) of the firm's complaint handling procedure, Product Complaints, SOP13, Rev H, and Section 9 (Section 6.9 Rev I) of the firm's complaint handling procedure, Product Complaints, SOP13, Rev H.\na. Investigators observed (b)(4) complaints reporting Faulty Motors, including one reporting the patient suffered Diabetic Ketoacidosis, confirmed by your firm to be device malfunctions, where you took no corrective actions and provided no justification for inaction, despite identified safety risks.\nb. Investigators observed (b)(4) complaints reporting hypoglycemic episodes that were attributed to Use Error – Unintended Insulin Delivery associated with the patients’ incorrectly changing the insulin cartridges. 107 complaints were submitted to the FDA as serious injury Medical Device Reports for severe hypoglycemia or intervention required to prevent severe hypoglycemia. Your firm's User-Related Risk Analysis, RA000021, identified that use errors with the iLet Bionic Pancreas System could trigger unintended insulin doses potentially large enough to cause death (classified as the highest risk level, Severity (b)(4)). Despite this identified safety risk, your firm closed 56 related complaints without implementing corrective actions to address the identified use errors or documenting justification for why corrective actions were deemed unnecessary.\nii. Your firm conducts complaint trending through your risk management procedure, Risk Management Review, SOP 14.1, Rev B, Release Date 2023-03-13, to determine if escalation to corrective and preventive action (CAPA) is warranted. Your firm’s complaint trending process is inadequate, in that:\na. Inconsistencies were observed between what your firm claims to analyze versus what is documented in your trending analysis. For example:\n1. Your firm’s complaint trending provided uses “As Reported Complaint Code: Term” and the part of the system (e.g., iLet device, luer connector, cartridge, etc.), but it does not trend complaints by “Complaint Conclusion” unless there was an associated MDR. Your firm’s Vice President of Quality Assurance stated that they also look at complaint conclusions on everything (with the exception of “not our product”) but that it was just not in the presentation.\n2. Multiple codes with identical or nearly identical meanings were found (e.g., \"Use Error – User Did Not Announce Meals\" vs. \"User Error – Did Not Announce Meals\"). Similar codes could dilute trending data for specific complaint types like meal announcements.\nb. Your firm uses multiple trending rates for complaint analysis that could lead to underestimation of meal announcement complaint rates, potentially affecting safety signals and risk assessment accuracy. For example: Your firm’s complaint trending uses trending rates, such as quantity of complaints per month and as a percentage of the total iLet shipments within a given time period. Your firm’s Vice President of Quality Assurance explained that they also use rates per opportunity. For example, users have approximately ten (10) opportunities to change their cartridge per month, so your firm will trend the percentage by (b)(4). A second example is that users have approximately 90 opportunities to meal announce (three times a day over 30 days), so your firm will trend the same as previous except (b)(4). Your trending rate for meal announcements (90 per month) is not representative of all users’ eating habits and as such might be affecting the rate at which your firm is trending meal announcement related complaints. In addition, your firm’s instructions state that “If you eat a very low carb diet or no carbs at all, you should not announce meals.”\nB. Your firm's verification of effectiveness (VOE) for CAPA 0050 is inadequate, in that, it tested (b)(4) employees on updated training materials, rather than actual iLet users, which was not representative of user population base (e.g. people 6 years of age or older with diabetes mellitus). Additionally, your CAPA 0050 does not address the allegations of hypoglycemia during the adaptation phase of initial use of the iLet.\nYour firm opened CAPA 0050 to investigate hypoglycemia allegations during the iLet Bionic Pancreas System's initial adaptation phase. Your firm determined that the root cause was users' inadequate understanding of diabetes management while using the device, leading to maladaptive behaviors and misuses. Your firm documented the related misuses in RA000021, Rev. E, User-Related Risk Analysis. Your firm initiated preventive actions for CAPA 0050, to include: 1) Holding office hours for health care providers; 2) Improving user training materials; 3) Creating information materials for users transitions from hybrid closed-loop systems and for users new to pump therapy; and 4) Improving guidance materials for health care providers.\nAdditionally, Section 2.8.3 of your firm's corrective and preventive action procedure, Corrective and Preventive Actions, SOP05, Rev H, Release Date 2024-01-09, and section 1.1 of your firm’s work instruction, CAPA Process, WI000053, Rev C, Release Date 2024-01-09, state that an independent investigator and not the CAPA owner is responsible for executing the verification of effectiveness plan and documenting such activity. However, your firm’s CAPA owner also completed the verification of effectiveness activities for CAPA 0050.\nC. Your firm’s procedure, Corrective and Preventive Actions, SOP05, Revs G – I, states that CAPA requests are warranted for systemic issues that affect the quality of products or services, especially if: an incident caused injury or death; there are multiple occurrences of the same event, typically three within a rolling (b)(4) period; or a risk assessment identifies the issue as critical. Your firm failed to maintain records to demonstrate that the cause of nonconformities was investigated; the appropriate action(s) needed to correct and prevent recurrence of nonconforming product were identified; actions taken were verified or validated to ensure the actions were effective and did not adversely affect the products; changes in methods and procedures were implemented; and that information related to the nonconforming products was disseminated to those directly responsible for assuring the quality of the products or prevention of such products.\nSpecifically, investigators observed 15 complaints (dated from July 2023 – December 2023) reporting damaged pump displays, where your firm's product evaluation confirmed the screens were bowed or delaminated. Per your firm’s System Risk Analysis, iLet Bionic Pancreas System, DeLorean (Insulin), RA000005, the risk to patients from being unable to read the display can result in hyper or hypoglycemia and is assigned a Severity of (b)(4) (Life-threatening serious injury that requires emergency professional medical intervention). Your firm implemented design changes to address these nonconformities (adding Vent to housing to vent internal volume of iLet to ambient pressure, per QP000171); however, no records were maintained to document any corrective actions or reference to CAPA records.\nD. Your firm failed to adequately document its investigation into device failures due to 5-minute delayed glucose readings instead of real-time data. Your associated Health Hazard Analysis, HHA-2024-002, dated 04\u002F12\u002F2024, states that this issue could potentially lead to the basal and\u002For correction controller not increasing insulin dosing for high or upward trending Continued Glucose Monitoring (CGM) values or the basal controller not reducing or suspending insulin based on downward trending CGM values. Reportedly, this issue was investigated in collaboration with your CGM supplier, resulting in your firm implementing a temporary software change on 04\u002F05\u002F2024 to mitigate patient risks, while your supplier implemented a permanent solution, however, your firm failed to document this investigation.\nWe reviewed your firm’s responses dated July 18, 2025, August 29, 2025, and October 29, 2025, and conclude that they are not adequate. Your firm's assessment conducted in CAPA 0061 - CAPA VoE Review states, in relation to CAPA-0050, that the Verification of Effectiveness (VoE) was appropriate because it directly measured users' understanding after updated training, addressing the identified root cause, user knowledge gaps. The 100% pass rate on the assessment demonstrates that the revised training effectively improved comprehension related to safe iLet use. However, your firm also indicated in your response that you updated your VoE plan for CAPA-0050 and established a new plan to evaluate CGM-measured percent median time below 54 mg\u002FdL in the user population before and after corrective measures implementation. Your success criteria was established as a (b)(4)% or greater reduction in percent median time below 54 mg\u002FdL, which you state would indicate effectiveness of the corrective measures. Supporting evidence of new CAPA-0050 Verification of Effectiveness (VoE) plan was not provided. The root cause determination and verification of effectiveness criteria for CAPA-0050 is deficient in that it fails to distinguish between system design issues versus user training deficiencies and subsequently the preventive actions were solely focused on training improvements without addressing potential device design issues. It is not clear if an evaluation was made of whether the iLet's design of device (e.g. user interface, alert systems, or other potential design issues) could have contributed to maladaptive behaviors.\n2. Failure to adequately establish and maintain procedures for validating the device design to include an adequate risk analysis, as required by 21 CFR 820.30(g). For example:\nYour firm’s risk management procedure, Risk Management Review, SOP 14.1, Rev B, Release Date: 2023-03-13 states in Sections 1.2 – 1.3 that the Head of QA has overall responsibility for collecting and reporting post market feedback information to management to determine if the product is performing within the risk profile as determined by the products risk management documentation. The following sources provide information that is assessed against the associated risk management documentation: Management Review, Design Testing (non-clinical), Regulatory affairs information pertinent to the bionic pancreas, Nonconforming Material Reports (NCMRs), Manufacturing Data (e.g., yields), Complaints, Health Hazard Assessments, Competitor Information, Published Literature, Customer Feedback including surveys, Clinical Investigations and Follow up. The review of design, production and post market surveillance data and its assessment against the risk profiles per the related risk management documentation shall occur (b)(4), at a minimum.\nYour firm's System Risk Analysis, RA000005, for your iLet Bionic Pancreas, failed to include post-market risks identified through your firm’s complaint data, as required by your procedure. Specifically,\nA. Your firm has failed to incorporate known post-market safety data into your risk management processes.\ni. Investigators observed (b)(4) complaints, dated October 2024 – June 2025, reporting various malfunctions of the iLet Bionic Pancreas Model TA000036 caused by failure of the devices’ printed circuit board assembly manufactured by a supplier. Your firm’s risk analysis does not assess, or control identified hardware hazards.\nii. Investigators observed two complaints, received on 02\u002F07\u002F2024, and 01\u002F01\u002F2025, reporting over infusion of insulin resulting in severe hypoglycemia or hypoglycemia requiring medical intervention where the users reported involuntary meal announcements. Your firm’s risk analysis fails to assess hypoglycemia risk from involuntary meal announcements.\nB. Your firm’s risk management procedure, Risk Management Review, SOP 14.1, Rev B, Release Date: 2023-03-13 states in Section 4 – Unanticipated Risks that as a result of the risk management assessment per this SOP, any unanticipated events are assessed based upon the severity and occurrence of the associated harm and hazard. This assessment includes a review of prior Design Verification Testing (DVT) and\u002For Process Validation activities to verify potential, applicable risk mitigations previously established. Rationale for non-escalation shall be documented in the RMRR and approved by the Head of Quality.\nYour firm has identified a hazard; however, the risk control implementation and validation are absent in your firm’s risk analysis. Specifically,\nComplaint # COM-0000000790 was reviewed reporting a patient with dementia gave themselves multiple successive meal boluses, although they were not eating. The following morning the patient’s blood glucose was 40 mg\u002Fdl. The caregiver attempted to wake the patient, but the patient was unresponsive. While your firm’s System Risk Analysis identifies that vulnerable populations (patients with diminished capacity), might be making inappropriate therapy decisions, resulting in hyper or hypo glycemia, your risk analysis fails to: 1) Document any risk control measures to address this specific hazard; 2) Demonstrate calculation of post-mitigation risks; 3) Show how the identified risk is being adequately controlled.\nC. Despite approximately 529 complaints reporting insulin cartridges or cartridge connectors leaking while in use, your firm's System Risk Analysis, RA000005, for the iLet Bionic Pancreas does not evaluate the risk to patients from cartridges and cartridge connectors leaking during use.\nWe reviewed your firm’s responses dated July 18, 2025, August 29, 2025, and October 29, 2025, and conclude that they are not adequate. Your firm’s response states that you plan to update your risk management procedures; however, it does not address whether and how data sources from your firm’s quality system, such as complaints, CAPAs, nonconforming product, etc., will interface with your firm’s risk analysis process to determine if further corrective actions or regulatory decisions are required.\n3. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\nA. Your firm failed to adequately investigate complaints involving the possible failure of a device, labeling, or packaging to meet any of its specifications. For example:\ni. Investigators review of complaint data from June 2023 – June 2025 found over 500 complaints reporting iLet Bionic Pancreas system insulin cartridges or cartridge connectors leaking. The System Risk Analysis, iLet Bionic Pancreas System, DeLorean (Insulin), RA000005, does not identify the risk to patient from cartridge\u002Fconnector leaks leading to under delivery of insulin to patients; however, the Risk Analysis identifies the risk of system under-delivery of drug resulting in hyper or hypo glycemia due to administration sets leaking as Critical - Results in permanent impairment of life-threatening injury.\nYour firm did not adequately address 31 complaints relating to cartridge or connector leaking. Specifically, your firm closed these complaints without investigation, concluding that no product deficiencies or defects were indicated, and that the complaints did not warrant an investigation. Additionally, by not investigating these product failures, your firm failed to recognize safety risks that could cause adverse events. For example, 18 of the 31 complaints (e.g., COM-0000007869, COM-0000007398, and COM-0000007157) reported that patients experienced hyperglycemic health effects.\nii. Investigators observed that your firm failed to adequately investigate 21 complaints involving bent cannulas or infusion set failures associated with reports of diabetic ketoacidosis (DKA). Your iLet Bionic Pancreas System is distributed to customers with Convatec Inset and Contact Detach infusion sets manufactured for you by your infusion set supplier. Your firm is responsible for intake of complaints for the infusion sets and forwarding them to Convatec. Review of your complaint data shows that approximately 33% of the complaints in your complaint database are related to failure of the infusion sets, with the top failures reported as bent cannula, adhesive issues, and infusion set failures, and with 99.7% of the affected sets not returned by the customers. However, your firm did not request the sets to be returned for further investigation by your infusion set supplier.\nB. Your firm failed to implement and maintain adequate complaint files, per your procedures.\nSpecifically, investigators observed that your firm had not adequately implemented your complaint handling procedure, Product Complaints, SOP13, Rev H, Release Date 2023-01-28, which requires review of all reported product experiences within (b)(4) to determine if they constitute a complaint. (b)(4) is the electronic quality management system, used by your firm. Your firm’s work instruction, WI000085, provides instructions for completing the product complaint process. Section 6 of work instruction WI000085, Revs A-C, state that if a complaint was created via (b)(4) (e.g., Case), various fields such as Event as Reported, Event Date, Aware Date, etc. will be auto filled into (b)(4). It also describes how new complaints can be directly entered into (b)(4).\nFor example, your firm did not adequately address a user reported hyperglycemic event, (b)(4) Case 00015304, involving your iLet device. Specifically, on June 3, 2024, a user reported hyperglycemic event requiring emergency room treatment and insulin administration. On June 5, 2024, the user provided additional details including blood glucose reached 476 mg\u002Fdl, stayed high for over 4 hours, and patient developed diabetic ketoacidosis (DKA). On June 5, 2024, your firm closed the case without proper evaluation to determine if it required escalating to a product complaint or if it required reporting. Your firm’s Vice President of Quality Assurance confirmed this was a complaint on June 11, 2025.\nThe adequacy of your firm’s responses cannot be determined at this time, as corrective actions are ongoing. Your firm has committed to implementing a new complaint handling system by October 29, 2025. Corrective actions, such as a retrospective review of complaints, are ongoing, and your firm did not provide complete evidence of implementation of your new complaint handling system. Without this documentation in hand, FDA cannot make an assessment with respect to adequacy. Please continue to send updates regarding the implementation of your corrective actions.\n4. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements, as required by 21CFR 820.90(a). For example:\nYour firm failed to adequately control product that does not conform to specified requirements. Firm's procedure for controlling nonconforming product is SOP09, Nonconformance Reporting.\nNonconformance Report NCR #191 was opened after 61 out of (b)(4) iLet Bionic Pancreas printed circuit board assembly (PCBA) Mainboards failed testing due to faulty (b)(4) connections. Your firm claimed to have investigated with their supplier, your Vice President of Quality Assurance acknowledged that this investigation was not documented, and no corrective action was taken from the supplier, because this was considered a first-time issue. Your firm later received 19 customer complaints related to iLet Bionic Pancreas Model TA000036 failures caused by defective PCBA Mainboards with improperly installed components.\nWe reviewed your firm’s responses dated July 18, 2025, August 29, 2025, and October 29, 2025, and conclude that they are not adequate. Your firm’s CAPA 0064 NCR\u002FSCAR Review table shows instances where your firm has decided no SCAR is to be opened. The justifications for the following instances are inadequate:\nComponents no longer active (i.e. Component is no longer active in current iLet (TA000048) configuration). It is not clear if these non-conformances still being tracked and adequately investigated. Your response does not address if there are devices in the field that still contain this component or if the supplier still provides components that are active. There are repeated instances in table where the same supplier has sent mixed lots of components, manufactured to incorrect part number or sent mislabeled components, but no SCARs were issued.\nComponent manufactured to incorrect Part Number or Revision (i.e. the components were found manufactured to the incorrect part number. […] No SCAR will be issued as the parts were manufactured using equivalent materials. […] No additional NCRs were issued for a similar incident.)\nDamage during transportation (i.e. Damage to external shippers). It is not clear if these non-conformances still being tracked and adequately investigated.\nTypographical errors (i.e. Expiration Date on CoC was incorrect. […] The incorrect expiration on the CoC was a typographical error. The CoC was updated to the correct expiration date that was stated on the product.)\nMedical Device Reporting (MDR) Violations\nOur inspection also revealed that your firm’s iLet Dosing Decision Software and the iLet ACE Pump are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i. 21 CFR Part 803 - Medical Device Reporting was promulgated under section 519 of the Act, among other provisions. Significant violations include, but are not limited to, the following:\n1. Failure to report to the FDA the information required by 21 CFR 803.52 in accordance with the requirements of § 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1). Manufacturers should submit a separate report for each device that it markets that may have caused or contributed to a death or serious injury. For example,\nA. The information included for Complaint COM-0000008592 describes an event in which a patient experienced hyperglycemia and chest pains while using your firm’s iLet Dosing Decision Software and was subsequently treated with IV fluids and Insulin. The IV fluids rehydrated the patient and corrected electrolyte imbalances, while IV insulin provided a way to lower the high blood sugar (hyperglycemia). If left untreated, chronic hyperglycemia can lead to diabetes complications, such as cardiovascular disease, nerve damage, eye disease and kidney damage. Based on the information included for the complaint and the medical intervention given to the patient, we determined that your firm’s device may have caused or contributed to a serious injury as defined by 21 CFR 803.3(w)(3). The medical intervention was necessary to preclude permanent impairment of a body function or permanent damage to a body structure. Therefore, this event meets the definition of a MDR reportable event under 21 CFR 803.3(o)(2)(i) because the serious injury was or may have been attributed to the iLet Dosing Decision Software, or the iLet Dosing Decision Software was or may have been a factor in a serious injury. Your firm became aware of the event on August 19, 2024, when you acquired the information in this complaint that reasonably suggested a reportable event had occurred. However, no MDR was received by the FDA.\nB. The information included for Complaints COM-0000025536, COM-0000026475, COM-0000026763, COM-0000003142 and COM-0000005866 describe adverse events in which patients experienced hypoglycemia with blood sugar levels below 70 mg\u002FdL, while using your firm’s iLet Dosing Decision Software, and were treated with glucose drink or candies to raise their blood glucose level. We determined that treatment for hypoglycemia that includes glucose drinks or candies is a medical intervention necessary to preclude permanent impairment of a body function or permanent damage to a body structure because, if left untreated, hypoglycemia can lead to confusion, shakiness, dizziness, and weakness, but if severe and untreated, it can progress to serious complications like seizures, loss of consciousness (fainting), brain damage, coma, and even death. Repeated episodes can also cause reduced cognitive function, cardiovascular issues, and increased risk for future severe lows. Therefore, based on the information included for the complaints involving your firm’s device and the medical intervention given to the patients, we determined that your firm’s device may have caused or contributed to a serious injury as defined by 21 CFR 803.3(w)(3). Each of these events therefore meet the definition of an MDR reportable event under 21 CFR 803.3(o)(2)(i) because the serious injury was or may have been attributed to the iLet Dosing Decision Software, or the iLet Dosing Decision Software was or may have been a factor in a serious injury. Your firm became aware of the information included for Complaint COM-0000025536, which reasonably suggests a reportable event has occurred, on April 23, 2025, and FDA received the corresponding MDR 3019004087-2025-00443 on July 14, 2025, which exceeds the required 30-calendar day timeframe in 21 CFR 803.50(a). Your firm became aware of the information included for Complaint COM-0000026475, which reasonably suggests a reportable event has occurred, on April 30, 2025, and FDA received the corresponding MDR 3019004087-2025-00461 on July 9, 2025, which exceeds the required 30-calendar day timeframe. Your firm became aware of the information corresponding to Complaint COM-0000026763, which reasonably suggests a reportable event has occurred, on May 3, 2025, and FDA received the corresponding MDR 3019004087-2025-00581 on June 10, 2025, which exceeds the required 30-calendar day timeframe. Your firm became aware of the information corresponding to Complaint COM-0000003142, which reasonably suggests a reportable event has occurred, on April 1, 2024, and FDA has not yet received an MDR. Your firm became aware of the information included for Complaint COM-0000005866 on June 20, 2024, however, FDA has not yet received an MDR.\n2. Failure to report to FDA the information required by 21 CFR 803.52 in accordance with the requirements of § 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\nFor example, the information included for complaints COM-0000004919, COM-0000008065 and COM-0000008452 reasonably suggests that the firm’s iLet ACE Pump malfunctioned (e.g. component failures: memory chips,) while in use, meaning the device failed to meet its performance specifications or otherwise perform as intended under 21 CFR 803.3(k). Specifically, complaint COM-0000004919 describes an “Alert 60 - Bluetooth Communication” error, complaint COM-0000008065 describes a “Touchscreen unresponsive” error, and complaint COM-0000008452 describes a sleep\u002Fwake button unresponsive” error. Although the malfunction alerts reference different alert codes, each malfunction is associated with a defective hoverboard. A device malfunction that is associated with a defective hoverboard has previously resulted in a patient sustaining a serious injury. (Refer to complaint COM-0000003142). This prior incident demonstrates that such a malfunction (i.e., one that is associated with a defective hoverboard) is linked to a serious injury. It is reasonable to conclude that a recurrence of these malfunctions that are associated with a defective hoverboard would therefore be likely to cause or contribute to a serious injury. As such, the malfunctions listed in these complaints represent MDR reportable events for which MDRs must be submitted. Your firm became aware of Complaint COM-0000004919 on 5\u002F25\u002F2024, Complaint COM-0000008065 on 8\u002F8\u002F2024 and Complaint COM-0000008065 on 8\u002F8\u002F2024 however, based on our records, FDA has not yet received an MDR for each of the referenced malfunction events.\nThe adequacy of your firm’s response dated July 18, 2025, cannot be determined at this time. In the response, your firm noted it initiated corrective actions to address the reporting issue, including a retrospective review of complaints received since June 2023. However, documentation of these corrective actions was not provided, as they are still ongoing.\nThe adequacy of your firm’s response dated August 28, 2025, cannot be determined at this time. Your firm’s response dated August 28, 2025, is a periodic update and did not include any additional new information.\nThe adequacy of your firm’s response dated October 29, 2025, cannot be determined at this time. Your firm’s response dated October 29, 2025, noted that your firm has a three-phase plan to address the reporting issue. However, documentation of the completion of these corrective actions was not provided, as they are still ongoing.\nIn addition, the inspection revealed that your firm failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17(a)(1). For example, during the inspection, your firm presented a document titled “Guidelines for FDA Reporting”, SOP 13.1, Rev. A, dated 2023-10-23, as its MDR procedure. After reviewing the procedure, we conclude that the procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, there are inadequate definitions of what constitutes a reportable event under 21 CFR Part 803. The fact that the procedure does not include a definition from 21 CFR 803.3 for the term “cause or contributed” may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\nYour firm’s response dated August 28, 2025, appears to be adequate. In the response, your firm included a copy of its revised MDR procedure titled “Guidelines for FDA Reporting”, Documents Number: SOP 13.1, Rev. B, dated 2025-07-16, along with staff training records. Upon review, the revised procedures have adequately addressed the deficiency described above.\nCorrections and Removals Violation(s)\nOur inspection also revealed that your firm’s iLet Dosing Decision Software and the iLet ACE Pump are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i. 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals was promulgated under section 519 of the Act, among other provisions. Significant violations include, but are not limited to, the following:\nFailure to submit to the FDA within 10 working days of initiating a correction or removal a report required by 21 CFR 806.10. For example:\nA. Your firm discovered that the iLet Dosing Decision Software had failures regarding glucose values that were 5 minutes old (delayed readings), instead of using new readings as expected. The iLet Dosing Decision Software autonomously determines and commands an increase, decrease, maintenance, or suspension of all basal doses of insulin and autonomously determines and commands correction doses of insulin based on glucose readings, and it autonomously determines, and commands meal doses of insulin based on meal announcements. Use of the delayed glucose readings resulted in your iLet Dosing Decision Software not performing as intended, not dosing insulin to the patient and patient experiencing elevated blood glucose levels that presents a risk to health. Your firm implemented a software change\u002Frelease version 1.4.4 to mitigate the risk to health posed by your iLet Dosing Decision Software. The new software version was uploaded to the cloud and made available to the customers for download on 4\u002F5\u002F2024. This action constitutes a medical device correction or removal initiated to reduce a risk to health posed by your device or remedy a violation of the Act caused by your device which may present a risk to health, under 21 CFR 806.10(a). You have not already provided this information as set forth in 21 CFR 806.10(f) (see 21 CFR 806.10(a)(2)), nor was the correction or removal action exempt from the reporting requirements under 21 CFR 806.1(b) (see 21 CFR 806.10(a)(2)). You were therefore required to submit a Report of Correction or Removal to FDA within 10 working days of initiation, under 21 CFR 806.10(b).\nB. Your firm discovered that the iLet ACE Pump had cybersecurity vulnerability for the Limited Access feature of the iLet Bionic Pancreas System, which is used as a security measure to prevent unwanted access to the pump controls. When either the lockscreen or Limited Access Passcode screen is viewed on the iLet display, other icons are present and active, and (b)(4). This results in unsecured access to change settings, including stopping insulin delivery or giving boluses inappropriately, both of which present a risk to health. Your firm implemented a software fix via DCO #3203 and released Software Version 1.4.3 on 3\u002F26\u002F2024. Beta Bionics sent an email to all customers on 4\u002F1\u002F2024, titled “iLet Software Update”, notifying them that Beta Bionics, Inc. released an iLet Bionic Pancreas Software update. This action constitutes a medical device correction or removal initiated to reduce a risk to health posed by the device or remedy a violation of the Act caused by the device which may present a risk to health, under 21 CFR 806.10(a). You have not already provided this information as set forth in 21 CFR 806.10(f) (see 21 CFR 806.10(a)(2)), nor was the correction or removal action exempt from the reporting requirements under 21 CFR 806.1(b) (see 21 CFR 806.10(a)(2)). You were therefore required to submit a Report of Correction or Removal to FDA within 10 working days of initiation, under 806.10(b).\nYour firm’s responses to the FDA-483, dated July 18, 2025, August 29, 2025, and October 29, 2025, are not adequate. For the issue related to delayed glucose readings described in paragraph A above, you categorized your action as a device enhancement, stating that the change was to improve a non-violative device’s safety or performance. Even if you categorized the software update as a “device enhancement,” the evidence still indicates that a report of correction or removal was required to have been submitted to FDA because you initiated the correction (i.e., updated the software) in order to reduce a risk to health posed by the device (i.e., inaccurate insulin dosing). The fact that the issue might have also involved a third-party CGM does not change the fact that you initiated the correction to reduce a risk to health posed by your device. Furthermore, there is no evidence that you designed and tested the iLet device to function with the particular CGM at issue.\nFor the issue related to the cybersecurity vulnerability for the Limited Access feature described in paragraph B above, your firm alleges that the issue is non-reportable. We do not agree with this assessment. The evidence indicates that a report of correction or removal was required to have been submitted to FDA because you initiated the correction (i.e., updated the software) in order to reduce a risk to health posed by the device (i.e., prevent unsecured access to the pump controls).\nIn addition, regarding your statement that your firm was conducting a Class III recall, we note that a recall’s classification is assigned by FDA, not the recalling firm (e.g., 21 CFR 7.3(m) and 7.41(b)), and that conducting a voluntary recall does not exempt a firm from the requirement to submit a report of correction or removal under Part 806 (e.g., 21 CFR 806.10(a)(2)). As explained above, you were required to submit a report of correction or removal to FDA.\nYou have not submitted Reports of Correction or Removal to FDA as of 01\u002F15\u002F2026 for either of the failures listed above.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 717927” when replying. If you have any questions about the contents of this letter, please contact: Shaquenta Perkins at shaquenta.perkins@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or concerning your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nActing Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","beta-bionics-inc-717927-01282026-0","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbeta-bionics-inc-717927-01282026-0","2026-10-26T08:08:03.799098+00:00","2026-03-03","2026-08-19T04:53:09.252+00:00","VIA Electronic Mail",{"id":66,"raw":67,"subject":72,"body_html":73,"body_text":74,"firm_name":75,"letter_id":76,"created_at":77,"fei_number":19,"letter_url":78,"updated_at":79,"action_type":22,"case_status":23,"posted_date":80,"marcs_cms_no":81,"product_type":82,"closeout_date":19,"issuing_office":71,"recipient_name":83,"body_fetched_at":84,"delivery_method":85,"recipient_title":19,"reference_number":19,"action_taken_date":86,"medical_device_id":19,"response_letter_date":19},2681,[68,69,70,71,72,13,13,13],"\u003Ctime datetime=\"2022-05-09T16:00:00Z\">05\u002F09\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-05-04T04:00:00Z\">05\u002F04\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-nutritional-supplements-llc-622055-05042022\">Advanced Nutritional Supplements LLC\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","Dietary Supplement\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Brandon March\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Advanced Nutritional Supplements LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3872 Union Deposit Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Harrisburg\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>17109\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Dear Mr. March:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your products New God of Rage, God of War, New God of Fire, Legion: Extreme Fat Burner, Laxovar: Natural Recomposition, and Uprising: Natural Testosterone Support which are labeled as dietary supplements. As explained further below, introducing or delivering these products for introduction into interstate commerce violates the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) because the products are adulterated dietary supplements. You can find the FD&amp;C Act through links on FDA’s website at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Flaws-enforced-fda\u002Ffederal-food-drug-andcosmetic-act-fdc-act, and the FDA regulations at https:\u002F\u002Fwww.ecfr.gov\u002Fcurrent\u002Ftitle-21.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Dietary Supplements: Unsafe Food Additives\u003C\u002Fstrong>&nbsp;\u003C\u002Fp>\n\n\u003Cp>The labels of the following products declare dietary ingredients: New God of Rage declares higenamine HCl &amp; hordenine HCl, God of War declares hordenine HCl, New God of Fire declares hordenine HCl, Legion: Extreme Fat Burner declares higenamine HCl, Laxovar: Natural Recomposition declares 5ahydroxy-laxogenin, an abbreviated name for 5-alpha-hydroxy-laxogenin\u003Ca id=\"footnoteref1_rujmm7u\" href=\"#footnote1_rujmm7u\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>, and Uprising: Natural Testosterone Support declares 5-alpha-hydroxy-laxogenin. However, higenamine HCl, hordenine HCl, and 5-alpha-hydroxy-laxogenin are not dietary ingredients. Under section 201(ff)(1) of the FD&amp;C Act [21 U.S.C. § 321(ff)(1)], a dietary ingredient is a vitamin; a mineral; an herb or other botanical; an amino acid; a dietary substance for use by man to supplement the diet by increasing the total dietary intake; or a concentrate, metabolite, constituent, extract, or combination of any dietary ingredient from the preceding categories. Higenamine HCl, hordenine HCl, and 5-alpha-hydroxy-laxogenin do not qualify as dietary ingredients under section 201(ff)(1) of the FD&amp;C Act because they are not a vitamin, a mineral, an amino acid, an herb or other botanical, a dietary substance for use by man to supplement the diet by increasing the total dietary intake, or a concentrate, metabolite, constituent, extract, or a combination of any dietary ingredient from the preceding categories.\u003C\u002Fp>\n\n\u003Cp>If a substance is not generally recognized as safe (GRAS) by qualified experts for its intended use in food and does not qualify for any of the other exemptions from the food additive definition, it is a food additive. Food additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. § 342(a)(2)(C)(i)]. Adulterated foods cannot be legally imported or marketed in the United States.\u003C\u002Fp>\n\n\u003Cp>Section 201(s) of the FD&amp;C Act [21 U.S.C § 321(s)] exempts dietary ingredients used in dietary supplements from the food additive definition. However, non-dietary ingredients intended for use in dietary supplements, such as the higenamine HCl, hordenine HCl, and 5-alpha-hydroxy-laxogenin used in your products, are not exempt from the food additive definition and must meet the same requirements as substances added to conventional foods. In other words, a non-dietary ingredient added to a dietary supplement must be used in accordance with a food additive regulation or be GRAS for its intended use, unless it qualifies for another exception to the food additive definition.\u003C\u002Fp>\n\n\u003Cp>Higenamine HCl, hordenine HCl, and 5-alpha-hydroxy-laxogenin are not generally recognized as safe under its conditions of use in your dietary supplement products. Because higenamine HCl, hordenine HCl, and 5-alpha-hydroxy-laxogenin do not qualify as dietary ingredients and are not GRAS or otherwise exempt from the food additive definition, your New God of Rage, God of War, New God of Fire, Legion: Extreme Fat Burner, Laxovar: Natural Recomposition, and Uprising: Natural Testosterone Support products are adulterated under section 402(a)(2)(C)(i) of the FD&amp;C Act because they contain unsafe food additives. The introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address these matters. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written reply should be directed to Aaron Dotson, Compliance Officer, via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nAnn M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\u003Col>\n                  \u003Cli id=\"footnote1_rujmm7u\">\u003Ca href=\"#footnoteref1_rujmm7u\">1\u003C\u002Fa>Chemists commonly use “a” as an abbreviation for “alpha.”\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nBrandon March\n\nAdvanced Nutritional Supplements LLC\n\n3872 Union Deposit Rd\n\nHarrisburg, PA 17109\n\nUnited States\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nDear Mr. March:\n\nThis letter concerns your products New God of Rage, God of War, New God of Fire, Legion: Extreme Fat Burner, Laxovar: Natural Recomposition, and Uprising: Natural Testosterone Support which are labeled as dietary supplements. As explained further below, introducing or delivering these products for introduction into interstate commerce violates the Federal Food, Drug, and Cosmetic Act (the FD&C Act) because the products are adulterated dietary supplements. You can find the FD&C Act through links on FDA’s website at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Flaws-enforced-fda\u002Ffederal-food-drug-andcosmetic-act-fdc-act, and the FDA regulations at https:\u002F\u002Fwww.ecfr.gov\u002Fcurrent\u002Ftitle-21.\n\nAdulterated Dietary Supplements: Unsafe Food Additives\n\nThe labels of the following products declare dietary ingredients: New God of Rage declares higenamine HCl & hordenine HCl, God of War declares hordenine HCl, New God of Fire declares hordenine HCl, Legion: Extreme Fat Burner declares higenamine HCl, Laxovar: Natural Recomposition declares 5ahydroxy-laxogenin, an abbreviated name for 5-alpha-hydroxy-laxogenin1, and Uprising: Natural Testosterone Support declares 5-alpha-hydroxy-laxogenin. However, higenamine HCl, hordenine HCl, and 5-alpha-hydroxy-laxogenin are not dietary ingredients. Under section 201(ff)(1) of the FD&C Act [21 U.S.C. § 321(ff)(1)], a dietary ingredient is a vitamin; a mineral; an herb or other botanical; an amino acid; a dietary substance for use by man to supplement the diet by increasing the total dietary intake; or a concentrate, metabolite, constituent, extract, or combination of any dietary ingredient from the preceding categories. Higenamine HCl, hordenine HCl, and 5-alpha-hydroxy-laxogenin do not qualify as dietary ingredients under section 201(ff)(1) of the FD&C Act because they are not a vitamin, a mineral, an amino acid, an herb or other botanical, a dietary substance for use by man to supplement the diet by increasing the total dietary intake, or a concentrate, metabolite, constituent, extract, or a combination of any dietary ingredient from the preceding categories.\n\nIf a substance is not generally recognized as safe (GRAS) by qualified experts for its intended use in food and does not qualify for any of the other exemptions from the food additive definition, it is a food additive. Food additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. § 342(a)(2)(C)(i)]. Adulterated foods cannot be legally imported or marketed in the United States.\n\nSection 201(s) of the FD&C Act [21 U.S.C § 321(s)] exempts dietary ingredients used in dietary supplements from the food additive definition. However, non-dietary ingredients intended for use in dietary supplements, such as the higenamine HCl, hordenine HCl, and 5-alpha-hydroxy-laxogenin used in your products, are not exempt from the food additive definition and must meet the same requirements as substances added to conventional foods. In other words, a non-dietary ingredient added to a dietary supplement must be used in accordance with a food additive regulation or be GRAS for its intended use, unless it qualifies for another exception to the food additive definition.\n\nHigenamine HCl, hordenine HCl, and 5-alpha-hydroxy-laxogenin are not generally recognized as safe under its conditions of use in your dietary supplement products. Because higenamine HCl, hordenine HCl, and 5-alpha-hydroxy-laxogenin do not qualify as dietary ingredients and are not GRAS or otherwise exempt from the food additive definition, your New God of Rage, God of War, New God of Fire, Legion: Extreme Fat Burner, Laxovar: Natural Recomposition, and Uprising: Natural Testosterone Support products are adulterated under section 402(a)(2)(C)(i) of the FD&C Act because they contain unsafe food additives. The introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nWithin fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address these matters. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour written reply should be directed to Aaron Dotson, Compliance Officer, via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nFood and Drug Administration\n\n1Chemists commonly use “a” as an abbreviation for “alpha.”","Advanced Nutritional Supplements LLC","advanced-nutritional-supplements-llc-622055-05042022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-nutritional-supplements-llc-622055-05042022","2026-10-26T08:07:50.550656+00:00","2022-05-09","622055","Dietary Supplements","Brandon March","2026-08-20T01:55:24.118+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","2022-05-04",{"id":88,"raw":89,"subject":94,"body_html":95,"body_text":96,"firm_name":97,"letter_id":98,"created_at":99,"fei_number":19,"letter_url":100,"updated_at":101,"action_type":22,"case_status":23,"posted_date":102,"marcs_cms_no":103,"product_type":104,"closeout_date":19,"issuing_office":93,"recipient_name":105,"body_fetched_at":106,"delivery_method":107,"recipient_title":19,"reference_number":108,"action_taken_date":109,"medical_device_id":19,"response_letter_date":19},1007,[90,91,92,93,94,13,13,13],"\u003Ctime datetime=\"2025-03-18T04:00:00Z\">03\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-03-14T04:00:00Z\">03\u002F14\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-pharmaceutical-technology-692576-03142025\">Advanced Pharmaceutical Technology\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceutical\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-55\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Frank M. Bardani\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Advanced Pharmaceutical Technology\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>132 South Central Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Elmsford\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10523\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-55\u003C\u002Fp>\u003Cp>March 14, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Bardani:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Advanced Pharmaceutical Technology Inc., FEI 3009963974, at 132 South Central Avenue, Elmsford, from July 10 to August 1, 2024. The products you manufacture at this facility are combination products under section 503(g) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 353(g) as your products include drug and device constituent parts.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) requirements for combination products\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. See Title 21 Code of Federal Regulations (CFR) part 4, 21 CFR parts 210 and 211 (drug CGMP), and 21 CFR part 820 (Quality System or QS Regulation).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to drug CGMP requirements, 21 CFR parts 210 and 211, your combination products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>In addition, information and records gathered during the course of the inspection reflect that your products, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans. Therefore, these products meet the definition of drug as defined in section 201(g)(1) of the FD&amp;C Act [21 U.S.C. 321(g)(1)].\u003C\u002Fp>\u003Cp>We reviewed your August 22, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. We also acknowledge that you recently registered as a 503B Outsourcing Facility. However, you have been distributing your drug products in the United States since 2023, prior to registering as a 503B Outsourcing Facility.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You lacked appropriate controls to ensure the sterility of \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products that purport to be sterile. For example, you relied on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization process without monitoring pre-sterilization bioburden. In addition, you failed to establish an adequate system, as was required by your standard operating procedure (SOP), for monitoring environmental conditions (including the frequency performed) to ensure your manufacturing areas were suitable for sterile drug production.\u003C\u002Fp>\u003Cp>In your response, you state that you plan to test for bioburden, prior to release, and will reject lots that fail to meet appropriate specifications for endotoxin. You also state that environmental monitoring is not required because your drug products are \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilized, and that you tested product that was manufactured more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> prior for microbial content and the samples showed no signs of positive cultures.\u003C\u002Fp>\u003Cp>Your response is inadequate because you failed to include relevant details for pre-sterilization bioburden testing, including limits you have established, and the steps you will take in the event these limits are exceeded. In addition, appropriate environmental conditions for the manufacture of your drugs, including appropriate air quality, must be provided to protect products from microbiological contamination, even when \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilized, in order to minimize sterilization challenges and the byproducts of excessive bioburden.\u003C\u002Fp>\u003Cp>It should be noted that although the sterility test is a critical final quality control for products that purport to be sterile, it cannot be solely relied upon as justification to release each drug product batch, as the test is only the last in a series of design and control provisions intended to protect the consumer from distribution of an unsafe batch. Sample sizes for sterility testing are typically small compared to the total number of units in a batch and may not detect issues that result in sporadic non-sterility. For example, inadequate \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization validation studies or failure to consistently execute a \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization cycle within its validated state may go undetected for substantial periods if your firm places too much reliance on the final quality control test for sterility to identify a sterility assurance problem. It is also essential to note that any positive sterility test result represents a serious CGMP issue that requires a comprehensive investigation into the cause and extent of the problem, and prompt review of the qualification status of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization process.\u003C\u002Fp>\u003Cp>This is a repeat violation from your 2019 and 2021 inspections.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm failed to have, for each batch of controlled-release dosage form, appropriate laboratory determination of satisfactory conformance to the specifications for the rate of release of each active ingredient (21 CFR 211.167(c)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to provide adequate data demonstrating your drug products, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, have a \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the active ingredient. For example, you claim your \u003Cstrong>(b)(4)\u003C\u002Fstrong> lasts for up to \u003Cstrong>(b)(4)\u003C\u002Fstrong> and that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> products have \u003Cstrong>(b)(4)\u003C\u002Fstrong> effect for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your release and stability data for dissolution does not provide data that drug \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Drug products should not be released without appropriate determination of conformance to final specifications and intended use. There is a lack of assurance of appropriate quality and that your drug will have the intended effect it purports to possess.\u003C\u002Fp>\u003Cp>In your response, you state that you estimated the therapeutic duration and that you will remove \u003Cstrong>(b)(4)\u003C\u002Fstrong> claims until you perform adequate studies. Your response is inadequate because you did not provide a retrospective assessment of your drug products on the U.S. market within expiry to identify and take appropriate action on any product quality or patient safety risks.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilized, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You lacked adequate scientific rationale to demonstrate that your drug manufacturing processes are appropriately validated, reproducible, and controlled to consistently yield drug products of uniform character and quality. For example, you increased the commercial production batch size and released drug product without appropriate validation. You also failed to include critical process parameters in your batch records.\u003C\u002Fp>\u003Cp>In your response, you plan to revalidate manufacturing processes and include more detailed production steps. Your response is inadequate because you failed to provide a detailed plan or supportive documentation for adequately validating your drug production process.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle. See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>This is a repeat violation from your 2019 and 2021 inspections.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Contract Testing Laboratories\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your quality unit (QU) did not exercise its responsibility to oversee your contract testing laboratory to ensure the appropriate finish product testing was being conducted. For example, you failed to ensure your contract testing laboratory completed the method validation protocol for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The Method Validation Report did not identify potential impurities of \u003Cstrong>(b)(4)\u003C\u002Fstrong> referenced in the method validation protocol. You did not adequately ensure the executed test method was suitable to monitor all potential impurities.\u003C\u002Fp>\u003Cp>In your response, you provided an impurity method that did not adequately identify and characterize the potential impurities of your drug products. Your response is inadequate because the method validation protocol should include all potential impurities with the scientific justification for which ones would be included in the test method. You did not commit to performing a retrospective assessment of all the product lots currently on the market within expiry once new method validations are completed.\u003C\u002Fp>\u003Cp>In addition, your contract testing laboratory was conducting a single dissolution test point for your drug products without scientific justification that a single time point demonstrates a consistent drug absorption over an extended period of time.\u003C\u002Fp>\u003Cp>Your response states that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> label claims were removed. Your response is inadequate because you did not provide sufficient scientific justification to support inadequately testing your finished drug product.\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. See the FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cem>Contract Manufacturing Organizations\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm utilizes a contract manufacturing organization (CMO) to manufacture your prescription sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You stated to our investigators that you received a batch of \u003Cstrong>(b)(4)\u003C\u002Fstrong> from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You received this drug product without performing an evaluation of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You do not have adequate procedures to ensure that the sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> produced for your firm met appropriate quality attributes.\u003C\u002Fp>\u003Cp>In your response, you provide documentation indicating that the CMO of \u003Cstrong>(b)(4)\u003C\u002Fstrong> is \u003Cstrong>(b)(4)\u003C\u002Fstrong> and provided documentation of an audit performed at this facility. Your response is inadequate because your QU did not ensure the drug product was manufactured in accordance with CGMP requirements.\u003C\u002Fp>\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\u003Cp>FDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the FD&amp;C Act, 21 U.S.C. 374(a)(4) to your CMO of \u003Cstrong>(b)(4)\u003C\u002Fstrong> Injection USP), \u003Cstrong>(b)(4)\u003C\u002Fstrong>. After multiple follow-up requests, your CMO failed to respond to these attempted communications or otherwise provide the requested records or other information. It is a prohibited act under section 301(e) of the FD&amp;C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a). Because your CMO failed to respond to the section 704(a)(4) records requests and associated communication attempts, FDA placed all drugs and drug products manufactured by your CMO on Import Alert 66-79. Drugs manufactured by facilities on Import Alert 66-79 are subject to refusal of admission pursuant to section 801(a)(3) of the FD&amp;C Act in that all drugs from their facility appear to be adulterated under section 501(j) because they have been manufactured, processed, packed, or held in any factory, warehouse, or establishment and the owner, operator or agent of such factory, warehouse, or establishment delays, denies, or limits an inspection, or refuses to permit entry or inspection.\u003C\u002Fp>\u003Cp>You are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved Drugs\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> products, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as well as your \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection product are listed in FDA’s electronic Drug Registration and Listing System (eDRLS) as “Export Only.” However, information obtained during the inspection of your firm indicates that your firm plans to distribute these products commercially in the United States. Please be advised that, based on review of the product labeling collected during the inspection of your firm and the labeling that your firm submitted to FDA’s eDRLS, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act and require FDA premarket approval under section 505 of the FD&amp;C Act [21 U.S.C. 355]. Distribution of an unapproved new drug in the United States is prohibited under section 301(d) of the FD&amp;C Act [21 U.S.C. 331(d)].\u003C\u002Fp>\u003Cp>We encourage you to contact FDA’s Office of New Drugs at ONDCommunications@fda.hhs.gov for assistance with the application process for your unapproved drug products.\u003C\u002Fp>\u003Cp>\u003Cstrong>503B Registration\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 503B(b) of the FD&amp;C Act, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FD&amp;C Act [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FD&amp;C Act [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements in section 582 of the FD&amp;C Act [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FD&amp;C Act are met. However, outsourcing facilities must comply with other applicable provisions of the FD&amp;C Act, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding CGMP requirements.\u003Cem>\u003Cstrong>\u003Csup>2,3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>Drugs Manufactured for Importation into the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Drug products imported into the United States must comply with all applicable requirements under the FD&amp;C Act and the corresponding regulations set forth in Title 21 of the Code of Federal Regulations. These requirements include compliance with labeling requirements, firm registration and drug listing, and adherence to CGMP. Facilities that manufacture drug products and drug components intended for importation into the United States are subject to inspection by the FDA to determine compliance with these regulatory standards. For drugs requiring NDA or ANDA approval, the application must be submitted to and approved by the FDA’s Center for Drug Evaluation and Research (CDER) prior to importation, as required by section 505(a) of the FD&amp;C Act and 21 CFR part 314.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drugs Manufactured for Exportation out of the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Drug products exported from the United States under section 802 of the FD&amp;C Act, must comply with applicable requirements under the FD&amp;C Act, including those specified in section 802(f) [21 U.S.C. § 382(f)]. Under this provision, a drug may not be exported if it is not “manufactured, processed, packaged, and held in substantial conformity with current good manufacturing practice requirements.” Furthermore, a drug is considered adulterated under section 501(a)(2)(B) of the FD&amp;C Act [21 U.S.C. § 351(a)(2)(B)] if the methods, facilities, or controls used in its manufacture, processing, packaging, or holding do not conform to CGMP standards.\u003C\u002Fp>\u003Cp>We therefore encourage you to review your manufacturing processes to ensure that unapproved new drugs intended for export comply with CGMP requirements. Non-compliance with these requirements prevents your ability to export these drugs under section 802(f) of the FD&amp;C Act [21 U.S.C. § 382(f)].\u003C\u002Fp>\u003Cp>\u003Cstrong>Repeat Violations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In previous inspections from September 10 to 27, 2019, and August 5 to 23, 2021, FDA cited similar CGMP violations. You proposed specific remediation for these violations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Because you failed to correct repeat violations, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3009963974 and ATTN: Kevin Maguire.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Jill P. Furman\u003Cbr>Director\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_______________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1 \u003C\u002Fstrong>\u003C\u002Fem>The terms combination product and drug are used interchangeably in this letter.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> For additional information, please see FDA’s “Information for Outsourcing Facilities” webpage, available at https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fhuman-drug-compounding\u002Finformation-outsourcing-facilities. Furthermore, FDA’s Compounding Quality Center Of Excellence (CQCOE) supports outsourcing facilities’ efforts to improve the quality of drugs they produce through training, research and engagement activities with FDA and other supporting stakeholders. For additional information on the CQCOE, please visit https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fhuman-drug-compounding\u002Fcompounding-quality-center-excellence.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-25-55\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Frank M. Bardani\n\nRecipient Title\n\nPresident\n\nAdvanced Pharmaceutical Technology\n\n132 South Central Avenue\n\nElmsford, NY 10523\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-55\nMarch 14, 2025\nDear Mr. Bardani:\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Advanced Pharmaceutical Technology Inc., FEI 3009963974, at 132 South Central Avenue, Elmsford, from July 10 to August 1, 2024. The products you manufacture at this facility are combination products under section 503(g) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 353(g) as your products include drug and device constituent parts.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) requirements for combination products1. See Title 21 Code of Federal Regulations (CFR) part 4, 21 CFR parts 210 and 211 (drug CGMP), and 21 CFR part 820 (Quality System or QS Regulation).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to drug CGMP requirements, 21 CFR parts 210 and 211, your combination products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nIn addition, information and records gathered during the course of the inspection reflect that your products, (b)(4), are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans. Therefore, these products meet the definition of drug as defined in section 201(g)(1) of the FD&C Act [21 U.S.C. 321(g)(1)].\nWe reviewed your August 22, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. We also acknowledge that you recently registered as a 503B Outsourcing Facility. However, you have been distributing your drug products in the United States since 2023, prior to registering as a 503B Outsourcing Facility.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all sterilization processes (21 CFR 211.113(b)).\nYou lacked appropriate controls to ensure the sterility of (b)(4) drug products that purport to be sterile. For example, you relied on the (b)(4) sterilization process without monitoring pre-sterilization bioburden. In addition, you failed to establish an adequate system, as was required by your standard operating procedure (SOP), for monitoring environmental conditions (including the frequency performed) to ensure your manufacturing areas were suitable for sterile drug production.\nIn your response, you state that you plan to test for bioburden, prior to release, and will reject lots that fail to meet appropriate specifications for endotoxin. You also state that environmental monitoring is not required because your drug products are (b)(4) sterilized, and that you tested product that was manufactured more than (b)(4) prior for microbial content and the samples showed no signs of positive cultures.\nYour response is inadequate because you failed to include relevant details for pre-sterilization bioburden testing, including limits you have established, and the steps you will take in the event these limits are exceeded. In addition, appropriate environmental conditions for the manufacture of your drugs, including appropriate air quality, must be provided to protect products from microbiological contamination, even when (b)(4) sterilized, in order to minimize sterilization challenges and the byproducts of excessive bioburden.\nIt should be noted that although the sterility test is a critical final quality control for products that purport to be sterile, it cannot be solely relied upon as justification to release each drug product batch, as the test is only the last in a series of design and control provisions intended to protect the consumer from distribution of an unsafe batch. Sample sizes for sterility testing are typically small compared to the total number of units in a batch and may not detect issues that result in sporadic non-sterility. For example, inadequate (b)(4) sterilization validation studies or failure to consistently execute a (b)(4) sterilization cycle within its validated state may go undetected for substantial periods if your firm places too much reliance on the final quality control test for sterility to identify a sterility assurance problem. It is also essential to note that any positive sterility test result represents a serious CGMP issue that requires a comprehensive investigation into the cause and extent of the problem, and prompt review of the qualification status of your (b)(4) sterilization process.\nThis is a repeat violation from your 2019 and 2021 inspections.\n2. Your firm failed to have, for each batch of controlled-release dosage form, appropriate laboratory determination of satisfactory conformance to the specifications for the rate of release of each active ingredient (21 CFR 211.167(c)).\nYou failed to provide adequate data demonstrating your drug products, (b)(4), have a (b)(4) of the active ingredient. For example, you claim your (b)(4) lasts for up to (b)(4) and that your (b)(4) products have (b)(4) effect for (b)(4). Your release and stability data for dissolution does not provide data that drug (b)(4). Drug products should not be released without appropriate determination of conformance to final specifications and intended use. There is a lack of assurance of appropriate quality and that your drug will have the intended effect it purports to possess.\nIn your response, you state that you estimated the therapeutic duration and that you will remove (b)(4) claims until you perform adequate studies. Your response is inadequate because you did not provide a retrospective assessment of your drug products on the U.S. market within expiry to identify and take appropriate action on any product quality or patient safety risks.\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYour firm manufactures (b)(4) sterilized, (b)(4). You lacked adequate scientific rationale to demonstrate that your drug manufacturing processes are appropriately validated, reproducible, and controlled to consistently yield drug products of uniform character and quality. For example, you increased the commercial production batch size and released drug product without appropriate validation. You also failed to include critical process parameters in your batch records.\nIn your response, you plan to revalidate manufacturing processes and include more detailed production steps. Your response is inadequate because you failed to provide a detailed plan or supportive documentation for adequately validating your drug production process.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle. See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nThis is a repeat violation from your 2019 and 2021 inspections.\n4. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\nContract Testing Laboratories\nYour quality unit (QU) did not exercise its responsibility to oversee your contract testing laboratory to ensure the appropriate finish product testing was being conducted. For example, you failed to ensure your contract testing laboratory completed the method validation protocol for (b)(4). The Method Validation Report did not identify potential impurities of (b)(4) referenced in the method validation protocol. You did not adequately ensure the executed test method was suitable to monitor all potential impurities.\nIn your response, you provided an impurity method that did not adequately identify and characterize the potential impurities of your drug products. Your response is inadequate because the method validation protocol should include all potential impurities with the scientific justification for which ones would be included in the test method. You did not commit to performing a retrospective assessment of all the product lots currently on the market within expiry once new method validations are completed.\nIn addition, your contract testing laboratory was conducting a single dissolution test point for your drug products without scientific justification that a single time point demonstrates a consistent drug absorption over an extended period of time.\nYour response states that the (b)(4) label claims were removed. Your response is inadequate because you did not provide sufficient scientific justification to support inadequately testing your finished drug product.\nYour firm’s quality systems are inadequate. See the FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nContract Manufacturing Organizations\nYour firm utilizes a contract manufacturing organization (CMO) to manufacture your prescription sterile (b)(4) drug product, (b)(4). You stated to our investigators that you received a batch of (b)(4) from (b)(4). You received this drug product without performing an evaluation of (b)(4). You do not have adequate procedures to ensure that the sterile (b)(4) produced for your firm met appropriate quality attributes.\nIn your response, you provide documentation indicating that the CMO of (b)(4) is (b)(4) and provided documentation of an audit performed at this facility. Your response is inadequate because your QU did not ensure the drug product was manufactured in accordance with CGMP requirements.\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\nFDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the FD&C Act, 21 U.S.C. 374(a)(4) to your CMO of (b)(4) Injection USP), (b)(4). After multiple follow-up requests, your CMO failed to respond to these attempted communications or otherwise provide the requested records or other information. It is a prohibited act under section 301(e) of the FD&C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a). Because your CMO failed to respond to the section 704(a)(4) records requests and associated communication attempts, FDA placed all drugs and drug products manufactured by your CMO on Import Alert 66-79. Drugs manufactured by facilities on Import Alert 66-79 are subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that all drugs from their facility appear to be adulterated under section 501(j) because they have been manufactured, processed, packed, or held in any factory, warehouse, or establishment and the owner, operator or agent of such factory, warehouse, or establishment delays, denies, or limits an inspection, or refuses to permit entry or inspection.\nYou are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\nUnapproved Drugs\nYour (b)(4) products, (b)(4), as well as your (b)(4) injection product are listed in FDA’s electronic Drug Registration and Listing System (eDRLS) as “Export Only.” However, information obtained during the inspection of your firm indicates that your firm plans to distribute these products commercially in the United States. Please be advised that, based on review of the product labeling collected during the inspection of your firm and the labeling that your firm submitted to FDA’s eDRLS, these products are new drugs within the meaning of section 201(p) of the FD&C Act and require FDA premarket approval under section 505 of the FD&C Act [21 U.S.C. 355]. Distribution of an unapproved new drug in the United States is prohibited under section 301(d) of the FD&C Act [21 U.S.C. 331(d)].\nWe encourage you to contact FDA’s Office of New Drugs at ONDCommunications@fda.hhs.gov for assistance with the application process for your unapproved drug products.\n503B Registration\nUnder section 503B(b) of the FD&C Act, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FD&C Act [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements in section 582 of the FD&C Act [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FD&C Act are met. However, outsourcing facilities must comply with other applicable provisions of the FD&C Act, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding CGMP requirements.2,3\nDrugs Manufactured for Importation into the United States\nDrug products imported into the United States must comply with all applicable requirements under the FD&C Act and the corresponding regulations set forth in Title 21 of the Code of Federal Regulations. These requirements include compliance with labeling requirements, firm registration and drug listing, and adherence to CGMP. Facilities that manufacture drug products and drug components intended for importation into the United States are subject to inspection by the FDA to determine compliance with these regulatory standards. For drugs requiring NDA or ANDA approval, the application must be submitted to and approved by the FDA’s Center for Drug Evaluation and Research (CDER) prior to importation, as required by section 505(a) of the FD&C Act and 21 CFR part 314.\nDrugs Manufactured for Exportation out of the United States\nDrug products exported from the United States under section 802 of the FD&C Act, must comply with applicable requirements under the FD&C Act, including those specified in section 802(f) [21 U.S.C. § 382(f)]. Under this provision, a drug may not be exported if it is not “manufactured, processed, packaged, and held in substantial conformity with current good manufacturing practice requirements.” Furthermore, a drug is considered adulterated under section 501(a)(2)(B) of the FD&C Act [21 U.S.C. § 351(a)(2)(B)] if the methods, facilities, or controls used in its manufacture, processing, packaging, or holding do not conform to CGMP standards.\nWe therefore encourage you to review your manufacturing processes to ensure that unapproved new drugs intended for export comply with CGMP requirements. Non-compliance with these requirements prevents your ability to export these drugs under section 802(f) of the FD&C Act [21 U.S.C. § 382(f)].\nRepeat Violations at Facility\nIn previous inspections from September 10 to 27, 2019, and August 5 to 23, 2021, FDA cited similar CGMP violations. You proposed specific remediation for these violations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\nCGMP Consultant Recommended\nBecause you failed to correct repeat violations, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3009963974 and ATTN: Kevin Maguire.\nSincerely,\n\u002FS\u002F\nJill P. Furman\nDirector\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_______________\n1 The terms combination product and drug are used interchangeably in this letter.\n2 We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FD&C Act.\n3 For additional information, please see FDA’s “Information for Outsourcing Facilities” webpage, available at https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fhuman-drug-compounding\u002Finformation-outsourcing-facilities. Furthermore, FDA’s Compounding Quality Center Of Excellence (CQCOE) supports outsourcing facilities’ efforts to improve the quality of drugs they produce through training, research and engagement activities with FDA and other supporting stakeholders. For additional information on the CQCOE, please visit https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fhuman-drug-compounding\u002Fcompounding-quality-center-excellence.","Advanced Pharmaceutical Technology","advanced-pharmaceutical-technology-692576-03142025","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-pharmaceutical-technology-692576-03142025","2026-10-26T08:07:50.58707+00:00","2025-03-18","692576","Drugs","Mr. Frank M. Bardani","2026-08-19T16:55:57.953+00:00","VIA UPS","320-25-55","2025-03-14",{"id":111,"raw":112,"subject":118,"body_html":119,"body_text":120,"firm_name":121,"letter_id":122,"created_at":123,"fei_number":19,"letter_url":124,"updated_at":125,"action_type":22,"case_status":23,"posted_date":126,"marcs_cms_no":127,"product_type":104,"closeout_date":19,"issuing_office":116,"recipient_name":128,"body_fetched_at":129,"delivery_method":130,"recipient_title":19,"reference_number":19,"action_taken_date":131,"medical_device_id":19,"response_letter_date":19},2384,[113,114,115,116,117,13,13,13],"\u003Ctime datetime=\"2022-10-25T13:20:00Z\">10\u002F25\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-09-26T04:00:00Z\">09\u002F26\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-cosmetic-research-laboratories-inc-635176-09262022\">Advanced Cosmetic Research Laboratories Inc.\u003C\u002Fa>","Division of Pharmaceutical Quality Operations IV","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FUnapproved New Drug\u003Cbr \u002F>\r\n","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FUnapproved New Drug","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL CONFIRMED DELIVERY\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Kitty Hunter\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Advanced Cosmetic Research Laboratories Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>20550 Prairie Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chatsworth\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91311-6006\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 26, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Hunter:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration inspected your drug manufacturing facility, Advanced Cosmetic Research Laboratories Inc., FEI 3003059934, at 20550 Prairie Street, Chatsworth, from April 21 to 27, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>In addition, \u003Cstrong>(b)(4)\u003C\u002Fstrong> 5% LIDOCAINE CREAM is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>We have not received a detailed response from your firm for corrective actions to the observations identified during the inspection in our Form FDA 483. The correspondence received included a commitment to respond on or before October 1, 2022, with more information.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to maintain buildings used in the manufacture, processing, packing, or holding of drug products in a good state repair (21 CFR 211.58).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately design your facility, which is used to manufacture over-the-counter (OTC) topical drug products such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> Antibacterial Acne Soap, and maintain it in a good state of repair.\u003C\u002Fp>\n\n\u003Cp>For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Pipes with apparent rust, dirt and\u002For debris were located directly above partially open mixing tanks. Our investigators observed foreign particles floating in a mixing tank used to manufacture human drug products that was located directly underneath one of these pipes.\u003C\u002Fli>\n\t\u003Cli>Numerous aluminum sheet panels located on the ceiling above partially open mixing tanks and filling\u002Fpackaging lines were falling, torn or had gaps which exposed the environment below to apparent dirt and debris from plywood sheeting supporting the roof.\u003C\u002Fli>\n\t\u003Cli>Multiple bug zappers were observed in close proximity to filling\u002Fpackaging lines. Insects killed by the zappers could fall into open equipment and finished product packaging.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>It is essential that your facility is in a good state of repair and sanitary conditions are maintained.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your corrective action and preventative action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\n\t\u003Cli>Photographic evidence of any repairs made to your facilities and equipment.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22(a) and (d)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) failed to have adequate procedures, documentation and practices to properly exercise its functions.\u003C\u002Fp>\n\n\u003Cp>For example, regarding your batch record for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Sunscreen SPF-30 lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Finished drug “Product Analysis Report” used for batch release, was signed as reviewed and approved on March 23, 2022, even though the batch was still being filled on March 28, 2022.\u003C\u002Fli>\n\t\u003Cli>Out-of-specification (OOS) results for viscosity and specific gravity in bulk and finished drug product were not investigated.\u003C\u002Fli>\n\t\u003Cli>“LINE SET-UP” form did not have an approval signature, yet the line was used to manufacture drug product.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The procedure for handling complaints was not followed as both your firm’s CEO and Project Manager confirmed that product quality complaints are not recorded, evaluated, or investigated.\u003C\u002Fp>\n\n\u003Cp>Furthermore, OOS results were not being appropriately investigated per your procedure for handling OOS results and non-conforming drug product. During the inspection, our investigators were informed that your firm did not maintain a list of OOS test results and that investigations were not conducted. FDA inspected your firm’s contract testing laboratory from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, where numerous analytical OOS results involving your firm’s drug products were observed. An investigation is required whenever an OOS test result is obtained and a written record of the investigation must include conclusions and follow-up.\u003C\u002Fp>\n\n\u003Cp>Without adequate quality procedures and oversight, you cannot ensure the consistency of your manufacturing processes and the purported identity, strength, quality, and purity of drug products released to the market. See FDA's guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of the CGMP regulations (21 CFR, parts 210 and 211) at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>\n&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging\u003Cbr>\nmanufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\t\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\n\t\u003Cli>An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> 5% LIDOCAINE CREAM is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a topical external analgesic.\u003C\u002Fp>\n\n\u003Cp>Examples of labeling claims observed on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> 5% LIDOCAINE CREAM product label that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>(b)(4)\u003C\u002Fstrong> 5% LIDOCAINE CREAM\u003Cbr>\n“Lidocaine 5% . . . Uses: for the temporary relief of pain and itching associated with minor burns, sunburn, minor cuts and scrapes . . . 30g | 5% Lidocaine Cream . . .” [from your product label]\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> 5% LIDOCAINE CREAM is a topical external analgesic drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G(a)(1) of the FD&amp;C Act, 21 U.S.C. 355h(a)(1), category I drugs that were subject to a tentative final monograph (TFM) that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 are deemed to be generally recognized as safe and effective (GRASE) and not “new drugs,” as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM and comply with all other applicable requirements. We note that over-the-counter (OTC) topical external analgesic products were addressed in the TFM for External Analgesic Drug Products for Over-the-Counter Human Use (external analgesic TFM; 48 FR 5852, February 8, 1983) and subsequent rulemakings. Under 505G(b)(8) of the FD&amp;C Act, the 1983 external analgesic TFM, in combination with subsequent rulemakings, was deemed to be a final administrative order.\u003C\u002Fp>\n\n\u003Cp>However, \u003Cstrong>(b)(4)\u003C\u002Fstrong> 5% LIDOCAINE CREAM does not conform to the conditions of use specified in the final administrative order. Specifically, the labeled active ingredient in the product, Lidocaine 5%, is above the allowable dosage concentration for use as an over-the-counter external analgesic product (0.5 – 4%).\u003C\u002Fp>\n\n\u003Cp>In addition, FDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that \u003Cstrong>(b)(4)\u003C\u002Fstrong> 5% LIDOCAINE CREAM is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling. Moreover, there is no evident basis under the FD&amp;C Act under which this product would be legally marketed without an approved application. Accordingly, this product is an unapproved new drug marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section and 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>Lastly, this product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because \u003Cstrong>(b)(4)\u003C\u002Fstrong> 5% LIDOCAINE CREAM is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should refer to unique identifier CMS 631902 and be sent electronically to ORAPHARM4_Responses@fda.hhs.gov or mailed to:\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\n19701 Fairchild Road\u003Cbr>\nIrvine, CA 92612\u003Cbr>\n\u003Cbr>\nIf you have any questions regarding this letter, please contact Jamie Dion, compliance officer, at 303-236-3133 or by email at Jamie.Dion@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\u003Cp>CC: Ms. Celeste Guillen, CEO (via email \u003Cstrong>(b)(6)\u003C\u002Fstrong>)\u003Cbr>\nAdvanced Cosmetic Research Laboratories Inc.\u003Cbr>\n20550 Prairie Street\u003Cbr>\nChatsworth, CA 91311-6006\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL CONFIRMED DELIVERY\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Kitty Hunter\n\nRecipient Title\n\nPresident and Owner\n\nAdvanced Cosmetic Research Laboratories Inc.\n\n20550 Prairie Street\n\nChatsworth, CA 91311-6006\n\nUnited States\n\n(b)(6)\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations IV\n\nUnited States\n\nWARNING LETTER\n\nSeptember 26, 2022\n\nDear Ms. Hunter:\n\nThe U.S. Food and Drug Administration inspected your drug manufacturing facility, Advanced Cosmetic Research Laboratories Inc., FEI 3003059934, at 20550 Prairie Street, Chatsworth, from April 21 to 27, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nIn addition, (b)(4) 5% LIDOCAINE CREAM is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nWe have not received a detailed response from your firm for corrective actions to the observations identified during the inspection in our Form FDA 483. The correspondence received included a commitment to respond on or before October 1, 2022, with more information.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to maintain buildings used in the manufacture, processing, packing, or holding of drug products in a good state repair (21 CFR 211.58).\n\nYou failed to adequately design your facility, which is used to manufacture over-the-counter (OTC) topical drug products such as (b)(4) Antibacterial Acne Soap, and maintain it in a good state of repair.\n\nFor example:\n\nPipes with apparent rust, dirt and\u002For debris were located directly above partially open mixing tanks. Our investigators observed foreign particles floating in a mixing tank used to manufacture human drug products that was located directly underneath one of these pipes.\n\nNumerous aluminum sheet panels located on the ceiling above partially open mixing tanks and filling\u002Fpackaging lines were falling, torn or had gaps which exposed the environment below to apparent dirt and debris from plywood sheeting supporting the roof.\n\nMultiple bug zappers were observed in close proximity to filling\u002Fpackaging lines. Insects killed by the zappers could fall into open equipment and finished product packaging.\n\nIt is essential that your facility is in a good state of repair and sanitary conditions are maintained.\n\nIn response to this letter, provide:\n\nYour corrective action and preventative action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n\nPhotographic evidence of any repairs made to your facilities and equipment.\n\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22(a) and (d)).\n\nYour quality unit (QU) failed to have adequate procedures, documentation and practices to properly exercise its functions.\n\nFor example, regarding your batch record for (b)(4) Sunscreen SPF-30 lot (b)(4):\n\nFinished drug “Product Analysis Report” used for batch release, was signed as reviewed and approved on March 23, 2022, even though the batch was still being filled on March 28, 2022.\n\nOut-of-specification (OOS) results for viscosity and specific gravity in bulk and finished drug product were not investigated.\n\n“LINE SET-UP” form did not have an approval signature, yet the line was used to manufacture drug product.\n\nThe procedure for handling complaints was not followed as both your firm’s CEO and Project Manager confirmed that product quality complaints are not recorded, evaluated, or investigated.\n\nFurthermore, OOS results were not being appropriately investigated per your procedure for handling OOS results and non-conforming drug product. During the inspection, our investigators were informed that your firm did not maintain a list of OOS test results and that investigations were not conducted. FDA inspected your firm’s contract testing laboratory from (b)(4), where numerous analytical OOS results involving your firm’s drug products were observed. An investigation is required whenever an OOS test result is obtained and a written record of the investigation must include conclusions and follow-up.\n\nWithout adequate quality procedures and oversight, you cannot ensure the consistency of your manufacturing processes and the purported identity, strength, quality, and purity of drug products released to the market. See FDA's guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of the CGMP regulations (21 CFR, parts 210 and 211) at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nAlso describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging\n\nmanufacturing\u002Fquality issues and to assure a continuing state of control.\n\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\nAn assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\n\nUnapproved New Drug and Misbranding Violations\n\n(b)(4) 5% LIDOCAINE CREAM is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a topical external analgesic.\n\nExamples of labeling claims observed on the (b)(4) 5% LIDOCAINE CREAM product label that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\n\n“(b)(4) 5% LIDOCAINE CREAM\n\n“Lidocaine 5% . . . Uses: for the temporary relief of pain and itching associated with minor burns, sunburn, minor cuts and scrapes . . . 30g | 5% Lidocaine Cream . . .” [from your product label]\n\n(b)(4) 5% LIDOCAINE CREAM is a topical external analgesic drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G(a)(1) of the FD&C Act, 21 U.S.C. 355h(a)(1), category I drugs that were subject to a tentative final monograph (TFM) that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 are deemed to be generally recognized as safe and effective (GRASE) and not “new drugs,” as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM and comply with all other applicable requirements. We note that over-the-counter (OTC) topical external analgesic products were addressed in the TFM for External Analgesic Drug Products for Over-the-Counter Human Use (external analgesic TFM; 48 FR 5852, February 8, 1983) and subsequent rulemakings. Under 505G(b)(8) of the FD&C Act, the 1983 external analgesic TFM, in combination with subsequent rulemakings, was deemed to be a final administrative order.\n\nHowever, (b)(4) 5% LIDOCAINE CREAM does not conform to the conditions of use specified in the final administrative order. Specifically, the labeled active ingredient in the product, Lidocaine 5%, is above the allowable dosage concentration for use as an over-the-counter external analgesic product (0.5 – 4%).\n\nIn addition, FDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that (b)(4) 5% LIDOCAINE CREAM is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling. Moreover, there is no evident basis under the FD&C Act under which this product would be legally marketed without an approved application. Accordingly, this product is an unapproved new drug marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section and 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nLastly, this product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because (b)(4) 5% LIDOCAINE CREAM is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour response should refer to unique identifier CMS 631902 and be sent electronically to ORAPHARM4_Responses@fda.hhs.gov or mailed to:\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nU.S. Food and Drug Administration\n\n19701 Fairchild Road\n\nIrvine, CA 92612\n\nIf you have any questions regarding this letter, please contact Jamie Dion, compliance officer, at 303-236-3133 or by email at Jamie.Dion@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCDR Steven E. Porter\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nCC: Ms. Celeste Guillen, CEO (via email (b)(6))\n\nAdvanced Cosmetic Research Laboratories Inc.\n\n20550 Prairie Street\n\nChatsworth, CA 91311-6006","Advanced Cosmetic Research Laboratories Inc.","advanced-cosmetic-research-laboratories-inc-635176-09262022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-cosmetic-research-laboratories-inc-635176-09262022","2026-10-26T08:07:50.485867+00:00","2022-10-25","635176","Ms. Kitty Hunter","2026-08-20T01:29:18.013+00:00","VIA EMAIL CONFIRMED DELIVERY","2022-09-26",{"id":133,"raw":134,"subject":139,"body_html":140,"body_text":141,"firm_name":142,"letter_id":143,"created_at":123,"fei_number":19,"letter_url":144,"updated_at":145,"action_type":22,"case_status":23,"posted_date":146,"marcs_cms_no":147,"product_type":104,"closeout_date":19,"issuing_office":148,"recipient_name":149,"body_fetched_at":150,"delivery_method":151,"recipient_title":19,"reference_number":19,"action_taken_date":152,"medical_device_id":19,"response_letter_date":19},2085,[135,136,137,138,139,13,13,13],"\u003Ctime datetime=\"2023-05-30T13:20:00Z\">05\u002F30\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-05-16T04:00:00Z\">05\u002F16\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnew-england-life-care-inc-dba-advanced-compounding-solutions-659161-05162023\">New England Life Care, Inc. dba Advanced Compounding Solutions\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations I ","Compounding Pharmacy\u002FAdulterated Drug Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>John A. Fantasia\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>New England Life Care, Inc. dba Advanced Compounding Solutions\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4 Constitution Way, Suite L\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Woburn\u003C\u002Fspan>, \u003Cspan>MA\u003C\u002Fspan> \u003Cspan>01801-1042\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations I \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER (WL) # 430004\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>May 16, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Fantasia:\u003C\u002Fp>\n\n\u003Cp>You registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> on March 2, 2017, and most recently on December 20, 2022. From March 21 to April 28, 2022, FDA investigators inspected your facility, New England Life Care, Inc. dba Advanced Compounding Solutions located at 4 Constitution Way, Suite L, Woburn, MA 01801. During the inspection, the investigators noted that drug products you produced failed to meet the conditions of section 503B of the FDCA necessary for drugs produced by an outsourcing facility to qualify for exemptions from certain provisions of the FDCA. In addition, the investigators noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\u003C\u002Fp>\n\n\u003Cp>FDA issued a Form FDA 483 to your facility on April 28, 2022. FDA acknowledges receipt of your facility’s responses, dated May 19, 2022, August 19, 2022, November 19, 2022, and February 17, 2023. Based on this inspection, it appears you produced drugs that violate the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A. Compounded Drug Products under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Under section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003Cbr>\n\u003Cbr>\nAn outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>In addition, for a compounded drug product to qualify for the exemptions under section 503B, the labeling of the drug must include certain information (section 503B(a)(10) of the FDCA [21 U.S.C. §353b(a)(10)]).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>B. Failure to Meet the Conditions of Section 503B\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During the inspection, FDA investigators noted that drug products produced by your facility failed to meet the conditions of section 503B. For example, the investigators noted that some of your facility’s drug products, including Diltiazem HCl 125mg in 100mL bag, Norepinephrine Bitartrate 8mg Dextrose 5% 250mL bag, Vancomycin HCl 750mg in 0.9% Sodium Chloride 250mL bag, and Phenylephrine HCl 20mg in 250mL bag, did not include the dosage form on the product label.\u003C\u002Fp>\n\n\u003Cp>Because your compounded drug products have not met all of the conditions of section 503B, they are not eligible for the exemptions in that section from the FDA approval requirements of section 505, the requirement under section 502(f)(1) that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements described in section 582 of the FDCA.\u003C\u002Fp>\n\n\u003Cp>Specific violations are described below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>C. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA investigators noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed:\u003C\u002Fp>\n\n\u003Cp>1. An operator rested their hands on the work surface of the hood during aseptic production.\u003C\u002Fp>\n\n\u003Cp>2. An operator placed components and equipment within the ISO 5 work area that had the potential to block the movement of first air to critical in-process operations.\u003C\u002Fp>\n\n\u003Cp>3. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 area. Therefore, your products intended to be sterile are produced in an environment that may not provide adequate protection against the risk of contamination.\u003C\u002Fp>\n\n\u003Cp>4. Your aseptic processing areas included areas that were difficult to clean, including but not limited to, scratches on the work surfaces of all \u003Cstrong>(b)(4)\u003C\u002Fstrong> laminar flow hoods.\u003C\u002Fp>\n\n\u003Cp>5. Pools of unidentified liquid on the floors of classified rooms in clean status.\u003C\u002Fp>\n\n\u003Cp>6. Your facility is maintained in a way that may permit the influx of lesser quality air into a higher quality air area and fails to prevent pests from entering classified spaces. Your firm had at least five documented instances where pests were found in the “compounding suite” from June 2020 through September 2021.\u003C\u002Fp>\n\n\u003Cp>7. Multiple air returns in your ISO 7 “compounding room” were observed to be either fully or mostly blocked by your laminar flow hoods.\u003C\u002Fp>\n\n\u003Cp>FDA investigators also noted CGMP violations at your facility, that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\u003C\u002Fp>\n\n\u003Cp>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fp>\n\n\u003Cp>2. Your firm failed to establish and follow adequate written procedures describing the handling of all written and oral complaints regarding a drug product, including provisions for review by the quality control unit of any complaint involving the possible failure of a drug product to meet any of its specifications and, for such drug products, a determination as to the need for an investigation in accordance with 21 CFR 211.192 (21 CFR 211.198(a)).\u003C\u002Fp>\n\n\u003Cp>3. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fp>\n\n\u003Cp>4. Your firm failed to establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions (21 CFR 211.42(c)(10)(v)).\u003C\u002Fp>\n\n\u003Cp>5. Your firm failed to maintain buildings used in the manufacture, processing, packing, or holding of drug products in a good state of repair (21 CFR 211.58).\u003C\u002Fp>\n\n\u003Cp>6. Your firm failed to establish an adequate air supply filtered through high-efficiency particulate air filters under positive pressure in the aseptic processing areas (21 CFR 211.42(c)(10)(iii)).\u003C\u002Fp>\n\n\u003Cp>Outsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, \u003Cem>Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&amp;C Act\u003C\u002Fem>. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\u003Cbr>\n\u003Cbr>\nUnder section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is also a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You do not have any FDA-approved applications on file for drug products that you compound.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 331(d)] a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You compound drug products that are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses causing them to be misbranded under section 502(f)(1) of the FDCA.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. Further, it is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>D. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We have reviewed your facility’s responses to the Form FDA 483. Some of your corrective actions appear adequate; however, we are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation:\u003C\u002Fp>\n\n\u003Cp>1. Your responses to Observation 2A state that the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> is no longer allowed. The responses included product information for a \u003Cstrong>(b)(4)\u003C\u002Fstrong> solution to be used in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and a \u003Cstrong>(b)(4)\u003C\u002Fstrong> that you stated should \u003Cstrong>(b)(4)\u003C\u002Fstrong> as well. There was no updated procedure provided to explain when and how the \u003Cstrong>(b)(4)\u003C\u002Fstrong> solution would be applied during gowning. Your May 19, 2022, response included draft SOP-PROD-017, Gowning and Hand Hygiene, which your response cover letter stated required the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> solution on the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, that language was not found in the included draft procedure. Your responses also stated that the relative humidity of the general “compounding rooms” was&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, but no additional details were provided.\u003Cbr>\n\u003Cbr>\n2. Your responses to Observation 3B include an email from your cleaning contractor that included their suggestion on how to prevent standing cleaning fluid on the floors of the cleanroom suite (via a \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Your responses focus on the use of the contractor and fail to discuss the cleaning contractor’s recommendations. No supporting documentation was provided to demonstrate that the proposed corrective actions were implemented.\u003C\u002Fp>\n\n\u003Cp>3. Your responses to Observation 3B state that your firm determined the scratches observed on the decks of the ISO 5 hoods to be normal wear and are not deep enough to significantly impact the work surface of the ISO 5 space. Your responses failed to provide your documented justification\u002Frisk evaluation for that determination.\u003C\u002Fp>\n\n\u003Cp>4. Your responses to Observation 3B also state that material sanitization was the primary topic during your \u003Cstrong>(b)(4)\u003C\u002Fstrong> CGMP training. No details related to the date, trainer, trainees, or content of training were included in the responses.\u003C\u002Fp>\n\n\u003Cp>5. DEV-22-024, submitted in support of your response to Observation 3B, states your firm will implement random auditing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> that will be conducted at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> by the Director of Quality or designee as an immediate corrective action. No supporting documentation was provided to determine how the audits will be conducted (in person vs. review of video recordings), the timeframe for their initiation, or how identified deficiencies will be handled.\u003C\u002Fp>\n\n\u003Cp>6. Your responses to Observation 4A state that you intend to change the classification of the ISO 8 finished product room to clean, not classified. Your responses do not include a product impact assessment or risk evaluation for this change or an anticipated timeframe.\u003C\u002Fp>\n\n\u003Cp>7. Your responses to Observation 4D outline a new process that includes a \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection of the cleanroom suite and associated equipment while your maintenance contractor is conducting their \u003Cstrong>(b)(4)\u003C\u002Fstrong> assessment outside the cleanroom suite and references a draft policy (SOP-FE-007, Operation &amp; Maintenance of the Production Suite (Draft)). The updated requirements, as outlined in the responses, were not found in the provided draft policy. The draft policy states that the production suite should be inspected \u003Cstrong>(b)(4)\u003C\u002Fstrong> or not exceeding \u003Cstrong>(b)(4)\u003C\u002Fstrong>, does not assign the inspection responsibility to the Quality Unit, and does not require that results be reviewed by production and quality management.\u003C\u002Fp>\n\n\u003Cp>8. Your responses to Observation 5B state you have remediated the blockage of the air returns by removing the laminar flow hood (LFH) located in the southwest corner of the “compounding room.” No updated diagram showing the updated layout and location of the LFHs in the “compounding room” was provided. The Form FDA 483 identifies the LFH located in the southwest corner as 34LFH-07. However, the maintenance record dated May 22, 2022, provided with your firm’s August 2022 response, states, “Removed LFH-05 from the general “compounding room.” LFH-05 is stored in the warehouse.” It is unclear from the information available whether LFH-05 in the maintenance record is the same hood as 34LFH-07 or if it is 32LFH-05. There is no explanation in the response how removal of hood 32LFH-05 would remediate the blockage of the air returns. The responses do not explain whether the remaining hoods were relocated or moved within the “compounding room.”\u003Cbr>\n\u003Cbr>\nSome of your corrective actions appear deficient:\u003C\u002Fp>\n\n\u003Cp>1. Your responses fail to address any of the individual investigations and complaints cited in Observation 1. Your responses do not indicate whether the cited investigations were conducted if absent or reopened if previously closed, if product impact and\u002For risk assessments were completed, or if there were resulting corrective and\u002For preventive actions (CAPAs).\u003C\u002Fp>\n\n\u003Cp>2. Your responses to Observation 1B appear to solely focuses on improvements to be made to the investigation process. Your responses fail to address any immediate actions that were taken to mitigate the deficiencies pending the implementation of the planned improvements.\u003C\u002Fp>\n\n\u003Cp>3. Your responses to Observation 1C indicate that your firm considers the current complaint process and procedure, as outlined in SOP-QA-006, adequate and do not intend on making changes. However, our investigators found the one complaint reviewed during the inspection, that was handled under the new procedure, to be inadequate. Specifically, Complaint Record PQC-21-001 was opened October 20, 2021, and was reviewed by our investigators during the inspection. Our investigators noted that the required elements from the new procedure were not included in that complaint. No investigation was conducted related to Complaint Record PQC-21-001 and no justification was provided in the record to support that decision.\u003C\u002Fp>\n\n\u003Cp>In addition, your responses to Observation 1C state that the Quality Unit plans to provide further training to customer service representatives but does not outline what that training will include. The responses do not provide details about the current training process\u002Fprogram for handling customer complaints. The responses do not include supporting documentation to demonstrate that training was conducted for all applicable personnel on the new complaint procedure that became effective August 19, 2021.\u003C\u002Fp>\n\n\u003Cp>4. In your responses to Observation 2B, you provided draft SOP-PROD-011, Filling of Bulk Drug Products, which includes photos to show where air samplers should be located. In \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;(for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>), the air samplers appear to be in the same location as observed during the inspection, in the back of the hood, up against the HEPA filters, which not only blocks first air to any objects placed in front of them, but also does not represent conditions at the critical processing area where manipulations are taking place.\u003C\u002Fp>\n\n\u003Cp>Your responses to Observation 2B also include a document change request (DCR) to draft a “GMP Aseptic Technique Training” and state that training and assessment will be performed \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> thereafter. Your responses fail to address how the new training program is improved from the current training program and how it will be more effective. The training procedure collected during the inspection also requires that all employees train on “Clean Room Etiquette &amp; General Aseptic Technique” and \u003Cstrong>(b)(4)\u003C\u002Fstrong> performing operations. The DCR states that “aseptic technique assessment\" will be based on: personnel media fill requalification \u003Cstrong>(b)(4)\u003C\u002Fstrong>; gowning re-qualification \u003Cstrong>(b)(4)\u003C\u002Fstrong>; \u003Cstrong>(b)(4)\u003C\u002Fstrong> training occurs and \u003Cstrong>(b)(4)\u003C\u002Fstrong> test. However, it was noted in the review of your media fills that personnel monitoring excursions during media fills are no longer considered when evaluating the aseptic technique\u002Fqualification of operators.\u003C\u002Fp>\n\n\u003Cp>5. Your responses to Observation 3A do not address the differences in your planned disinfectant efficacy study and the approved protocol\u002Fcompleted study from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It is unclear if the remaining variables from VP31.01 will be included in later studies, or what the anticipated timeframe would be. The noted differences between the approved protocol\u002Fcompleted study from \u003Cstrong>(b)(4)\u003C\u002Fstrong> and your planned study under VP31.01 include, but are not limited to:\u003Cbr>\n\u003Cbr>\n• The intended study design was to include \u003Cstrong>(b)(4)\u003C\u002Fstrong> surfaces (materials of construction); \u003Cstrong>(b)(4)\u003C\u002Fstrong> study includes \u003Cstrong>(b)(4)\u003C\u002Fstrong> surfaces\u003Cbr>\n• The intended study design was to include all \u003Cstrong>(b)(4)\u003C\u002Fstrong> allowable cleaning\u002Fdisinfecting agents; \u003Cstrong>(b)(4)\u003C\u002Fstrong> study includes \u003Cstrong>(b)(4)\u003C\u002Fstrong> disinfectants\u003Cbr>\n• The intended study design was to include \u003Cstrong>(b)(4)\u003C\u002Fstrong> inoculants, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> commonly recovered organisms from the facility; \u003Cstrong>(b)(4)\u003C\u002Fstrong> study includes \u003Cstrong>(b)(4)\u003C\u002Fstrong> inoculants (\u003Cstrong>(b)(4)\u003C\u002Fstrong>)\u003C\u002Fp>\n\n\u003Cp>Additionally, the disinfectant efficacy study from \u003Cstrong>(b)(4)\u003C\u002Fstrong> submitted with your February 2023 response does not include all disinfectants allowed by your revised cleaning and disinfection procedure, draft SOP-PROD-014. The revised draft procedure includes \u003Cstrong>(b)(4)\u003C\u002Fstrong> as an approved disinfectant for your classified areas (the only sporicidal agent included), however \u003Cstrong>(b)(4)\u003C\u002Fstrong> was not included in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> study. The draft procedure also requires that dwell times be met for disinfectants but does not specify the required dwell times for the approved disinfectants.\u003C\u002Fp>\n\n\u003Cp>6. Your responses to Observation 3B include a Maintenance report from July 29, 2022 – July 31, 2022, where multiple repairs and updates to the cleanroom and LFHs were documented. The maintenance report email describes unplugging and disassembly of LFHs (removal of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and removal of \u003Cstrong>(b)(4)\u003C\u002Fstrong> screens to facilitate cleaning of the screens and \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> worksurface). Your responses fail to address what actions were taken prior to returning the LFHs to service (e.g., cleanings and requalification) for sterile operations.\u003C\u002Fp>\n\n\u003Cp>7. Your responses to Observation 4 (specifically 4A and 4C) do not address pest control, do not include an evaluation of the damaged rubber gaskets and floor sweeps as they relate to the pests identified in the compounding suite, and do not include any updated pest control plans pending repair of the doors. Your responses did not address what immediate corrective actions were taken, if any, to prevent the ingress of pests into the compounding suite in the over \u003Cstrong>(b)(4)\u003C\u002Fstrong> timeframe before the doors were repaired.\u003C\u002Fp>\n\n\u003Cp>8. Your responses to Observation 4C include an Incident Report related to the loose case around cables in the “compounding room”, which states that the root cause of the detached casing was being bumped by one of the hoods when the hood was moved back into place after cleaning. There was no discussion of changes to the cleaning process to prevent the hoods from needing to be moved during routine cleaning. There was no discussion of the potential effect on the hoods and unidirectional airflow from movement of the hoods during routine cleaning.\u003C\u002Fp>\n\n\u003Cp>9. Your smoke studies do not demonstrate adequate airflow throughout the entire production process, from introduction of materials into the hood through completion of compounding. Your smoke study videos include smoke that is directed only at the given port where an aseptic connection or manipulation is being performed. It does not provide assurance that other movements, activities, operations, or materials placement does not allow or promote the ingress of air from the surrounding ISO 7 cleanroom into the hood via turbulence, eddies, or other airflow disruptions, which could lead to potential contamination of the aseptic processing area. In addition, your validation protocol only requires dynamic smoke studies to be performed in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm requires that all hoods undergo static smoke studies, and your firm contends that the static conditions testing provides equivalency between the hoods. This approach is inadequate as the dynamic conditions of \u003Cstrong>(b)(4)\u003C\u002Fstrong> do not provide assurance of adequate unidirectional airflow of the other hoods.\u003C\u002Fp>\n\n\u003Cp>In addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b).]\u003C\u002Fp>\n\n\u003Cp>In addition, regarding observations related to the conditions of section 503B of the FDCA, your corrective actions appear adequate. Specifically, you state that, “ACS initiated a change control to update CSP labels to include the dosage forms on all drug product labels.”\u003C\u002Fp>\n\n\u003Cp>Should you continue to compound and distribute drug products that do not meet the conditions of section 503B, the compounding and distribution of your drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the Drug Supply Chain Security Act requirements.\u003C\u002Fp>\n\n\u003Cp>FDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>E. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to ORAPHARM1_RESPONSES@fda.hhs.gov. Please identify your response with FEI #3010371376 and refer to WL# 430004. If you have questions regarding the content of this letter, please contact Compliance Officers Lisa Orr at Lisa.Orr@fda.hhs.gov and Nancy Espinal at Nancy.Espinal@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lisa Harlan\u003Cbr>\nProgram Division Director\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nOPQO Division I\u003C\u002Fp>\n\n\u003Cp>cc: Michael G. Souza, Chief Executive Officer\u003Cbr>\nNew England Life Care, Inc.\u003Cbr>\n200 French Farm Road\u003Cbr>\nNorth Andover, MA 01845\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> The specific products made by your firm are drugs within the meaning of section 201(g) of the Act, [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Your compounded drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJohn A. Fantasia\n\nRecipient Title\n\nVice President\n\nNew England Life Care, Inc. dba Advanced Compounding Solutions\n\n4 Constitution Way, Suite L\n\nWoburn, MA 01801-1042\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nWARNING LETTER (WL) # 430004\n\nMay 16, 2023\n\nDear Mr. Fantasia:\n\nYou registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]1 on March 2, 2017, and most recently on December 20, 2022. From March 21 to April 28, 2022, FDA investigators inspected your facility, New England Life Care, Inc. dba Advanced Compounding Solutions located at 4 Constitution Way, Suite L, Woburn, MA 01801. During the inspection, the investigators noted that drug products you produced failed to meet the conditions of section 503B of the FDCA necessary for drugs produced by an outsourcing facility to qualify for exemptions from certain provisions of the FDCA. In addition, the investigators noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\n\nFDA issued a Form FDA 483 to your facility on April 28, 2022. FDA acknowledges receipt of your facility’s responses, dated May 19, 2022, August 19, 2022, November 19, 2022, and February 17, 2023. Based on this inspection, it appears you produced drugs that violate the FDCA.\n\nA. Compounded Drug Products under the FDCA\n\nUnder section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.2\n\nAn outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\n\nIn addition, for a compounded drug product to qualify for the exemptions under section 503B, the labeling of the drug must include certain information (section 503B(a)(10) of the FDCA [21 U.S.C. §353b(a)(10)]).\n\nB. Failure to Meet the Conditions of Section 503B\n\nDuring the inspection, FDA investigators noted that drug products produced by your facility failed to meet the conditions of section 503B. For example, the investigators noted that some of your facility’s drug products, including Diltiazem HCl 125mg in 100mL bag, Norepinephrine Bitartrate 8mg Dextrose 5% 250mL bag, Vancomycin HCl 750mg in 0.9% Sodium Chloride 250mL bag, and Phenylephrine HCl 20mg in 250mL bag, did not include the dosage form on the product label.\n\nBecause your compounded drug products have not met all of the conditions of section 503B, they are not eligible for the exemptions in that section from the FDA approval requirements of section 505, the requirement under section 502(f)(1) that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements described in section 582 of the FDCA.\n\nSpecific violations are described below.\n\nC. Violations of the FDCA\n\nAdulterated Drug Products\n\nFDA investigators noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed:\n\n1. An operator rested their hands on the work surface of the hood during aseptic production.\n\n2. An operator placed components and equipment within the ISO 5 work area that had the potential to block the movement of first air to critical in-process operations.\n\n3. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 area. Therefore, your products intended to be sterile are produced in an environment that may not provide adequate protection against the risk of contamination.\n\n4. Your aseptic processing areas included areas that were difficult to clean, including but not limited to, scratches on the work surfaces of all (b)(4) laminar flow hoods.\n\n5. Pools of unidentified liquid on the floors of classified rooms in clean status.\n\n6. Your facility is maintained in a way that may permit the influx of lesser quality air into a higher quality air area and fails to prevent pests from entering classified spaces. Your firm had at least five documented instances where pests were found in the “compounding suite” from June 2020 through September 2021.\n\n7. Multiple air returns in your ISO 7 “compounding room” were observed to be either fully or mostly blocked by your laminar flow hoods.\n\nFDA investigators also noted CGMP violations at your facility, that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\n\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\n2. Your firm failed to establish and follow adequate written procedures describing the handling of all written and oral complaints regarding a drug product, including provisions for review by the quality control unit of any complaint involving the possible failure of a drug product to meet any of its specifications and, for such drug products, a determination as to the need for an investigation in accordance with 21 CFR 211.192 (21 CFR 211.198(a)).\n\n3. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n\n4. Your firm failed to establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions (21 CFR 211.42(c)(10)(v)).\n\n5. Your firm failed to maintain buildings used in the manufacture, processing, packing, or holding of drug products in a good state of repair (21 CFR 211.58).\n\n6. Your firm failed to establish an adequate air supply filtered through high-efficiency particulate air filters under positive pressure in the aseptic processing areas (21 CFR 211.42(c)(10)(iii)).\n\nOutsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&C Act. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\n\nUnder section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is also a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\n\nUnapproved New Drug Products\n\nYou do not have any FDA-approved applications on file for drug products that you compound.3 Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 331(d)] a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA\n\nMisbranded Drug Products\n\nYou compound drug products that are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses causing them to be misbranded under section 502(f)(1) of the FDCA.4 The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. Further, it is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\n\nD. Corrective Actions\n\nWe have reviewed your facility’s responses to the Form FDA 483. Some of your corrective actions appear adequate; however, we are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation:\n\n1. Your responses to Observation 2A state that the use of (b)(4) is no longer allowed. The responses included product information for a (b)(4) solution to be used in the (b)(4) and a (b)(4) that you stated should (b)(4) as well. There was no updated procedure provided to explain when and how the (b)(4) solution would be applied during gowning. Your May 19, 2022, response included draft SOP-PROD-017, Gowning and Hand Hygiene, which your response cover letter stated required the use of (b)(4) solution on the (b)(4). However, that language was not found in the included draft procedure. Your responses also stated that the relative humidity of the general “compounding rooms” was (b)(4), but no additional details were provided.\n\n2. Your responses to Observation 3B include an email from your cleaning contractor that included their suggestion on how to prevent standing cleaning fluid on the floors of the cleanroom suite (via a (b)(4)). Your responses focus on the use of the contractor and fail to discuss the cleaning contractor’s recommendations. No supporting documentation was provided to demonstrate that the proposed corrective actions were implemented.\n\n3. Your responses to Observation 3B state that your firm determined the scratches observed on the decks of the ISO 5 hoods to be normal wear and are not deep enough to significantly impact the work surface of the ISO 5 space. Your responses failed to provide your documented justification\u002Frisk evaluation for that determination.\n\n4. Your responses to Observation 3B also state that material sanitization was the primary topic during your (b)(4) CGMP training. No details related to the date, trainer, trainees, or content of training were included in the responses.\n\n5. DEV-22-024, submitted in support of your response to Observation 3B, states your firm will implement random auditing of (b)(4) that will be conducted at least (b)(4) by the Director of Quality or designee as an immediate corrective action. No supporting documentation was provided to determine how the audits will be conducted (in person vs. review of video recordings), the timeframe for their initiation, or how identified deficiencies will be handled.\n\n6. Your responses to Observation 4A state that you intend to change the classification of the ISO 8 finished product room to clean, not classified. Your responses do not include a product impact assessment or risk evaluation for this change or an anticipated timeframe.\n\n7. Your responses to Observation 4D outline a new process that includes a (b)(4) inspection of the cleanroom suite and associated equipment while your maintenance contractor is conducting their (b)(4) assessment outside the cleanroom suite and references a draft policy (SOP-FE-007, Operation & Maintenance of the Production Suite (Draft)). The updated requirements, as outlined in the responses, were not found in the provided draft policy. The draft policy states that the production suite should be inspected (b)(4) or not exceeding (b)(4), does not assign the inspection responsibility to the Quality Unit, and does not require that results be reviewed by production and quality management.\n\n8. Your responses to Observation 5B state you have remediated the blockage of the air returns by removing the laminar flow hood (LFH) located in the southwest corner of the “compounding room.” No updated diagram showing the updated layout and location of the LFHs in the “compounding room” was provided. The Form FDA 483 identifies the LFH located in the southwest corner as 34LFH-07. However, the maintenance record dated May 22, 2022, provided with your firm’s August 2022 response, states, “Removed LFH-05 from the general “compounding room.” LFH-05 is stored in the warehouse.” It is unclear from the information available whether LFH-05 in the maintenance record is the same hood as 34LFH-07 or if it is 32LFH-05. There is no explanation in the response how removal of hood 32LFH-05 would remediate the blockage of the air returns. The responses do not explain whether the remaining hoods were relocated or moved within the “compounding room.”\n\nSome of your corrective actions appear deficient:\n\n1. Your responses fail to address any of the individual investigations and complaints cited in Observation 1. Your responses do not indicate whether the cited investigations were conducted if absent or reopened if previously closed, if product impact and\u002For risk assessments were completed, or if there were resulting corrective and\u002For preventive actions (CAPAs).\n\n2. Your responses to Observation 1B appear to solely focuses on improvements to be made to the investigation process. Your responses fail to address any immediate actions that were taken to mitigate the deficiencies pending the implementation of the planned improvements.\n\n3. Your responses to Observation 1C indicate that your firm considers the current complaint process and procedure, as outlined in SOP-QA-006, adequate and do not intend on making changes. However, our investigators found the one complaint reviewed during the inspection, that was handled under the new procedure, to be inadequate. Specifically, Complaint Record PQC-21-001 was opened October 20, 2021, and was reviewed by our investigators during the inspection. Our investigators noted that the required elements from the new procedure were not included in that complaint. No investigation was conducted related to Complaint Record PQC-21-001 and no justification was provided in the record to support that decision.\n\nIn addition, your responses to Observation 1C state that the Quality Unit plans to provide further training to customer service representatives but does not outline what that training will include. The responses do not provide details about the current training process\u002Fprogram for handling customer complaints. The responses do not include supporting documentation to demonstrate that training was conducted for all applicable personnel on the new complaint procedure that became effective August 19, 2021.\n\n4. In your responses to Observation 2B, you provided draft SOP-PROD-011, Filling of Bulk Drug Products, which includes photos to show where air samplers should be located. In (b)(4) (for (b)(4) and (b)(4)), the air samplers appear to be in the same location as observed during the inspection, in the back of the hood, up against the HEPA filters, which not only blocks first air to any objects placed in front of them, but also does not represent conditions at the critical processing area where manipulations are taking place.\n\nYour responses to Observation 2B also include a document change request (DCR) to draft a “GMP Aseptic Technique Training” and state that training and assessment will be performed (b)(4) and (b)(4) thereafter. Your responses fail to address how the new training program is improved from the current training program and how it will be more effective. The training procedure collected during the inspection also requires that all employees train on “Clean Room Etiquette & General Aseptic Technique” and (b)(4) performing operations. The DCR states that “aseptic technique assessment\" will be based on: personnel media fill requalification (b)(4); gowning re-qualification (b)(4); (b)(4) training occurs and (b)(4) test. However, it was noted in the review of your media fills that personnel monitoring excursions during media fills are no longer considered when evaluating the aseptic technique\u002Fqualification of operators.\n\n5. Your responses to Observation 3A do not address the differences in your planned disinfectant efficacy study and the approved protocol\u002Fcompleted study from (b)(4). It is unclear if the remaining variables from VP31.01 will be included in later studies, or what the anticipated timeframe would be. The noted differences between the approved protocol\u002Fcompleted study from (b)(4) and your planned study under VP31.01 include, but are not limited to:\n\n• The intended study design was to include (b)(4) surfaces (materials of construction); (b)(4) study includes (b)(4) surfaces\n\n• The intended study design was to include all (b)(4) allowable cleaning\u002Fdisinfecting agents; (b)(4) study includes (b)(4) disinfectants\n\n• The intended study design was to include (b)(4) inoculants, including (b)(4) commonly recovered organisms from the facility; (b)(4) study includes (b)(4) inoculants ((b)(4))\n\nAdditionally, the disinfectant efficacy study from (b)(4) submitted with your February 2023 response does not include all disinfectants allowed by your revised cleaning and disinfection procedure, draft SOP-PROD-014. The revised draft procedure includes (b)(4) as an approved disinfectant for your classified areas (the only sporicidal agent included), however (b)(4) was not included in the (b)(4) study. The draft procedure also requires that dwell times be met for disinfectants but does not specify the required dwell times for the approved disinfectants.\n\n6. Your responses to Observation 3B include a Maintenance report from July 29, 2022 – July 31, 2022, where multiple repairs and updates to the cleanroom and LFHs were documented. The maintenance report email describes unplugging and disassembly of LFHs (removal of (b)(4) and removal of (b)(4) screens to facilitate cleaning of the screens and (b)(4) of the (b)(4) worksurface). Your responses fail to address what actions were taken prior to returning the LFHs to service (e.g., cleanings and requalification) for sterile operations.\n\n7. Your responses to Observation 4 (specifically 4A and 4C) do not address pest control, do not include an evaluation of the damaged rubber gaskets and floor sweeps as they relate to the pests identified in the compounding suite, and do not include any updated pest control plans pending repair of the doors. Your responses did not address what immediate corrective actions were taken, if any, to prevent the ingress of pests into the compounding suite in the over (b)(4) timeframe before the doors were repaired.\n\n8. Your responses to Observation 4C include an Incident Report related to the loose case around cables in the “compounding room”, which states that the root cause of the detached casing was being bumped by one of the hoods when the hood was moved back into place after cleaning. There was no discussion of changes to the cleaning process to prevent the hoods from needing to be moved during routine cleaning. There was no discussion of the potential effect on the hoods and unidirectional airflow from movement of the hoods during routine cleaning.\n\n9. Your smoke studies do not demonstrate adequate airflow throughout the entire production process, from introduction of materials into the hood through completion of compounding. Your smoke study videos include smoke that is directed only at the given port where an aseptic connection or manipulation is being performed. It does not provide assurance that other movements, activities, operations, or materials placement does not allow or promote the ingress of air from the surrounding ISO 7 cleanroom into the hood via turbulence, eddies, or other airflow disruptions, which could lead to potential contamination of the aseptic processing area. In addition, your validation protocol only requires dynamic smoke studies to be performed in (b)(4). Your firm requires that all hoods undergo static smoke studies, and your firm contends that the static conditions testing provides equivalency between the hoods. This approach is inadequate as the dynamic conditions of (b)(4) do not provide assurance of adequate unidirectional airflow of the other hoods.\n\nIn addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b).]\n\nIn addition, regarding observations related to the conditions of section 503B of the FDCA, your corrective actions appear adequate. Specifically, you state that, “ACS initiated a change control to update CSP labels to include the dosage forms on all drug product labels.”\n\nShould you continue to compound and distribute drug products that do not meet the conditions of section 503B, the compounding and distribution of your drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the Drug Supply Chain Security Act requirements.\n\nFDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\n\nE. Conclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\n\nSend your electronic reply to ORAPHARM1_RESPONSES@fda.hhs.gov. Please identify your response with FEI #3010371376 and refer to WL# 430004. If you have questions regarding the content of this letter, please contact Compliance Officers Lisa Orr at Lisa.Orr@fda.hhs.gov and Nancy Espinal at Nancy.Espinal@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nLisa Harlan\n\nProgram Division Director\n\nU.S. Food and Drug Administration\n\nOPQO Division I\n\ncc: Michael G. Souza, Chief Executive Officer\n\nNew England Life Care, Inc.\n\n200 French Farm Road\n\nNorth Andover, MA 01845\n\n_________________________\n\n1 See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\n\n2 We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\n\n3 The specific products made by your firm are drugs within the meaning of section 201(g) of the Act, [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n\n4 Your compounded drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).","New England Life Care, Inc. dba Advanced Compounding Solutions","new-england-life-care-inc-dba-advanced-compounding-solutions-659161-05162023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnew-england-life-care-inc-dba-advanced-compounding-solutions-659161-05162023","2026-10-26T08:09:32.236038+00:00","2023-05-30","659161","Division of Pharmaceutical Quality Operations I","John A. Fantasia","2026-08-20T01:05:43.148+00:00","Via Email","2023-05-16",{"id":154,"raw":155,"subject":139,"body_html":161,"body_text":162,"firm_name":163,"letter_id":164,"created_at":165,"fei_number":19,"letter_url":166,"updated_at":167,"action_type":22,"case_status":168,"posted_date":169,"marcs_cms_no":170,"product_type":104,"closeout_date":171,"issuing_office":159,"recipient_name":172,"body_fetched_at":173,"delivery_method":174,"recipient_title":19,"reference_number":19,"action_taken_date":175,"medical_device_id":19,"response_letter_date":19},3024,[156,157,158,159,139,13,160,13],"\u003Ctime datetime=\"2021-11-16T14:20:00Z\">11\u002F16\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-11-10T05:00:00Z\">11\u002F10\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-nutriceuticals-llc-dba-guyer-institute-molecular-medicine-615908-11102021\">Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine\u003C\u002Fa>","Division of Pharmaceutical Quality Operations Division III","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-nutriceuticals-llc-dba-guyer-institute-molecular-medicine-615908-02242026\">\u003Ctime datetime=\"2026-03-17T04:00:00Z\">03\u002F17\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS Next Day\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Leonard D. Guyer, MD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder and Medical Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>836 E. 86th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Indianapolis\u003C\u002Fspan>, \u003Cspan>IN\u003C\u002Fspan> \u003Cspan>46240-1806\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations Division III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WL # 615908\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 10, 2021\u003Cbr>\n\u003Cbr>\nDear Dr. Guyer:\u003C\u002Fp>\n\n\u003Cp>From October 13, 2020, to October 29, 2020, U.S. Food and Drug Administration (FDA) investigators inspected your facility, Advanced Nutriceuticals LLC dba The Guyer Institute of Molecular Medicine located at 836 E. 86th Street, Indianapolis, Indiana 46240. During the inspection, the investigators collected evidence indicating that drug products you produced failed to meet the conditions of section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353a] for exemption from certain provisions of the FDCA. In addition, the investigators noted serious deficiencies in your practices for producing sterile drug products, which put patients at risk.\u003C\u002Fp>\n\n\u003Cp>FDA issued a Form FDA 483 to your firm on October 29, 2020. FDA acknowledges receipt of your facility’s response, dated November 18, 2020. Additionally, FDA acknowledges that your firm voluntarily ceased sterile production while corrective actions are implemented and, on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, initiated a voluntary recall of all compounded sterile products within expiry due to a lack of sterility assurance. Based on this inspection, it appears that you produced drug products that violate the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A. Compounded Drug Products Under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Section 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a state licensed pharmacy or a federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Receipt of valid prescriptions for individually-identified patients is one of the conditions for the exemptions under section 503A.\u003C\u002Fp>\n\n\u003Cp>In addition, for a compounded drug product to qualify for the exemptions under section 503A, bulk drug substances used to compound it must: (I) comply with the standards of an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph, if a monograph exists, and the USP chapter on pharmacy compounding; (II) if such a monograph does not exist, be components of drugs approved by the Secretary; or (III) if such a monograph does not exist and the drug substance is not a component of a drug approved by the Secretary, appear on a list developed by the Secretary through regulation (“503A bulks list”) (section 503A(b)(1)(A)(i) of the FDCA).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>B. Failure to Meet the Conditions of Section 503A\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During the inspection, the FDA investigators collected evidence indicating that drug products produced by your firm failed to meet the conditions of section 503A. For example, the investigators collected evidence indicating:\u003C\u002Fp>\n\n\u003Cp>1. Your firm did not receive valid prescriptions for individually-identified patients for a portion of the drug products you produced, such as your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” products, including Energy Boost.\u003C\u002Fp>\n\n\u003Cp>2. Your firm compounded drug products using \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Drug products compounded using \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> are not eligible for the exemptions provided by section 503A(a), because \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> are not the subject of an applicable USP or NF monograph, are not components of FDA-approved human drugs, and do not appear on the 503A bulks list.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Therefore, you compounded drug products that do not meet the conditions of section 503A and are not eligible for the exemptions in that section, including the FDA approval requirement of section 505 of the FDCA, the requirement under section 502(f)(1) of the FDCA that labeling bear adequate directions for use, and the requirement of compliance with CGMP under section 501(a)(2)(B) of the FDCA. In the remainder of this letter, we refer to your drug products that do not qualify for exemptions under section 503A as the “ineligible drug products.”\u003C\u002Fp>\n\n\u003Cp>Specific violations are described below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>C. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The FDA investigators noted that drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed that:\u003C\u002Fp>\n\n\u003Cp>1. Your operator was observed conducting aseptic operations outside of a certified ISO 5 area. The filling of sterile drug products into syringes, which were not for immediate administration to patients, but for shipment to patients across the country, was conducted in the unclassified dispensary area by personnel in street clothes with no gloves donned.\u003C\u002Fp>\n\n\u003Cp>2. Your “IV Hood” used to produce drug products purporting to be sterile is located in an unclassified room. In addition, this hood has not been certified in over two years.\u003C\u002Fp>\n\n\u003Cp>3. Your personnel performing sterile operations have never conducted media fills. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\u003C\u002Fp>\n\n\u003Cp>4. Your operator engaged in aseptic processing while wearing non-sterile gloves, street clothes, and with exposed skin within the ISO 5 aseptic processing area.\u003C\u002Fp>\n\n\u003Cp>5. Your personnel engaged in poor aseptic technique on multiple occasions during the processing of sterile drug products. For example:\u003Cbr>\n&nbsp; a. An operator placed their gloved hands outside the ISO 5 work area repeatedly to retrieve supplies without sanitizing their gloved hands before re-entry into the ISO 5 hood.\u003Cbr>\n&nbsp; b. An operator failed to sanitize or change gloves after contact with non-sterile materials (e.g., face mask, trash can) during sterile processing.\u003Cbr>\n&nbsp; c. An operator blocked first air by placing gloved hands directly in line with the sterile filter and open sterile containers.\u003C\u002Fp>\n\n\u003Cp>6. An operator was observed manually stoppering sterile drug vials and touching product contact surfaces during the process.\u003C\u002Fp>\n\n\u003Cp>7. Your firm exposed a stock solution intended to be sterile to worse than ISO 5 air after the stopper had been punctured multiple times. Specifically, the stock solution was stored in an unclassified area for further use after the container closure system had been punctured multiple times, and therefore compromised, throughout the assigned expiry period.\u003C\u002Fp>\n\n\u003Cp>8. Your firm stores unused product vials in non-sterile plastic bags, which are allowed to be reused in sterile production. The vials stored in these bags are not \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Moreover, your firm’s temperature and time conditions used for \u003Cstrong>(b)(4)\u003C\u002Fstrong> of product vials are not known to be \u003Cstrong>(b)(4)\u003C\u002Fstrong> microorganisms.\u003C\u002Fp>\n\n\u003Cp>9. Your firm has not conducted environmental monitoring since 2018.\u003C\u002Fp>\n\n\u003Cp>10. Your aseptic processing and surrounding areas had difficult to clean and visibly dirty equipment or surfaces. For example:\u003Cbr>\n&nbsp; a. HEPA filters were discolored and\u002For damaged in the ISO 5 cleanroom hood.\u003Cbr>\n&nbsp; b. Your ISO 5 cleanroom workbench was constructed of laminated wood.\u003Cbr>\n&nbsp; c. A heating vent located below the ISO 5 cleanroom hood was visibly dirty and had no filtering device.\u003C\u002Fp>\n\n\u003Cp>11. Your firm handled hazardous drugs without providing adequate containment, segregation, or cleaning of work surfaces and utensils to prevent cross-contamination.\u003C\u002Fp>\n\n\u003Cp>Furthermore, the manufacture of the ineligible drug products is subject to FDA’s CGMP regulations, Title 21, Code of Federal Regulations (CFR), parts 210 and 211. The FDA investigators observed significant CGMP violations at your facility, causing the ineligible drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations included, for example:\u003C\u002Fp>\n\n\u003Cp>1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fp>\n\n\u003Cp>2. Your firm failed to ensure that manufacturing personnel wear clothing appropriate to protect drug product from contamination (21 CFR 211.28(a)).\u003C\u002Fp>\n\n\u003Cp>3. Your firm failed to clean and sterilize and process, where indicated by the nature of the drug, container closures to remove pyrogenic properties to assure they are suitable for their intended use (21 CFR 211.94(c)).\u003C\u002Fp>\n\n\u003Cp>4. Your firm failed to establish a system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\u003C\u002Fp>\n\n\u003Cp>5. Your firm failed to have buildings used in the manufacture, processing, packing, or holding of drug products of a suitable size, construction and location to facilitate cleaning, maintenance, and proper operations (21 CFR 211.42(a)).\u003C\u002Fp>\n\n\u003Cp>6. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fp>\n\n\u003Cp>7. Your firm failed to prepare batch production and control records for each batch of drug product that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch (21 CFR 211.188(b)).\u003C\u002Fp>\n\n\u003Cp>8. Your firm failed to retest or reexamine components, as appropriate, for identity, strength, quality, and purity and your quality control unit failed to approve or reject components (21 CFR 211.87).\u003C\u002Fp>\n\n\u003Cp>Under section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You do not have any FDA-approved applications on file for the ineligible drug products that you compounded.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. § 331(d)], a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The ineligible drug products you compounded are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Accordingly, these ineligible drug products are misbranded under section 502(f)(1) of the FDCA. The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. It is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>D. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response to the Form FDA 483. We acknowledge that your firm voluntarily ceased sterile production while corrective actions are implemented and, on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, initiated a voluntary recall of all compounded sterile products within expiry due to a lack of sterility assurance.\u003C\u002Fp>\n\n\u003Cp>Regarding your responses related to the insanitary conditions, some of your corrective actions appear adequate. Furthermore, we acknowledge your intention to install new modular cleanrooms in a separate building on your property to be used for sterile operations in the future. However, we cannot fully evaluate the adequacy of the following corrective actions described in your response because you did not include sufficient information or supporting documentation. For example:\u003C\u002Fp>\n\n\u003Cp>1. Your response to multiple observations includes the creation or revision of procedures and\u002For personnel training. None of the pertinent documentation was provided.\u003C\u002Fp>\n\n\u003Cp>2. You committed to the cessation of pre-filling syringes for shipment to patients. Your response states that staff have been counseled and refresher training on proper aseptic technique would be completed, but no documentation related to this was provided.\u003C\u002Fp>\n\n\u003Cp>3. Your response states that \u003Cstrong>(b)(4)\u003C\u002Fstrong>, but no further details about the kits were provided. It cannot be determined from the available information if the kits \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>4. Your response states you intend \u003Cstrong>(b)(4)\u003C\u002Fstrong> building which will include \u003Cstrong>(b)(4)\u003C\u002Fstrong>. No additional information or supporting documentation was provided regarding this renovation; no response updates have been received.\u003C\u002Fp>\n\n\u003Cp>5. Your response states your firm has implemented several corrections such as the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. No supporting documentation was provided for those corrective actions. No additional information was provided related to the ISO 5 hood with the laminated work surface, which you stated you are \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>6. Your response states that you plan to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, but intend to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, no information was provided about the type of equipment and proposed timeline for this corrective action.\u003C\u002Fp>\n\n\u003Cp>7. Your response states that you would \u003Cstrong>(b)(4)\u003C\u002Fstrong> which would be more conducive to maneuvering in the cleanroom. It is unclear whether this is referring to \u003Cstrong>(b)(4)\u003C\u002Fstrong> to go inside the hood or beside the hood. If inside, dynamic smoke studies have not been provided to evaluate the effect of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> on laminar airflow.\u003C\u002Fp>\n\n\u003Cp>If outside the hood, employees may continue to have issues reaching in and out of the hood to retrieve needed supplies during sterile operations.\u003C\u002Fp>\n\n\u003Cp>8. Your response did not provide sufficient detail for an evaluation of your corrections related to the handling of hazardous drugs to prevent cross contamination.\u003C\u002Fp>\n\n\u003Cp>9. Your response refers to staff members responsible for administering IVs being allowed to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It is unclear which staff members this refers to, where this operation is to occur, and whether those employees will also be conducting \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>You did not address certain observations related to insanitary conditions, for example:\u003C\u002Fp>\n\n\u003Cp>1. Your response states that \u003Cstrong>(b)(4)\u003C\u002Fstrong> building on the property. The response does not address how or if the current ISO 7\u002F8 suite of rooms will be used in the future.\u003C\u002Fp>\n\n\u003Cp>2. Your response states that \u003Cstrong>(b)(4)\u003C\u002Fstrong> units to be installed but does not address the \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring in your current classified areas.\u003C\u002Fp>\n\n\u003Cp>3. Your response did not address the lack of \u003Cstrong>(b)(4)\u003C\u002Fstrong> by your operators during aseptic production.\u003C\u002Fp>\n\n\u003Cp>4. Your response failed to address your lack of routine environmental monitoring.\u003C\u002Fp>\n\n\u003Cp>5. Your response did not address what actions, if any, were taken to ensure the IV hood located in the unclassified room is no longer used.\u003C\u002Fp>\n\n\u003Cp>6. Your response did not address the cleaning and mitigation of the visible drug residues on your current shared equipment that was observed during the inspection.\u003C\u002Fp>\n\n\u003Cp>Regarding your responses related to the insanitary conditions, the following corrective actions appear deficient:\u003C\u002Fp>\n\n\u003Cp>1. Your response states that opened vials will \u003Cstrong>(b)(4)\u003C\u002Fstrong> from opening or the date of expiry and the vials will only be \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your response did not provide justification for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It is unclear if the stoppers for your stock vials, which are prepared in house, are intended for&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your response states that employees have been instructed to visually inspect stock solution vials. Visual inspection of \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials is not a suitable indicator that the product remains sterile. Your response does not demonstrate how you will prevent contamination when \u003Cstrong>(b)(4)\u003C\u002Fstrong>, with or without use of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, are stored outside of an ISO 5 environment.\u003Cbr>\n\u003Cbr>\n2. Your firm uses \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product vials; however, your response states you are \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which would not be suitable for use in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It is unclear whether your firm has purchased \u003Cstrong>(b)(4)\u003C\u002Fstrong> for sterilization of the product vials. Your response does not address the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of product vials. You provided no information demonstrating that the current \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycle is adequate. Your response does not address the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> during sterilization or \u003Cstrong>(b)(4)\u003C\u002Fstrong> during \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The use of vials that have not been adequately \u003Cstrong>(b)(4)\u003C\u002Fstrong>, even if adequately sterilized \u003Cstrong>(b)(4)\u003C\u002Fstrong>, is not an acceptable practice.\u003C\u002Fp>\n\n\u003Cp>Please be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A.\u003C\u002Fp>\n\n\u003Cp>Should you continue to compound and distribute drug products that do not meet the conditions of section 503A, the compounding and distribution of such drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the drug CGMP regulations. Before doing so, you must comply with the requirements of section 505 and 502(f)(1) and fully implement corrections that meet the minimum requirements of the CGMP regulations.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>In addition, it appears you may have been compounding using the bulk drug substance piracetam. Drug products compounded using bulk piracetam are not eligible for the exemptions provided by section 503A(a), because piracetam is not the subject of an applicable USP or NF monograph, not a component of an FDA-approved human drug and does not appear on the 503A bulks list.\u003C\u002Fp>\n\n\u003Cp>Furthermore, it appears that your facility may have produced biological products. Please be advised that federal law does not provide a legal pathway for marketing biological products that have been prepared outside the scope of an approved biologics license application (BLA). Specifically, section 351(a)(1) of the Public Health Service Act (PHS Act) prohibits the introduction into interstate commerce of any biological product unless “a biologics license . . . is in effect for the biological product” (i.e., an approved BLA). Additionally, biological products subject to licensure under section 351 of the PHS Act are not eligible for the exemptions for compounded drugs under sections 503A and 503B of the FDCA. We also note that, as required by the Biologics Price Competition and Innovation Act of 2009, on March 23, 2020, an approved application for a biological product under section 505 of the FDCA was deemed to be a license for the biological product (i.e., an approved BLA) under the PHS Act. This transition affects compounding under sections 503A and 503B of the FDCA because, beginning on March 23, 2020, these biological products that previously could have been submitted in a marketing application under the FD&amp;C Act are subject to licensure under section 351 of the PHS Act and thus are not eligible for the exemptions for compounded drugs under sections 503A and 503B of the FDCA. \u003Cem>See\u003C\u002Fem> \u003Cem>Notice to Compounders: Changes that affect compounding as of March 23, 2020\u003C\u002Fem>\u003Csup>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009 for additional information. Although these biological products are not eligible for the exemptions in sections 503A and 503B, FDA issued guidance explaining the conditions under which we do not intend to take action when certain biological products are mixed, diluted, or repackaged in a manner not described in their approved labeling. See Guidance for Industry: Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application (available at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F90986\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F90986\u002Fdownload\u003C\u002Fa>).\u003C\u002Fp>\n\n\u003Cp>In addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b)].\u003C\u002Fp>\n\n\u003Cp>FDA strongly recommends that if you decide to resume production of sterile drugs, your management first undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug processing expertise should assist you in conducting this comprehensive evaluation.\u003C\u002Fp>\n\n\u003Cp>Lastly, during the inspection, investigators noted that your firm may be exporting products to other countries. Please be advised that if a product meets the FDCA’s requirements for sale and distribution in the United States, the FDCA has no additional restrictions on its exportation (i.e., sections 801 and 802 of the FDCA [21 U.S.C. § 381 and 382] do not apply to such exports). However, if the product does not meet FDCA’s domestic marketing requirements and is intended for export then you are required to be in compliance with applicable sections of the FDCA Chapter VIII – Imports and Exports. Furthermore, other federal statutes or regulations administered by other federal agencies (such as the Department of Commerce) may apply. For further information please see FDA’s Guidance for Industry: Exports Under the FDA Export Reform and Enhancement Act of 1996 (available at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fguidance-industry-exports-under-fda-export-reform-and-enhancement-act-1996\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fguidance-industry-exports-under-fda-export-reform-and-enhancement-act-1996\u003C\u002Fa>).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>E. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>If you decide to resume sterile operations, you should take prompt action to correct any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing if you have taken any specific steps to address any violations, or you may inform us that you do not intend to resume production of sterile drugs. If you intend to resume production of sterile drugs in the future, please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. In addition to taking appropriate corrective actions, you should notify this office fifteen (15) working days prior to resuming production of any sterile drugs in the future.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter Number above (615908). Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Attention: Tina M. Pawlowski, Compliance Officer\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nDivision of Pharmaceutical Quality Operations Division III\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Tina M. Pawlowski at (313) 393-8217.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Nicholas F. Lyons\u003Cbr>\nActing Program Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations Division III\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> On June 9, 2016, FDA issued a final guidance titled, \u003Cem>Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fem>. This guidance describes FDA’s interim regulatory policy for State-licensed pharmacies, Federal facilities, and licensed physicians that compound human drug products using bulk drug substances that do not otherwise meet the conditions of section 503A(b)(1)(A)(i) while the 503A bulks list is being developed. Specifically, the guidance sets out the conditions under which FDA does not intend to take action against a State-licensed pharmacy, Federal facility, or licensed physician for compounding a drug product using a bulk drug substance that is not the subject of an applicable USP or NF monograph or a component of an FDA-approved drug, until the substance is identified in a final rule as included or not included on the 503A bulks list. These conditions include that the substance may be eligible for inclusion on the 503A bulks list, was nominated with adequate support for FDA to evaluate it, and has not been identified by FDA as a substance that appears to present significant safety risks pending further evaluation. Cerebrolysin, thymosin alpha, thymosin beta, BPC-157, LL-37, pentosan, Selank, and Semax were not nominated for inclusion on the 503A bulks list. For additional information, see the guidance at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM469120.pdf\">http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM469120.pdf\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> The specific products made by your firm are drugs within the meaning of section 201(g) of the Act, [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) [21 U.S.C. 321(p)] of the FDCA because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Your ineligible drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> In this letter we do not address whether your proposed corrective actions would resolve the CGMP violations noted above.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> Available at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fhuman-drug-compounding\u002Fnotice-compounders-changes-affect-compounding-march-23-2020\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fhuman-drug-compounding\u002Fnotice-compounders-changes-affect-compounding-march-23-2020\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS Next Day\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nLeonard D. Guyer, MD\n\nRecipient Title\n\nFounder and Medical Director\n\nAdvanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine\n\n836 E. 86th Street\n\nIndianapolis, IN 46240-1806\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations Division III\n\nUnited States\n\nWARNING LETTER\n\nWL # 615908\n\nNovember 10, 2021\n\nDear Dr. Guyer:\n\nFrom October 13, 2020, to October 29, 2020, U.S. Food and Drug Administration (FDA) investigators inspected your facility, Advanced Nutriceuticals LLC dba The Guyer Institute of Molecular Medicine located at 836 E. 86th Street, Indianapolis, Indiana 46240. During the inspection, the investigators collected evidence indicating that drug products you produced failed to meet the conditions of section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353a] for exemption from certain provisions of the FDCA. In addition, the investigators noted serious deficiencies in your practices for producing sterile drug products, which put patients at risk.\n\nFDA issued a Form FDA 483 to your firm on October 29, 2020. FDA acknowledges receipt of your facility’s response, dated November 18, 2020. Additionally, FDA acknowledges that your firm voluntarily ceased sterile production while corrective actions are implemented and, on (b)(4), initiated a voluntary recall of all compounded sterile products within expiry due to a lack of sterility assurance. Based on this inspection, it appears that you produced drug products that violate the FDCA.\n\nA. Compounded Drug Products Under the FDCA\n\nSection 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a state licensed pharmacy or a federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].1 Receipt of valid prescriptions for individually-identified patients is one of the conditions for the exemptions under section 503A.\n\nIn addition, for a compounded drug product to qualify for the exemptions under section 503A, bulk drug substances used to compound it must: (I) comply with the standards of an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph, if a monograph exists, and the USP chapter on pharmacy compounding; (II) if such a monograph does not exist, be components of drugs approved by the Secretary; or (III) if such a monograph does not exist and the drug substance is not a component of a drug approved by the Secretary, appear on a list developed by the Secretary through regulation (“503A bulks list”) (section 503A(b)(1)(A)(i) of the FDCA).\n\nB. Failure to Meet the Conditions of Section 503A\n\nDuring the inspection, the FDA investigators collected evidence indicating that drug products produced by your firm failed to meet the conditions of section 503A. For example, the investigators collected evidence indicating:\n\n1. Your firm did not receive valid prescriptions for individually-identified patients for a portion of the drug products you produced, such as your “(b)(4)” products, including Energy Boost.\n\n2. Your firm compounded drug products using (b)(4). Drug products compounded using (b)(4), and (b)(4) are not eligible for the exemptions provided by section 503A(a), because (b)(4), and (b)(4) are not the subject of an applicable USP or NF monograph, are not components of FDA-approved human drugs, and do not appear on the 503A bulks list.2\n\nTherefore, you compounded drug products that do not meet the conditions of section 503A and are not eligible for the exemptions in that section, including the FDA approval requirement of section 505 of the FDCA, the requirement under section 502(f)(1) of the FDCA that labeling bear adequate directions for use, and the requirement of compliance with CGMP under section 501(a)(2)(B) of the FDCA. In the remainder of this letter, we refer to your drug products that do not qualify for exemptions under section 503A as the “ineligible drug products.”\n\nSpecific violations are described below.\n\nC. Violations of the FDCA\n\nAdulterated Drug Products\n\nThe FDA investigators noted that drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed that:\n\n1. Your operator was observed conducting aseptic operations outside of a certified ISO 5 area. The filling of sterile drug products into syringes, which were not for immediate administration to patients, but for shipment to patients across the country, was conducted in the unclassified dispensary area by personnel in street clothes with no gloves donned.\n\n2. Your “IV Hood” used to produce drug products purporting to be sterile is located in an unclassified room. In addition, this hood has not been certified in over two years.\n\n3. Your personnel performing sterile operations have never conducted media fills. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\n\n4. Your operator engaged in aseptic processing while wearing non-sterile gloves, street clothes, and with exposed skin within the ISO 5 aseptic processing area.\n\n5. Your personnel engaged in poor aseptic technique on multiple occasions during the processing of sterile drug products. For example:\n\na. An operator placed their gloved hands outside the ISO 5 work area repeatedly to retrieve supplies without sanitizing their gloved hands before re-entry into the ISO 5 hood.\n\nb. An operator failed to sanitize or change gloves after contact with non-sterile materials (e.g., face mask, trash can) during sterile processing.\n\nc. An operator blocked first air by placing gloved hands directly in line with the sterile filter and open sterile containers.\n\n6. An operator was observed manually stoppering sterile drug vials and touching product contact surfaces during the process.\n\n7. Your firm exposed a stock solution intended to be sterile to worse than ISO 5 air after the stopper had been punctured multiple times. Specifically, the stock solution was stored in an unclassified area for further use after the container closure system had been punctured multiple times, and therefore compromised, throughout the assigned expiry period.\n\n8. Your firm stores unused product vials in non-sterile plastic bags, which are allowed to be reused in sterile production. The vials stored in these bags are not (b)(4). Moreover, your firm’s temperature and time conditions used for (b)(4) of product vials are not known to be (b)(4) microorganisms.\n\n9. Your firm has not conducted environmental monitoring since 2018.\n\n10. Your aseptic processing and surrounding areas had difficult to clean and visibly dirty equipment or surfaces. For example:\n\na. HEPA filters were discolored and\u002For damaged in the ISO 5 cleanroom hood.\n\nb. Your ISO 5 cleanroom workbench was constructed of laminated wood.\n\nc. A heating vent located below the ISO 5 cleanroom hood was visibly dirty and had no filtering device.\n\n11. Your firm handled hazardous drugs without providing adequate containment, segregation, or cleaning of work surfaces and utensils to prevent cross-contamination.\n\nFurthermore, the manufacture of the ineligible drug products is subject to FDA’s CGMP regulations, Title 21, Code of Federal Regulations (CFR), parts 210 and 211. The FDA investigators observed significant CGMP violations at your facility, causing the ineligible drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations included, for example:\n\n1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n\n2. Your firm failed to ensure that manufacturing personnel wear clothing appropriate to protect drug product from contamination (21 CFR 211.28(a)).\n\n3. Your firm failed to clean and sterilize and process, where indicated by the nature of the drug, container closures to remove pyrogenic properties to assure they are suitable for their intended use (21 CFR 211.94(c)).\n\n4. Your firm failed to establish a system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\n\n5. Your firm failed to have buildings used in the manufacture, processing, packing, or holding of drug products of a suitable size, construction and location to facilitate cleaning, maintenance, and proper operations (21 CFR 211.42(a)).\n\n6. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\n7. Your firm failed to prepare batch production and control records for each batch of drug product that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch (21 CFR 211.188(b)).\n\n8. Your firm failed to retest or reexamine components, as appropriate, for identity, strength, quality, and purity and your quality control unit failed to approve or reject components (21 CFR 211.87).\n\nUnder section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\n\nUnapproved New Drug Products\n\nYou do not have any FDA-approved applications on file for the ineligible drug products that you compounded.3 Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. § 331(d)], a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\n\nMisbranded Drug Products\n\nThe ineligible drug products you compounded are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses.4 Accordingly, these ineligible drug products are misbranded under section 502(f)(1) of the FDCA. The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. It is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\n\nD. Corrective Actions\n\nWe have reviewed your firm’s response to the Form FDA 483. We acknowledge that your firm voluntarily ceased sterile production while corrective actions are implemented and, on (b)(4), initiated a voluntary recall of all compounded sterile products within expiry due to a lack of sterility assurance.\n\nRegarding your responses related to the insanitary conditions, some of your corrective actions appear adequate. Furthermore, we acknowledge your intention to install new modular cleanrooms in a separate building on your property to be used for sterile operations in the future. However, we cannot fully evaluate the adequacy of the following corrective actions described in your response because you did not include sufficient information or supporting documentation. For example:\n\n1. Your response to multiple observations includes the creation or revision of procedures and\u002For personnel training. None of the pertinent documentation was provided.\n\n2. You committed to the cessation of pre-filling syringes for shipment to patients. Your response states that staff have been counseled and refresher training on proper aseptic technique would be completed, but no documentation related to this was provided.\n\n3. Your response states that (b)(4), but no further details about the kits were provided. It cannot be determined from the available information if the kits (b)(4).\n\n4. Your response states you intend (b)(4) building which will include (b)(4). No additional information or supporting documentation was provided regarding this renovation; no response updates have been received.\n\n5. Your response states your firm has implemented several corrections such as the (b)(4), and (b)(4). No supporting documentation was provided for those corrective actions. No additional information was provided related to the ISO 5 hood with the laminated work surface, which you stated you are (b)(4).\n\n6. Your response states that you plan to (b)(4), but intend to (b)(4). However, no information was provided about the type of equipment and proposed timeline for this corrective action.\n\n7. Your response states that you would (b)(4) which would be more conducive to maneuvering in the cleanroom. It is unclear whether this is referring to (b)(4) to go inside the hood or beside the hood. If inside, dynamic smoke studies have not been provided to evaluate the effect of the (b)(4) on laminar airflow.\n\nIf outside the hood, employees may continue to have issues reaching in and out of the hood to retrieve needed supplies during sterile operations.\n\n8. Your response did not provide sufficient detail for an evaluation of your corrections related to the handling of hazardous drugs to prevent cross contamination.\n\n9. Your response refers to staff members responsible for administering IVs being allowed to (b)(4). It is unclear which staff members this refers to, where this operation is to occur, and whether those employees will also be conducting (b)(4).\n\nYou did not address certain observations related to insanitary conditions, for example:\n\n1. Your response states that (b)(4) building on the property. The response does not address how or if the current ISO 7\u002F8 suite of rooms will be used in the future.\n\n2. Your response states that (b)(4) units to be installed but does not address the (b)(4) monitoring in your current classified areas.\n\n3. Your response did not address the lack of (b)(4) by your operators during aseptic production.\n\n4. Your response failed to address your lack of routine environmental monitoring.\n\n5. Your response did not address what actions, if any, were taken to ensure the IV hood located in the unclassified room is no longer used.\n\n6. Your response did not address the cleaning and mitigation of the visible drug residues on your current shared equipment that was observed during the inspection.\n\nRegarding your responses related to the insanitary conditions, the following corrective actions appear deficient:\n\n1. Your response states that opened vials will (b)(4) from opening or the date of expiry and the vials will only be (b)(4). Your response did not provide justification for (b)(4). It is unclear if the stoppers for your stock vials, which are prepared in house, are intended for (b)(4). Your response states that employees have been instructed to visually inspect stock solution vials. Visual inspection of (b)(4) vials is not a suitable indicator that the product remains sterile. Your response does not demonstrate how you will prevent contamination when (b)(4), with or without use of (b)(4), are stored outside of an ISO 5 environment.\n\n2. Your firm uses (b)(4) drug product vials; however, your response states you are (b)(4), which would not be suitable for use in (b)(4). It is unclear whether your firm has purchased (b)(4) for sterilization of the product vials. Your response does not address the (b)(4) of product vials. You provided no information demonstrating that the current (b)(4) cycle is adequate. Your response does not address the use of (b)(4) during sterilization or (b)(4) during (b)(4). The use of vials that have not been adequately (b)(4), even if adequately sterilized (b)(4), is not an acceptable practice.\n\nPlease be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A.\n\nShould you continue to compound and distribute drug products that do not meet the conditions of section 503A, the compounding and distribution of such drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the drug CGMP regulations. Before doing so, you must comply with the requirements of section 505 and 502(f)(1) and fully implement corrections that meet the minimum requirements of the CGMP regulations.5\n\nIn addition, it appears you may have been compounding using the bulk drug substance piracetam. Drug products compounded using bulk piracetam are not eligible for the exemptions provided by section 503A(a), because piracetam is not the subject of an applicable USP or NF monograph, not a component of an FDA-approved human drug and does not appear on the 503A bulks list.\n\nFurthermore, it appears that your facility may have produced biological products. Please be advised that federal law does not provide a legal pathway for marketing biological products that have been prepared outside the scope of an approved biologics license application (BLA). Specifically, section 351(a)(1) of the Public Health Service Act (PHS Act) prohibits the introduction into interstate commerce of any biological product unless “a biologics license . . . is in effect for the biological product” (i.e., an approved BLA). Additionally, biological products subject to licensure under section 351 of the PHS Act are not eligible for the exemptions for compounded drugs under sections 503A and 503B of the FDCA. We also note that, as required by the Biologics Price Competition and Innovation Act of 2009, on March 23, 2020, an approved application for a biological product under section 505 of the FDCA was deemed to be a license for the biological product (i.e., an approved BLA) under the PHS Act. This transition affects compounding under sections 503A and 503B of the FDCA because, beginning on March 23, 2020, these biological products that previously could have been submitted in a marketing application under the FD&C Act are subject to licensure under section 351 of the PHS Act and thus are not eligible for the exemptions for compounded drugs under sections 503A and 503B of the FDCA. See Notice to Compounders: Changes that affect compounding as of March 23, 20206 and section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009 for additional information. Although these biological products are not eligible for the exemptions in sections 503A and 503B, FDA issued guidance explaining the conditions under which we do not intend to take action when certain biological products are mixed, diluted, or repackaged in a manner not described in their approved labeling. See Guidance for Industry: Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application (available at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F90986\u002Fdownload).\n\nIn addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b)].\n\nFDA strongly recommends that if you decide to resume production of sterile drugs, your management first undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug processing expertise should assist you in conducting this comprehensive evaluation.\n\nLastly, during the inspection, investigators noted that your firm may be exporting products to other countries. Please be advised that if a product meets the FDCA’s requirements for sale and distribution in the United States, the FDCA has no additional restrictions on its exportation (i.e., sections 801 and 802 of the FDCA [21 U.S.C. § 381 and 382] do not apply to such exports). However, if the product does not meet FDCA’s domestic marketing requirements and is intended for export then you are required to be in compliance with applicable sections of the FDCA Chapter VIII – Imports and Exports. Furthermore, other federal statutes or regulations administered by other federal agencies (such as the Department of Commerce) may apply. For further information please see FDA’s Guidance for Industry: Exports Under the FDA Export Reform and Enhancement Act of 1996 (available at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fguidance-industry-exports-under-fda-export-reform-and-enhancement-act-1996).\n\nE. Conclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nIf you decide to resume sterile operations, you should take prompt action to correct any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing if you have taken any specific steps to address any violations, or you may inform us that you do not intend to resume production of sterile drugs. If you intend to resume production of sterile drugs in the future, please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. In addition to taking appropriate corrective actions, you should notify this office fifteen (15) working days prior to resuming production of any sterile drugs in the future.\n\nYour written notification should refer to the Warning Letter Number above (615908). Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\n\nAttention: Tina M. Pawlowski, Compliance Officer\n\nU.S. Food and Drug Administration\n\nDivision of Pharmaceutical Quality Operations Division III\n\nIf you have questions regarding the contents of this letter, please contact Tina M. Pawlowski at (313) 393-8217.\n\nSincerely,\n\n\u002FS\u002F\n\nNicholas F. Lyons\n\nActing Program Division Director\n\nDivision of Pharmaceutical Quality Operations Division III\n\n______________________\n\n1 We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.\n\n2 On June 9, 2016, FDA issued a final guidance titled, Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. This guidance describes FDA’s interim regulatory policy for State-licensed pharmacies, Federal facilities, and licensed physicians that compound human drug products using bulk drug substances that do not otherwise meet the conditions of section 503A(b)(1)(A)(i) while the 503A bulks list is being developed. Specifically, the guidance sets out the conditions under which FDA does not intend to take action against a State-licensed pharmacy, Federal facility, or licensed physician for compounding a drug product using a bulk drug substance that is not the subject of an applicable USP or NF monograph or a component of an FDA-approved drug, until the substance is identified in a final rule as included or not included on the 503A bulks list. These conditions include that the substance may be eligible for inclusion on the 503A bulks list, was nominated with adequate support for FDA to evaluate it, and has not been identified by FDA as a substance that appears to present significant safety risks pending further evaluation. Cerebrolysin, thymosin alpha, thymosin beta, BPC-157, LL-37, pentosan, Selank, and Semax were not nominated for inclusion on the 503A bulks list. For additional information, see the guidance at http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM469120.pdf.\n\n3 The specific products made by your firm are drugs within the meaning of section 201(g) of the Act, [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) [21 U.S.C. 321(p)] of the FDCA because they are not generally recognized as safe and effective for their labeled uses.\n\n4 Your ineligible drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\n\n5 In this letter we do not address whether your proposed corrective actions would resolve the CGMP violations noted above.\n\n6 Available at: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fhuman-drug-compounding\u002Fnotice-compounders-changes-affect-compounding-march-23-2020.","Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine","advanced-nutriceuticals-llc-dba-guyer-institute-molecular-medicine-615908-11102021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-nutriceuticals-llc-dba-guyer-institute-molecular-medicine-615908-11102021","2026-10-26T08:07:50.520086+00:00","Closed Out","2021-11-16","615908","2026-03-17","Leonard D. Guyer, MD","2026-08-20T02:26:18.165+00:00","UPS Next Day","2021-11-10",8,{"510k":178,"classification":179,"enforcement":180,"event":181,"event_backfill":182,"pma":183,"warning_letter":184},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-19T04:00:36.695+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]